

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58919 A2

(15) International Patent Classification⁷: C07J 1/00

(21) International Application Number: PCT/US01/04266

(22) International Filing Date: 9 February 2001 (09.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/181,738 11 February 2000 (11.02.2000) US

(71) Applicant: SRI INTERNATIONAL [US/US]; 333 Ravenswood Avenue, Menlo Park, CA 94025 (US).

(72) Inventors: PETERS, Richard, H.; 365 Springpark Circle, San Jose, CA 95136 (US). LIU, Jyanwei; 681 Endicott Drive, Sunnyvale, CA 94087 (US). JOHANSSON, John, G.; 186 Sand Hill Circle, Menlo Park, CA 94025 (US).

RYAN, Kenneth, J.; 754 Lakemuir Drive, Sunnyvale, CA 94089 (US). CHAO, Wan-Ru; 1510 Oriole Avenue, Sunnyvale, CA 94087 (US). TANABE, Masato; 972 Moreno, Palo Alto, CA 94303 (US).

(74) Agents: REED, Dianne, E. et al.; Reed & Associates, 3282 Alpine Road, Portola Valley, CA 94028 (US).

(81) Designated States (*national*): CA, JP.


(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SYNTHESIS OF ANTI-ESTROGENIC AND OTHER THERAPEUTIC STEROIDS FROM 21-HYDROXY-19-NOR-PREGNA-4-EN-3-ONE



(57) Abstract: Syntheses of steroids such as 3-hydroxy-7 α -methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene citrate ("SR 16234") and analogs thereof are provided, wherein 21-hydroxy-19-norpregna-4-en-3-one serves as a starting material or intermediate. The latter compound may be readily prepared from estrone-3-methyl ether. Certain intermediates in these syntheses also have value as therapeutic agents, for example in the treatment of prostate disorders such as prostatic cancer.

WO 01/58919 A2

**SYNTHESIS OF ANTI-ESTROGENIC AND OTHER THERAPEUTIC
STERIODS FROM 21-HYDROXY-19-NORPREGNA-4-EN-3-ONE**

5

TECHNICAL FIELD

This invention relates generally to the chemical synthesis of steroids, and more particularly relates to the synthesis of anti-estrogenic and other therapeutic steroids such as 3-hydroxy-7 α -methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene citrate ("SR 16234") and analogs thereof. The invention additionally relates to starting materials and intermediates useful in conjunction with the novel synthesis.

BACKGROUND ART

Breast cancer is one of the most prevalent types of cancer, and epidemiological and clinical studies have shown that approximately two-thirds of breast tumors are estrogen-dependent. This means that estrogens are required for the growth of such breast tumors in both premenopausal and postmenopausal patients. In postmenopausal women, in whom breast cancer most commonly occurs, breast tumor concentrations of estrone and estradiol are considerably higher than blood estrogen levels. Although retention of estrogens in breast tumors by high-affinity binding proteins contributes to the level of estrogens in tumors, estrogen concentrations in the breast are higher than plasma levels in breast cancer patients regardless of whether their tumors are estrogen receptor-positive (ER+) or estrogen receptor-negative (ER-). *In situ* formation of estrogen from estrogen biosynthetic precursors within tumors is now known to make a major contribution to the estrogen content of breast tumors.

Numerous other estrogen-dependent conditions, disorders, and diseases have been identified as well, including, but not limited to, ovarian, uterine and pancreatic cancers, galactorrhea, McCune-Albright syndrome, benign breast disease, and endometriosis.

Estrogenic effects are mediated by specific receptors located in the nucleus of estrogen-responsive cells. The receptor contains a hormone-binding domain for binding

estrogen, transcription activating domains, and a DNA binding domain. The binding of the receptor-hormone complex to estrogen response elements (ERE's) in the DNA of target genes is necessary for regulating gene transcription.

5 Drugs that competitively block estrogen binding to its receptor, termed anti-estrogens, are capable of inhibiting the stimulatory effects of the hormone on cell proliferation and are therefore useful in the clinical treatment of breast cancer. Clinically, estrogen receptor-positive tumors respond with a higher frequency to anti-estrogens than do tumors lacking a significant level of receptors.

 Anti-estrogenic drugs fall into two chemical classes: nonsteroidal and steroidal.
10 The nonsteroidal anti-estrogen tamoxifen (Nolvadex™) has been used as an adjunctive treatment for breast cancer following chemotherapy or radiation therapy. However, tamoxifen itself exhibits estrogenic activity in reproductive tissue, resulting in an increased risk of endometrial cancer and possible recurrence of breast cancer after long-term therapy. Furthermore, tamoxifen behaves only as a partial agonist in the uterus.

15 To date, little work has been done in the development of selective competitive antagonists of estrogen. Several steroidal anti-estrogens have been synthesized which lack estrogenic activity. Included among these are ICI 164,384, ICI 182,780 and RU 58668. See, e.g.: Wakeling et al. *J. Steroid Biochem.* 31:645-653 (1988), which pertains to ICI 164,384; Wakeling et al., *Cancer Res.* 51:3867-3873 (1991), and Wakeling et al., *J. Steroid*
20 *Biochem. Molec. Biol.* 37:771-774 (1990), which pertain to ICI 182,780; and Van de Velde et al., *Ann. N.Y. Acad. Sci.* 761:164-175 (1995), Van de Velde et al., *Pathol. Biol.* 42:30 (1994), and Nique et al., *Drugs Future* 20:362-366 (1995), which relate to RU 58668. Unfortunately, these drugs are not orally active and must be administered in high doses intramuscularly. Furthermore, the manufacture of these drugs is laborious, requiring a
25 complicated, 14-16 step synthesis with very low overall yields. Potent steroidal anti-estrogens that are orally active have not yet been developed or commercialized, although the nonsteroidal mixed agonist/antagonist "raloxifene" is currently available.


 Accordingly, steroidal active agents have recently been developed that are extremely effective anti-estrogenic agents, i.e., are potent antagonists of estrogen in breast
30 and/or uterine tissue. The active agents are described in co-pending, commonly assigned

-3-

U.S. Patent Application Serial No. 08/998,877, filed December 24, 1997, and U.S. Patent Application Serial No. 09/220,408, filed December 23, 1998, as well as in PCT Publication No. WO 99/33859, published July 8, 1999. These active agents represent a significant advance in the art, particularly in the treatment of breast cancer and other diseases and conditions that are potentiated by the presence of estrogens. A number of those active agents have also been found to display tissue-selective pharmacology and are thus useful as tissue-selective estrogen agonists/antagonists, also termed "Selective Estrogen Receptor Modulators" or "SERMs." SERMs produce beneficial estrogen-like effects in some respects, notably on bone and lipid metabolism, while nevertheless acting as estrogen antagonists in the breast and/or uterus. The SERM profile may be distinguished from that of a pure estrogen such as 17 β -estradiol, which behaves as an estrogen agonist in all tissues, and from that of a pure anti-estrogen, which exhibits an estrogen antagonist profile in all tissue types.

An exemplary and representative anti-estrogen in the aforementioned group is the citrate salt of 3-hydroxy-7 α -methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene, developed at SRI International (Menlo Park, California) and also referred to herein as "SR 16234." SR 16234 can be represented as follows:

SR 16234:



SR 16234 has been found to have potent antitumor activity with remarkable tissue-selective properties: complete antagonist-antiestrogenic activity in human breast tumor cells; complete anti-uterotrophic antagonist activity in rat and human uterine tissue; agonist-estrogenic activity in the cardiovascular system, as reflected in lowered low-density lipoprotein (LDL) and increased high-density lipoprotein (HDL) cholesterol levels in rats; and agonist-estrogenic activity in the skeletal system, as manifested by maintenance of bone

and prevention of bone loss in rats. In addition, SR 16234 has been established to have good oral bioavailability, absorption and half-life, with sufficient uptake to sustain therapeutically effective plasma levels of the drug.

Currently, SR 16234 is synthesized using a nine-step synthetic procedure as outlined in FIG. 1. While the synthesis is effective and provides the product in a reasonable overall yield, it would be desirable to provide a simpler, more straightforward synthesis so as to reduce cost (synthesizing SR 16234 using the method of FIG. 1 is quite expensive), to improve overall yield, to avoid use of highly toxic reagents, and to avoid costly and difficult reaction steps such as aromatization with CuCl_2 .

DISCLOSURE OF THE INVENTION

Accordingly, the invention is directed to a new method for synthesizing SR 16234 and substituted analogs thereof, which is simpler, more straightforward and more cost-effective than previous synthetic methods, avoids the use of highly toxic reagents, and furthermore avoids costly materials and difficult reaction steps.

It is another object of the invention to provide such a method that employs 21-hydroxy-19-norpregna-4-en-3-one or a substituted analog thereof as a starting material or intermediate.

It is still another object of the invention to provide intermediate compounds and synthetic steps useful in conjunction with the aforementioned syntheses.

It is still another object of the invention to provide certain of such intermediate compounds as therapeutic agents, e.g., in the treatment of prostate disorders such as prostatic cancer.

Additional objects, advantages and novel features of the invention will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art upon examination of the following, or may be learned by practice of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a synthetic scheme illustrating a prior method for synthesizing SR 16234.

FIGS. 2, 3 and 4 are schemes illustrating methods of the invention for synthesizing SR 16234 from estrone-3-methyl ether (1) via 21-hydroxy-19-norpregna-4-en-3-one (3) as an intermediate.

FIGS. 5, 6 and 7 are schemes illustrating alternative methods of the invention for synthesizing 3-hydroxy-7 α -methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene ("SR 16233"), the free amine precursor to SR 16234.

FIGS. 8 and 9 are schemes illustrating methods of the invention for synthesizing SR 16234 from a crude 21-hydroxy-19-norpregna-4-en-3-one (3a).

FIG. 10 is a ¹H NMR spectrum of compound 2, the structure of which is shown in FIGS. 2, 3 and 4 (synthesized as described in Example 1).

FIG. 11 is a ¹H NMR spectrum of compound 3, the structure of which is shown in FIGS. 2, 3 and 4 (synthesized as described in Example 1).

FIG. 12 is a ¹H NMR spectrum of compound 4, the structure of which is shown in FIGS. 2 and 3 (synthesized as described in Example 2).

FIG. 13 is a ¹H NMR spectrum of compound 5, the structure of which is shown in FIGS. 2 and 3 (synthesized as described in Example 2).

FIG. 14 is a ¹H NMR spectrum of compound 6, the structure of which is shown in FIGS. 2 and 3 (synthesized as described in Example 2).

FIG. 15 is a ¹H NMR spectrum of compound SR 16233, the structure of which is shown in FIGS. 2 and 3 (synthesized as described in Example 2).

FIG. 16 is a mass spectrum of compound SR 16233.

FIG. 17 is a ¹H NMR spectrum of compound SR 16234, the structure of which is shown in FIGS. 2 and 3 (synthesized as described in Example 2).

FIG. 18 is a mass spectrum of compound SR 16234.

FIG. 19 is a ¹H NMR spectrum of compound 7, the structure of which is shown in FIGS. 2 and 3 (synthesized as described in Example 3).

FIG. 20 is a ^1H NMR spectrum of compound 11, the structure of which is shown in FIG. 4 (synthesized as described in Example 4).

FIG. 21 is a ^1H NMR spectrum of compound 12, the structure of which is shown in FIG. 4 (synthesized as described in Example 4).

5 FIG. 22 is a ^1H NMR spectrum of compound 13, the structure of which is shown in FIG. 4 (synthesized as described in Example 4).

FIG. 23 is a graph illustrating the % inhibition versus concentration of SR 16312 as evaluated in an androgen-independent human prostate cancer assay, described in Example 7.

10

MODES FOR CARRYING OUT THE INVENTION

DEFINITIONS:

It is to be understood that unless otherwise indicated, this invention is not limited to specific starting materials, reagents or reaction conditions, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

20

In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings:

The term "alkyl" as used herein refers to a branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *t*-butyl, octyl, decyl, tetradecyl, hexadecyl, eicosyl, tetracosyl and the like, as well as cycloalkyl groups such as cyclopentyl, cyclohexyl, and the like. The term "lower alkyl" intends an alkyl group of one to six carbon atoms, preferably one to four carbon atoms. The term "cycloalkyl" as used herein refers to a cyclic hydrocarbon of from 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

30

The term "alkenyl" as used herein refers to a branched or unbranched hydrocarbon group of 2 to 24 carbon atoms containing at least one double bond, such as ethenyl, *n*-propenyl, isopropenyl, *n*-butenyl, isobutenyl, octenyl, decenyl, tetradecenyl, hexadecenyl, eicosenyl, tetracosenyl, and the like. Preferred alkenyl groups herein contain 2 to 12 carbon atoms. The term "lower alkenyl" intends an alkenyl group of two to six carbon atoms, preferably two to four carbon atoms. The term "cycloalkenyl" intends a cyclic alkenyl group of three to eight, preferably five or six, carbon atoms.

The term "alkynyl" as used herein refers to a branched or unbranched hydrocarbon group of 2 to 24 carbon atoms containing at least one triple bond, such as ethynyl, *n*-propynyl, isopropynyl, *n*-butynyl, isobutynyl, octynyl, decynyl, and the like. Preferred alkynyl groups herein contain 2 to 12 carbon atoms. The term "lower alkynyl" intends an alkynyl group of two to six carbon atoms, preferably two to four carbon atoms.

The term "alkylene" as used herein refers to a difunctional branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methylene, ethylene, *n*-propylene, *n*-butylene, *n*-hexylene, decylene, tetradecylene, hexadecylene, and the like. The term "lower alkylene" refers to an alkylene group of one to six carbon atoms, preferably one to four carbon atoms.

The term "alkenylene" as used herein refers to a difunctional branched or unbranched hydrocarbon group of 2 to 24 carbon atoms containing at least one double bond, such as ethenylene, *n*-propenylene, *n*-butenylene, *n*-hexenylene, and the like. The term "lower alkenylene" refers to an alkylene group of two to six carbon atoms, preferably two to four carbon atoms.

The term "alkoxy" as used herein intends an alkyl group bound through a single, terminal ether linkage; that is, an "alkoxy" group may be defined as -O-alkyl where alkyl is as defined above. A "lower alkoxy" group intends an alkoxy group containing one to six, more preferably one to four, carbon atoms.

The term "acyl" is used in its conventional sense to refer to a substituent alkyl-C-(O)- wherein alkyl is as defined above. The term "lower acyl" refers to an acyl group wherein the alkyl moiety of the group contains one to six, more preferably one to four, carbon atoms.

The term "aryl" as used herein, and unless otherwise specified, refers to an aromatic species containing 1 to 3 aromatic rings, either fused or linked, and either unsubstituted or substituted with 1 or more substituents typically selected from the group consisting of lower alkyl, lower alkoxy, halogen, and the like. Preferred aryl substituents contain 1 aromatic ring or 2 fused or linked aromatic rings. The term "arylene" refers to a difunctional aromatic species containing 1 to 3 aromatic rings substituted with 1 or more substituents as above. Preferred arylene substituents contain 1 aromatic ring (e.g., phenylene) or 2 fused or linked aromatic rings (e.g., biphenylene).

The term "aralkyl" refers to an aryl group with an alkyl substituent. The term "aralkylene" refers to an arylene group with an alkyl substituent.

The term "alkaryl" refers to an alkyl group that has an aryl substituent. The term "alkarylene" refers to an alkylene group that has an aryl substituent.

The term "heterocyclic" refers to a five- or six-membered monocyclic structure or to an eight- to eleven-membered bicyclic heterocycle. The "heterocyclic" substituents herein may or may not be aromatic, i.e., they may be either heteroaryl or heterocycloalkyl. Each heterocycle consists of carbon atoms and from one to three, typically one or two, heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, typically nitrogen and/or oxygen.

The terms "halo" and "halogen" are used in the conventional sense to refer to a chloro, bromo, fluoro, or iodo substituent. The terms "haloalkyl," "haloalkenyl," or "haloalkynyl" (or "halogenated alkyl," "halogenated alkenyl," or "halogenated alkynyl") refers to an alkyl, alkenyl, or alkynyl group, respectively, in which at least one of the hydrogen atoms in the group has been replaced with a halogen atom.

The term "hydrocarbyl" is used in its conventional sense to refer to a hydrocarbon group containing carbon and hydrogen, and may be aliphatic, alicyclic, or aromatic, or may contain a combination of aliphatic, alicyclic, and/or aromatic moieties. Aliphatic and alicyclic hydrocarbyl may be saturated or they may contain one or more unsaturated bonds, typically double bonds. The hydrocarbyl substituents herein generally contain 1 to 24 carbon atoms, more typically 1 to 12 carbon atoms, and may be substituted with various

substituents and functional groups, or may be modified so as to contain ether, thioether, -NH-, -NR-, -C(O)-, -C(O)-O-, and/or other linkages.

"Optional" or "optionally" means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not. For example, the phrase "optionally substituted" means that a non-hydrogen substituent may or may not be present, and, thus, the description includes structures wherein a non-hydrogen substituent is present and structures wherein a non-hydrogen substituent is not present. Similarly, the phrase an "optionally present" double bond as indicated by a dotted line ---- in the chemical formulae herein means that a double bond may or may not be present, and, if absent, a single bond is indicated.

By "anti-estrogenic" as used herein is meant a compound that tends to inhibit the *in situ* activity of estrogens such as estradiol, following administration to a mammalian individual. Anti-estrogenic activity can be evaluated in terms of inhibition of estradiol-induced alkaline phosphatase activity in human Ishikawa cells using, for example, the procedures described in Example 40 of PCT Publication No. WO 99/33859.

The terms "treating" and "treatment" as used herein refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage. Thus, for example, a method of "treating" an estrogen-dependent disorder, as the term is used herein, encompasses both prevention of the disorder in a clinically asymptomatic individual and treatment of the disorder in a clinically symptomatic individual. Similarly, a method of "treating" a prostate disorder, as the term is used herein, encompasses both prevention of the disorder in a clinically asymptomatic individual and treatment of the disorder in a clinically symptomatic individual.


By the terms "effective amount" or "pharmaceutically effective amount" of a therapeutic agent are meant a nontoxic but sufficient amount of the agent to provide the desired prophylactic or therapeutic effect. As will be pointed out below, the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, and the particular agent and mode of administration, and the like. Thus, it is not possible to specify an exact

-10-

"effective amount." However, an appropriate "effective" amount in any individual case may be determined by one of ordinary skill in the art using only routine experimentation.

By "pharmaceutically acceptable carrier" is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the selected therapeutic agent without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. Similarly, a "pharmaceutically acceptable" salt or a "pharmaceutically acceptable" ester of a novel compound as provided herein is a salt or ester that is not biologically or otherwise undesirable.

In describing the location of groups and substituents, the following numbering system will be employed to conform the numbering of the cyclopentanophenanthrene nucleus to the convention used by the IUPAC or Chemical Abstracts Service:



The five- and six-membered rings of the steroid molecule are often designated A, B, C, and D as shown. The term "steroid" as used herein is intended to mean compounds having the aforementioned cyclopentanophenanthrene nucleus.


In these structures, the use of bold and dashed lines to denote particular conformation of groups follows the IUPAC steroid-naming convention. The symbols " α " and " β " indicate the specific stereochemical configuration of a substituent at an asymmetric carbon atom in a chemical structure as drawn. Thus " α ," denoted by a broken line, indicates that the group in question is below the general plane of the molecule as drawn, and " β ," denoted by a bold line, indicates that the group at the position in question is above the general plane of the molecule as drawn.

-11-

SYNTHETIC METHODS:

The synthetic methods of the invention all proceed from estrone-3-methyl ether via 21-hydroxy-19-norpregna-4-en-3-one as an intermediate. It will be understood by those working in the field of steroid chemistry that the cyclopentanophenanthrene nucleus may be substituted with one or more substituents that do not interfere with the synthetic steps described herein.

To prepare the substituted or unsubstituted 21-hydroxy-19-norpregna-4-en-3-one intermediate, a substituted or unsubstituted estrone-3-methyl ether is first converted to a compound having the structural formula (I) by reaction with a triethyl phosphonoacetate or an analogous reagent (see Example 1).



In structural formula (I):

X is lower hydrocarbyl;

R¹ is hydrogen or CR¹¹R¹², wherein R¹¹ and R¹² are hydrogen or lower alkyl;

R² is selected from the group consisting of hydrogen, hydroxyl, alkyl, -OR¹³, and -SR¹³ wherein R¹³ is alkyl;

R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consisting of hydrogen and lower alkyl;

R⁹ is hydrogen or hydrocarbyl; and


R¹⁰ is methyl or ethyl.

A preferred subset of the aforementioned compounds has the structure of formula

(II)

-12-

(II)




wherein X is lower alkyl and R^6 is hydrogen or lower alkyl.

For example, X may be ethyl, and R^6 may be methyl (see compound 2 in FIGS. 2, 3, and 4).

In order to convert compound (I) to the substituted or unsubstituted 21-hydroxy-19-norpregna-4-en-3-one intermediate (III)

(III)



compound (I) is treated with an alkali metal and ammonia or an alkylamine using known reaction conditions appropriate for a Birch reduction; see, e.g., March et al., *Advanced Organic Chemistry, Fourth Edition* (New York: Wiley, 1992), section 5-10 and references cited therein. Suitable alkali metals include lithium, potassium and sodium, and the reaction preferably takes place in liquid ammonia and optionally in the presence of an alcohol.


In compound (III):

R^1 , R^2 , R^4 , R^5 , R^7 , R^9 , and R^{10} are as defined for formula (I), R^3 is hydrogen or hydrocarbyl, typically hydrogen or alkyl, preferably hydrogen or lower alkyl such as methyl, and R^{19} is hydroxyl, hydroxymethyl (CH_2OH), protected hydroxyl, protected

-13-

hydroxymethyl, activated hydroxyl, or activated hydroxymethyl. By "activated" is meant that a hydroxyl group is modified so as to enable reaction with an incoming nucleophile; generally, this means that a hydroxyl group -OH is converted to an -O-LG moiety wherein LG is a leaving group. Activation can involve, for example, reaction with MsCl, TsCl, SOCl₂, SOBr₂, or the like ("Ms" meaning mesyl and "Ts" meaning tosyl). By "protected" is meant that the hydroxyl group will not undergo reaction in a particular step, but by virtue of a protecting group Pr, the -O-Pr moiety remains intact and can be treated, e.g., with base or acid, to regenerate the unprotected hydroxyl group following reaction. Suitable hydroxyl-protecting groups at the latter position include, but are not limited to, Ms, Ts, acetyl (Ac), and tetrahydropyranyl (THP). It is to be understood that the above-indicated activating and protecting moieties may be used as either protecting groups or activating groups depending on the specific reaction condition.

Preferred intermediates encompassed by structural formula (III) have the structure of formula (IV)




20 wherein:

R³ is hydrogen or lower alkyl; and

R¹⁹ is hydroxyl, hydroxymethyl, protected hydroxyl, or protected hydroxymethyl.

In a representative and specific example of the foregoing reaction, a method for synthesizing 21-hydroxy-19-norpregna-4-en-3-one is provided which comprises treating


25 (IX)



wherein X and Y are independently lower alkyl, with an alkali metal in the presence of ammonia or an alkylamine.

SR 16234 or its free base SR 16233 is synthesized from compound (III) using one of several methods, exemplified in the schemes of FIGS. 2, 3, 4, 8, and 9. In the first three of these methods, when R¹⁹ is hydroxyl or hydroxymethyl, preferably hydroxymethyl, the alcohol moiety is initially converted to a leaving group displaceable with an incoming nucleophile as explained above. The remaining steps in the first three methods then differ, as illustrated in FIGS. 2, 3, and 4. In the fourth method, as illustrated in the scheme of FIG. 8, the R¹⁹ alcohol moiety is initially converted to a protecting group, as explained above, a 7 α groups is attached to the B ring, the R¹⁹ protected group is unprotected and then activated with a leaving group. The fifth method, illustrated in FIG. 9, first protects the R¹⁹ position and then proceeds as indicated.


In methods 1 and 2 (illustrated in FIGS. 2 and 3), a compound having the structural formula (XII)



wherein m is zero or 1, and R¹, R², R⁴, R⁵, R⁷, and R¹⁰ are as defined above, is initially provided. This compound is a subset of formula III. The -OH group at the 20- or 21-position (depending on whether m is zero or 1, respectively) is then activated by conversion to an -O-LG moiety wherein LG is a leaving group displaceable by nucleophilic attack, as explained above; LG can be, for example, OMs, OTs, Cl, Br, etc.

At the same time that the -OH group at the 20- or 21-position is activated, or subsequently, the following three reaction steps are carried out: (1) the A ring of the steroid nucleus is oxidized (aromatized); (2) a 6-keto moiety is provided by exposure to gaseous oxygen in the presence of base (e.g., cesium carbonate or potassium acetate); and (3) a protecting group is introduced at the 3-position so as to provide a protected hydroxyl group -OPr wherein Pr is the protecting group. Suitable protecting groups include, but are not limited to alkyl, lower alkyl, Ms, Ts, Ac, and THP.

Next, the leaving group LG is displaced with a hydroxyl-containing compound having the structural formula (XIII)




wherein p is an integer in the range of 1 to 7 inclusive, R²¹ and R²² are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring, and Q¹, Q², Q³, and Q⁴ are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

Prior, during, or subsequent to the aforementioned reactions, substitution at the 7-position is effected by reaction with an alkyl halide such as methyl iodide, in a suitable base such as lithium diisopropylamide, to provide a 7 - lower alkyl, e.g., a 7-methyl, substituent. In method 1, illustrated in FIG. 2, alkylation at the 7-position is conducted prior to attachment of the aromatic side chain at the 17-position, using an alkyl halide such as methyl iodide. In method 2, illustrated in FIG. 3, alkylation at the 7-position is conducted after attachment of the aromatic side chain at the 17-position, again using an alkyl halide such as methyl iodide. In method 3, the 7-position is alkylated earlier, as implied above by the definition of R³ in structure (III). In either method 1 or 2, the compound provided (exemplified as 6 in FIGS. 2 and 3) can be generically represented as (XVIII)

-16-

5 (XVIII)




wherein R^{3A} represents the newly added lower alkyl group and the remaining substituents
 10 are as defined previously. It will be appreciated that other types of hydrocarbonyl groups
 could be added at the 7-position, i.e., as R^{3A} , by reaction with the appropriate hydrocarbonyl
 halide reagents.

Compound (XVIII) is then reduced so as to remove the 6-keto and amidocarbonyl
 moieties using a standard reducing agent and conditions, e.g., lithium aluminum hydride
 15 (LAH) in the presence of aluminum chloride ($AlCl_3$), which also deprotects at the 3-position
 to result in a free hydroxyl group. The resulting compound thus has the structure (XI)


20

(XI)




25 A representative compound of structure (XI) compound and key species is 3-hydroxy-7 α -
 methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene
 (SR 16233) as illustrated in FIGS. 2 and 3. Compound (XI) may then be converted to an
 acid addition salt by reaction with a suitable acid using conventional procedures. For
 example, to convert the compound to SR 16234, the citrate salt of SR 16233, the reaction is
 30 conducted with citric acid.

In method 3, illustrated in FIG. 4, the reaction steps following synthesis of compound (III) (exemplified as 3 in the figure) differ from the foregoing syntheses, as follows. Following protection of the hydroxyl or hydroxymethyl group at R¹⁹, the 7 α -lower alkyl, e.g., 7 α -methyl, group is synthesized by reaction with, for example, alkyl lithium, e.g., methyl lithium, in the presence of lithium bromide (see FIG. 4). The hydroxyl or hydroxymethyl group at R¹⁹ is then deprotected by treatment with base (e.g., an inorganic hydroxide such as KOH or NaOH, in alcohol) using conventional means, followed by reaction with an aldehyde that may be generically represented as (XIV)




a specific example of such an aldehyde, as illustrated in FIG. 4, is vanillin, i.e., 4-hydroxy-3-methoxybenzaldehyde. This results in an intermediate having the structural formula (XV)




Then, in order to provide the desired amine, (XV) is treated with an alkylamine having the structure HNR²¹R²² under reaction conditions effective to produce the amine (XVI)

-18-



While compound (XVI) is a valuable intermediate in the ultimate synthesis of SR 16234 and analogs thereof, it has additional value as a therapeutic agent, particularly in the treatment of prostate disorders such as prostatic cancer. Preferred compounds within this group have the structural formula (XVII)



wherein:

R^{3A} is alkyl, most preferably lower alkyl such as methyl;

m is zero or 1;

p is an integer in the range of 1 to 7 inclusive;

R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and


-19-

Q^1 , Q^2 , Q^3 , and Q^4 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

In method 3, the A ring is then oxidized (aromatized) using, for example, cuprous chloride in AcOH; or by using biological aromatization. SR 16233 results, which can be converted to SR 16234, as noted previously, by reaction with citric acid.

In method 4, as illustrated in FIG 8, a compound having the structural formula (XII) is used as the starting material. The -OH group at the 20- or 21-position (depending on whether m is zero or 1, respectively) is first protected by conversion to an -O-Pr moiety wherein Pr is a protecting group, as explained above. Suitable protecting groups include, but are not limited to alkyl, lower alkyl, Ms, Ts, Ac, and THP. As illustrated in FIG. 8, acetyl is a preferred protecting group for this purpose, as the acetate moiety allows for easy and efficient purification of the resultant acetate via recrystallization.


Next, a dienyl acetate having structural formula (XX) is formed by introduction of a protecting group, Pr^2 , at the 3-position.



In structural formula (XX), m, R^1 , R^2 , R^4 , R^5 , R^7 , and R^{10} are as defined above, and Pr^1 and Pr^2 are the respective protecting groups on the 20- or 21- and the 3- position and may be the same or different. As discussed above, preferred protecting groups include, but are not limited to, alkyl (particularly lower alkyl), acetyl, Ms, Ts, and THP. The 3-position protecting group, Pr^2 , is then removed to form a dienone having structural formula (XXI)


-20-

(XXI)



wherein Pr^1 , m , R^1 , R^2 , R^4 , R^5 , R^7 , and R^{10} are as defined above. Once the dienone has been synthesized, the compound is reacted with, for example, a lower alkyl lithium, e.g., methyl lithium, in the presence of lithium bromide to form a 7α -alkylated compound having the structure (XXII)

(XXII)




wherein R^{3A} represents the newly added lower alkyl group and the remaining substituents are as defined above (see FIG. 8). The use of acetate as the Pr^1 protecting group greatly facilitates the addition of the 7-alkyl group in the α position. While not wishing to be limited by theory, it is believed that the acetate moiety forms a complex with the lithium and promotes introduction of the 7-alkyl functionality from the α face of the steroid.

The A ring of the 7α -alkyl steroid is then aromatized and the Pr^1 protecting group removed using, for example, cuprous chloride in AcOH, biological aromatization, or the like. The resulting diol will have structural formula (XXIII)

-21-

5 (XXIII)




10

wherein the various substituents are as defined above. The 3-position and 20- or 21-position alcohol moieties of the diol are then protected with a suitable protecting group such as Ts, Ms, or the like. As discussed above, Ms is a preferred protecting group. The protected compound is then treated with a hydroxyl-containing compound having structural
 15 formula (XIII), as discussed above with respect to method 1, resulting in a compound having the structure (XXIV)

20

(XXIV)




25

wherein Pr represents the protecting group on the 3-position and the remaining substituents are as defined previously. This compound is then reduced using a standard reducing agent and conditions, e.g., lithium aluminum hydride (LAH), to reduce the amido moiety to an amine and deprotect at the 3-position resulting in a free hydroxyl group. The resulting
 30 compound thus has the structure (XI), which, as previously discussed, may then be

-22-

converted to an acid addition salt by reaction with a suitable acid using conventional procedures.

In the last method, method 5, illustrated in FIG. 9, the 3-position of a compound having the structural formula (XII) is protected, the A ring aromatized and the desired 6-ketone introduced by the use of a catalytic amount of iodine in isopropanol while air is bubbled through the reaction mixture. This process results in a 6-ketone having the structural formula (XXVI)




wherein Pr, m, R¹, R², R⁴, R⁵, R⁷, and R¹⁰ are as defined above. The 20- or 21-position hydroxyl group, depending on m, is then protected, e.g., as a THP ether. Once the 20- or 21-position protecting group is in place, substitution is effected at the 7-position by reaction with a lower alkyl halide such as methyl iodide, in a suitable base such as lithium diisopropylamide, to provide a 7 α -alkyl, e.g., a 7 α -methyl, substituent and remove the 20- or 21-position protecting group. After the 7 α -alkyl group is in place, the 6-ketone is catalytically removed using hydrogen and a platinum or palladium catalyst, e.g., 10% palladium on carbon, and the 3-position is deprotected with a suitable reagent to provide an alcohol, resulting in the diol having the structure (XXIII). The remainder of the method then proceeds as described for method 4.

Surprisingly, it has been discovered that a THP ether protecting group when used in conjunction with an alkyl halide and a base, allows for a highly stereoselective addition of a 7-alkyl group in the α position on standard 6-keto steroid compounds. While not

wishing to be limited by theory, it is believed that the THP moiety sterically hinders addition of the 7-alkyl functionality from the β face of the steroid, thereby promoting introduction of the 7-alkyl functionality from the α face of the steroid. The use of a THP ether in the 7 α -methylation of 6-keto estradiol is described in Example 8.

ADDITIONAL INTERMEDIATES:

Additional compounds within the scope of the invention are useful as intermediates in one or more of the foregoing syntheses and have the structural formula (V)



wherein:

R^1 is hydrogen or $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, $-OR^{13}$, and $-SR^{13}$ wherein R^{13} is alkyl;

R^3 is selected from the group consisting of hydrogen and hydrocarbyl, preferably hydrogen and alkyl, e.g., lower alkyl such as methyl;

R^4 , R^5 , and R^7 are independently selected from the group consisting of hydrogen and lower alkyl;

R^{6Mod} is selected from the group consisting of hydrogen, alkyl, acyl, $-C(O)$ -aryl, and $-C(O)$ -alkyl, hydroxyl-protecting groups, and hydroxyl-activating groups;


R^{8a} is selected from the group consisting of hydrogen, hydroxyl, oxo ($=O$), and $-OR^{18}$ wherein R^{18} is lower alkyl or lower acyl;

R^9 is hydrogen or alkyl;

R^{10} is methyl or ethyl; and

-24-

R^{20} is hydroxyl, hydroxymethyl, protected hydroxyl, protected hydroxymethyl, activated hydroxyl, activated hydroxymethyl, or




10 in which m is zero or 1, p is an integer in the range of 1 to 7 inclusive, and t is zero or 1, with the proviso that when R^{8a} is oxo, t is 1, and R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

Q^1 , Q^2 , Q^3 , and Q^4 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

15 Preferred compounds within this group have the structure of formula (VI)

(VI)

20



wherein:

R^3 is hydrogen or lower alkyl;

25 R^{6Mod} is hydrogen or a hydroxyl-protecting group;

R^{8b} is hydrogen, hydroxy, or oxo ($=O$); and

R^{19} is hydroxyl, hydroxymethyl, protected hydroxyl, or protected hydroxymethyl.

In particularly preferred compounds, R^{19} is hydroxymethyl.


Other novel compounds useful as intermediates herein have the general structure

(VII)

5

(VII)

10



wherein:

R^3 is hydrogen or hydrocarbyl, preferably hydrogen or alkyl, most preferably hydrogen or lower alkyl such as methyl;

15 R^{6Mod} is selected from the group consisting of hydrogen, alkyl, acyl, $-C(O)-aryl$, and $-C(O)-alkyl$, hydroxyl-protecting groups, and hydroxyl-activating groups;

R^{8b} is hydrogen, hydroxyl, or oxo ($=O$), but preferably is hydrogen or oxo ($=O$);

m is zero or 1;

p is an integer in the range of 1 to 7 inclusive;

20 t is zero or 1, with the proviso that when R^{8a} is hydrogen, t is zero, and when R^{8a} is oxo, t is 1;

R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and


25 Q^1 , Q^2 , Q^3 , and Q^4 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

Still other compounds useful as intermediates herein have the general structure

(VIII)

5

(VIII)




10

wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^{10} , and R^{19} are as defined previously.

Also useful are compounds having the structure (XXVII) and (XXVIII)

15


(XXVII)



20

25

(XXVIII)



wherein R^1 , R^2 , R^4 , R^5 , R^{6Mod} , R^7 , R^{10} , and R^{19} are as defined previously.


PHARMACEUTICAL UTILITY:

A number of those compounds identified herein as synthetic intermediates also find utility as pharmaceutical agents. For example, as alluded to in the preceding section, certain compounds useful as intermediates in the synthetic methods described in the
5 preceding section are also useful in the treatment of prostate disorders, particularly prostatic cancer.

Prostatic cancer is the second most common malignancy in American men. Prostatic cancer may produce symptoms of urethral obstruction, either by direct extension into the bladder or by spreading behind the bladder through the seminal vesicles. Like
10 benign prostatic hyperplasia, prostatic cancer increases in prevalence with patient age, requires androgens for growth and development, and responds to antiandrogen treatment. Bostwick, et al., *Cancer*, 70(1 Suppl): 291-301 (1992). Prostatic cancer has been treated medically with some success through surgical techniques such as radical prostatectomy, and through radiation therapy via either external beam or surgical implants of interstitial
15 radioactive seeds into the prostate. Hormonal therapies available include ablation by castration, administration of exogenous estrogens to deprive prostatic tumors of circulating androgens, releasing hormone analogues that inhibit testosterone synthesis, and/or administering antiandrogens which block androgen action in the prostate itself. Chemotherapy has yielded discouraging results. *See, e.g., Cecil Textbook of Medicine, 19th*
20 *ed.*, 1353 (Wyngaarden et al., eds., W.B. Saunders 1992).

Although a number of therapies have been proposed to treat each of these disorders, there remains a need in the art to provide a more effective method of treating prostatic disorders such as prostatic cancer. It is, thus, a significant discovery that certain compounds of the invention are useful in the treatment of prostatic cancer.

One group of compounds that may be used to treat prostatic cancer has the structural formula (XVI).



In compound (XVI), the various substituents are as follows:

R¹ is CR¹¹R¹², wherein R¹¹ and R¹² are hydrogen or lower alkyl;

R² is selected from the group consisting of hydrogen, hydroxyl, alkyl, -OR¹³, and -SR¹³ wherein R¹³ is alkyl;

R³ is hydrogen or hydrocarbonyl, preferably hydrogen or alkyl, more preferably hydrogen or lower alkyl such as methyl;

R⁴ and R⁵ are independently selected from the group consisting of hydrogen and lower alkyl;

R⁷ is hydrogen or lower alkyl;

R¹⁰ is methyl or ethyl;

m is zero or 1;


p is an integer in the range of 1 to 7 inclusive;

R²¹ and R²² are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

Q¹, Q², Q³, and Q⁴ are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

The compound may also be in the form of a pharmacologically acceptable acid addition salt.

Preferred compounds within the generic structure of formula (XVI) have the structural formula (XVII)




wherein:


R^3 , m , p , R^{21} , R^{22} , Q^1 , Q^2 , Q^3 , and Q^4 are as defined above for formula (XVI).

Two exemplary such compounds are as follows:

**COMPOUND 13,
FIG. 4:**



COMPOUND SR 16312:



The compounds may be in the form of pharmacologically acceptable salts, prodrugs, or other derivatives or analogs, or they may be modified by appending one or

more appropriate functionalities to enhance selected biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system, increase oral bioavailability, increase solubility to allow administration by injection, and the like.

5 Acid addition salts of the free amine compounds can be prepared using standard procedures known to those skilled in the art of synthetic organic chemistry and described, for example, by J. March, Advanced Organic Chemistry: Reactions, Mechanisms and Structure, 4th Ed. (New York: Wiley-Interscience, 1992); conventional preparation of an acid addition salt involves reaction of the free base with a suitable acid. Typically, the base
10 form of the compound is dissolved in a polar organic solvent such as methanol or ethanol and the acid is added at a temperature of about 0°C to about 100°C, preferably at ambient temperature. The resulting salt either precipitates or may be brought out of solution by addition of a less polar solvent. Suitable acids for preparing acid addition salts include both organic acids, e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic
15 acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like, as well as inorganic acids, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. An acid addition salt may be reconverted to the free base by treatment with a suitable base.
20 Preferred acid addition salts of the present compounds are the citrate, fumarate, succinate, benzoate, and malonate salts.

The therapeutic agents may be conveniently formulated into pharmaceutical compositions composed of one or more of the compounds in association with a pharmaceutically acceptable carrier. See Remington: The Science and Practice of Pharmacy, 19th Ed.
25 (Easton, PA: Mack Publishing Co., 1995), which discloses typical carriers and conventional methods of preparing pharmaceutical compositions which may be used as described or modified to prepare pharmaceutical formulations containing the compounds of the invention. The compounds may also be administered in the form of pharmaceutically acceptable salts, or as pharmaceutically acceptable esters, as described in the preceding
30 section.

The compounds may be administered orally, parenterally, transdermally, rectally, nasally, buccally, or via an implanted reservoir in dosage formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, and vehicles. The term "parenteral" as used herein is intended to include subcutaneous, intravenous, and intramuscular injection. The amount of active compound administered will, of course, be dependent on the subject being treated, the subject's weight, the manner of administration, and the judgment of the prescribing physician. Generally, however, dosage will be in the range of approximately 0.01 mg/kg/day to 10.0 mg/kg/day, more preferably in the range of about 1.0 mg/kg/day to 5.0 mg/kg/day.

Depending on the intended mode of administration, the pharmaceutical compositions may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage form suitable for single administration of a precise dosage. The compositions will include, as noted above, an effective amount of the selected drug in combination with a pharmaceutically acceptable carrier and, in addition, may include other pharmaceutical agents, adjuvants, diluents, buffers, etc.

For solid compositions, conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc., an active compound as described herein and optional pharmaceutical adjuvants in an excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, referenced above.

For oral administration, the composition will generally take the form of a tablet or capsule, or may be an aqueous or nonaqueous solution, suspension, or syrup. Tablets and capsules are preferred oral administration forms. Tablets and capsules for oral use will generally include one or more commonly used carriers such as lactose and cornstarch.

5 Lubricating agents, such as magnesium stearate, are also typically added. When liquid suspensions are used, the active agent is combined with emulsifying and suspending agents. If desired, flavoring, coloring, and/or sweetening agents may be added as well. Other optional components for incorporation into an oral formulation herein include, but are not limited to, preservatives, suspending agents, thickening agents, and the like.

10 Parenteral administration, if used, is generally characterized by injection. Injectable formulations can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Preferably, sterile injectable suspensions are formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The
15 sterile injectable formulation may also be a sterile injectable solution or a suspension in a nontoxic parenterally acceptable diluent or solvent. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.

20 The compounds of the invention may also be administered through the skin or mucosal tissue using conventional transdermal drug delivery systems, wherein the agent is contained within a laminated structure that serves as a drug delivery device to be affixed to the skin. In such a structure, the drug composition is contained in a layer, or "reservoir," underlying an upper backing layer. The laminated structure may contain a single reservoir,
25 or it may contain multiple reservoirs. In one embodiment, the reservoir comprises a polymeric matrix of a pharmaceutically acceptable contact adhesive material that serves to affix the system to the skin during drug delivery. Examples of suitable skin contact adhesive materials include, but are not limited to, polyethylenes, polysiloxanes, polyisobutylenes, polyacrylates, polyurethanes, and the like. Alternatively, the drug-
30 containing reservoir and skin contact adhesive are present as separate and distinct layers,

with the adhesive underlying the reservoir which, in this case, may be either a polymeric matrix as described above, or it may be a liquid or hydrogel reservoir, or may take some other form.

Alternatively, the pharmaceutical compositions of the invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycols.

The pharmaceutical compositions of the invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

Formulations for buccal administration include tablets, lozenges, gels and the like. Alternatively, buccal administration can be effected using a transmucosal delivery system.

It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, the foregoing description as well as the examples that follow are intended to illustrate and not limit the scope of the invention. Other aspects, advantages, and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

EXPERIMENTAL

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of synthetic organic chemistry, biological testing, and the like, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Fieser et al., Steroids (New York: Reinhold, 1959), Djerassi, Steroid Reactions: An Outline for Organic Chemists (San Francisco: Holden-Day, 1963), and Fried et al., Organic Reactions in Steroid Chemistry, vols. 1 and 2 (New York: Reinhold, 1972), for detailed information concerning steroid-related synthetic procedures. Reference may be had

to Littlefield et al., *Endocrinology* 127: 2757-2762 (1990) and Wakeling et al., *Endocrinology* 99: 447-453 (1983) for a description of the biological testing procedures useful to evaluate compounds such as some of the therapeutic agents described and claimed herein.

5 In the following examples, efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental error and deviation should be accounted for. Unless indicated otherwise, temperature is in degrees C and pressure is at or near atmospheric. All solvents were purchased as HPLC grade, and all reactions were routinely conducted under an inert atmosphere of argon unless otherwise indicated. All reagents were obtained commercially unless otherwise indicated. Estrone 3-methyl ether was purchased from Berlichem U.S.; ethamivan (vanillic acid diethylamide) was obtained from Fluka. NMR analyses were conducted on a Varian Gemini 300 and were referenced to chloroform at δ 7.27. Mass spectra were recorded on an LKB Model 9000 combination gas chromatograph-mass spectrometer, interfaced with a tekhnivent Vector-1
10 Data System.
15

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to prepare and use the compounds disclosed and claimed herein. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.) but some errors and deviations should be
20 accounted for.

EXAMPLE 1

SYNTHESIS OF 21-HYDROXY-19-NORPREGNA-4-EN-3-ONE (3):

This example describes preparation of 21-hydroxy-19-norpregna-4-en-3-one (3)
25 from estrone-3-methyl ether (1) as illustrated in the schemes of FIGS. 2, 3, and 4.

Synthesis of (2): To a mixture of 28.4 g (0.1 mol) of estrone-3-methyl ether (1) and 90 g (0.4 mol) of triethyl phosphonoacetate in 175 mL of THF and 90 mL of ethanol, heated to reflux, was added 130 mL (0.4 mol) of a 21% solution of sodium ethoxide in ethanol. The mixture was refluxed overnight. The mixture was cooled and the volume
30 reduced by half under vacuo. The mixture was poured into 2 L ice water with stirring. A

gummy solid precipitated which was filtered, washed with water and with stirring, and air-dried to give 2 as a solid. Yield 34 g (99 %). The identity of the product was confirmed using ^1H NMR spectroscopy, and the NMR spectrum is shown in FIG. 10.

Synthesis of (3): To a three-necked flask equipped with a dry-ice condenser, overhead stirrer, argon gas inlet, and dropping funnel in a dry-ice-acetone bath was added 1200 mL of liquid ammonia. To this -78°C liquid was added 23.6 (3 mol) g of lithium in 1- to 3-inch pieces. After stirring 15 min, 350 mL of dry THF was slowly added to the blue solution (containing lithium bronze). A solution of 30 g (84.6 mmol) of 2 in 380 mL of *t*-butanol and 120 mL of THF was slowly added to the blue mixture. After stirring on the dry-ice-acetone bath, 2 g (0.25 moles) more of lithium was added. After stirring for 2 hrs, on the dry-ice-acetone bath, the blue color was mostly gone and a white-solid mixture remained. After three more hrs of stirring, 100 mL of methanol was added and the stirred mixture was allowed to reach room temperature and the ammonia evaporated with a flow of argon overnight. A solution of 140 mL concentrated HCl, 350 mL of water and 500 mL of THF was slowly added to the white semi-solid mixture with overhead stirring. More concentrated HCl was added until pH = 1. The solution was stirred at room temperature for 3 hrs. The light yellow solution was poured into 1 L of water and extracted with 4x ethyl ether. The ether was washed with 500 mL of saturated brine, dried over magnesium sulfate, filtered, and evaporated to dryness. Yield 27 g (100%) of a semi-solid crude product 3. After silica gel column chromatography (0-20% ethyl acetate in dichloromethane), 21.8 g (85%) of 3 as a white solid was isolated. The identity of the product was confirmed using ^1H NMR spectroscopy, and the NMR spectrum is shown in FIG. 11.

EXAMPLE 2

25 SYNTHESIS OF 3-HYDROXY-7 α -METHYL-21-[2'-METHOXY-4'-(DIETHYLAMINOMETHYL)-PHENOXY]-19-NORPREGNA-1,3,5(10)TRIENE CITRATE ("SR 16234") FROM 21-HYDROXY-19-NORPREGNA-4-EN-3-ONE, METHOD 1:

SR 16234 was synthesized from 21-hydroxy-19-norpregna-4-en-3-one (3) as illustrated in FIG. 2, using the following procedure.

30 Synthesis of (4): To a solution of 1.32 g (4.36 mmol) of 3 (prepared in Example 1)

in 30 mL of CH_2Cl_2 was added 2 mL of DHP (dihydropyran). The mixture was cooled to 0°C and 40 mg (5%) of TsOH was added, and the mixture was stirred for 1.5 h.

Triethylamine (0.5 mL) was added to the mixture and the mixture was filtered through a pad of silica gel (ether). The filtrate was concentrated to give 1.79 g of crude product, which
5 was used right away without purification. To this crude product was added 1.23 g (13.1 mmol) of phenol and 4.26 g (13.1 mmol) of Cs_2CO_3 followed by addition of 30 mL of sulfolane. The resulting mixture was heated at $125\text{--}130^\circ\text{C}$ under a stream of air for 6.5 hrs., and the mixture was cooled to 65°C , and 10.7 mL of isopropyl bromide was added. The mixture was stirred for 2 hrs., and was cooled to ambient temperature, diluted with ether and
10 hexanes (80 mL/120 mL), washed with water (50 mL x 4), brine, dried, concentrated, and was chromatographed (10-15% EtOAc in hexanes) to give 735 mg (40%) of 4. The identity of the product was confirmed using ^1H NMR spectroscopy, and the NMR spectrum is shown in FIG. 12.

Synthesis of (5): To a solution of 210 mg (0.48 mmol) of 4 in 10 mL of THF was
15 added 1 mL (2 mmol) of a 2.0 M solution of LDA (lithium diisopropylamide) in THF at 0°C . The mixture was stirred for 1 h, warmed to ambient temperature, and was treated with 1 mL of MeI. The resulting mixture was refluxed for 30 min, and was cooled to 0°C . Methanol (10 mL) and TsOH (0.5 g) was added, and was stirred for 1.5 h. Triethylamine (1 mL) was added, and the mixture was concentrated, and was chromatographed (30% EtOAc
20 in hexanes) to give 70 mg (39%) of 5 as an oil. The identity of the product was confirmed using ^1H NMR spectroscopy, and the NMR spectrum is shown in FIG. 13.

Synthesis of (6): To a solution of 45 mg (0.12 mmol) of 5 and 1 mL of Et_3N in 10 mL of CH_2Cl_2 was added 0.5 mL of methanesulfonic anhydride at 0°C . The mixture was stirred for 20 min, and then filtered through a pad of silica gel (ether). The filtrate was
25 concentrated to give an oil, which was dissolved in 5 mL of DMF, and 67 mg (0.28 mmol) of vanillic acid diethylamide and 97 mg (0.30 mmol) of Cs_2CO_3 was added. The resulting mixture was heated at 110°C for 3 h, and was cooled and diluted with ether (75 mL). The mixture was washed with water, brine, dried, concentrated, and was chromatographed (50% EtOAc in hexanes) to give 60 mg (85%) of 6. The identity of the product was confirmed
30 using ^1H NMR spectroscopy, and the NMR spectrum is shown in FIG. 14.

Synthesis of SR 16233: To a solution of 20 mg (0.03 mmol) of 6 in 5 mL of CH_2Cl_2 was added 10 mg (0.07 mmol) of AlCl_3 at 0°C . The mixture was warmed to ambient temperature, stirred for 45 min, and filtered through a thin pad of silica gel (EtOAc). The filtrate was concentrated and dissolved in 10 mL of ether. This ether solution was added to a mixture of AlCl_3 (120 mg, 0.9 mmol) and LiAlH_4 (1 mL of a 1 M solution in ether) in 5 mL of ether at ambient temperature. The mixture was stirred overnight and an aqueous solution of NaOH (15%) was added to the mixture dropwise until a white suspension was formed, and was filtered through a pad of Celite. The filtrate was concentrated and chromatographed (5%-10% MeOH in CHCl_3) to give 6 mg (35%) of SR 16233. The identity of the product was confirmed using ^1H NMR spectroscopy, and the NMR spectrum is shown in FIG. 15. The mass spectrum is shown in FIG. 16.

Citrate salt of 3-hydroxy-7 α -methyl-21-[2'-methoxy-4'-(N,N-diethylamino-methyl)phenoxy]-pregna-1,3,5(10)-triene (SR 16234): The free base SR 16233 (240.5 g, 0.476 mol) was dissolved in a total volume of methanol (1.700 mL, ~ 7 mL/g of base). To the hot solution was added citric acid (93.5 g, 0.487 mol) (2% excess). The combined clear reaction mixture was stirred and crystallization started and quickly proceeded. Finally, the reaction mixture was left overnight. The crystalline material was filtered off and then washed with a small amount of cold methanol and ether. The crystalline material was dried under vacuum to give 309.0 g or 93% product as an off-white powder, m.p. 154-155 C. The ^1H NMR spectrum is shown in FIG. 17, and the mass spectrum is shown in FIG. 18.

EXAMPLE 3

SYNTHESIS OF 3-HYDROXY-7 α -METHYL-21-[2'-METHOXY-4'-(DIETHYLAMINOMETHYL)-PHENOXY]-19-NORPREGNA-1,3,5(10)TRIENE CITRATE ("SR 16234") FROM 21-HYDROXY-

19-NORPREGNA-4-EN-3-ONE, METHOD 2:

SR 16234 was synthesized from 21-hydroxy-19-norpregna-4-en-3-one (3) as illustrated in FIG. 3, using the following procedure.

Synthesis of (7): To a mixture of 1.512 g (5 mmol) of 3 (synthesized in Example 1) and 1.06 g (10.5 mmol) of Et_3N in 25 mL of sulfolane was added 1.03 g (9 mmol) of MsCl dropwise at ambient temperature, and then stirred for 30 min. To this mixture was added

1.34 g (6 mmol) of vanillic acid diethylamide and 1.96 g (6 mmol) of Cs_2CO_3 . The resulting mixture was heated at 110-115°C under a stream of air for 7 h, cooled to 85°C, and 2 mL of isopropyl bromide was added. The mixture was stirred for 1 h, and was diluted with ether and CHCl_3 (100 mL/20 mL), washed with water and brine, dried with sodium sulfate, concentrated, and chromatographed (5% acetone in CH_2Cl_2) to give 804 mg (27%) of 7 as a yellow glass. The identity of the product was confirmed using ^1H NMR spectroscopy. The NMR spectrum is shown in FIG. 19.

Synthesis of (6): To a solution of 302 mg (0.54 mmol) of 7 in 12 mL of THF was added 0.67 mL (1.35 mmol) of a 2.0 M solution of LDA in THF at 0°C. The mixture was stirred for 30 min, warmed to ambient temperature, and treated with 760 mg (5.4 mmol) of MeI. The resulting mixture was refluxed for 1.5 h, quenched into water, and extracted with ether (50 mL). The organic layer was dried (sodium sulfate), concentrated, and chromatographed (15% EtOAc in CH_2Cl_2) to give 233 mg (75%) of 6 as an oil.

SR 16233 and SR 16234 were then synthesized from 6 as described in Example 2.

EXAMPLE 4

SYNTHESIS OF 3-HYDROXY-7 α -METHYL-21-[2'-METHOXY-4'-

(DIETHYLAMINOMETHYL)PHENOXY]-19-NORPREGNA-1,3,5(10)TRIENE CITRATE ("SR 16234") FROM 21-HYDROXY-19-NORPREGNA-4-EN-3-ONE, METHOD 3:

SR 16234 was synthesized from 21-hydroxy-19-norpregna-4-en-3-one (3) as illustrated in FIG. 4, using the following procedure.

Synthesis of (8): To a suspension of alcohol 3 prepared in 84% yield from estrone (12.1 g, 40 mmol) in isopropenylacetate (120 mL) was added silica gel containing 3% sulfuric acid (0.55 g). This reaction mixture was heated at reflux for 4 h (after 2 h no change in TLC 30% EtOAc/hexane). The reaction mixture was filtered through a thin pad of celite/silica gel and the excess reagent was removed in vacuo. The residue became semisolid. The product was dried under high vacuum to give a crude yield (15.6 g or 100%). This compound was used in the synthetic step without further purification. NMR was in accordance with the proposed structure.

Synthesis of (9): Crude product 8 (~40 mmol) was dissolved into acetone (100 mL), water (32 mL), acetic acid (12 mL), and pyridine (7 mL), and to this solution was added sodium acetate (22.8 g). This mixture was cooled in an ice/water bath and N-bromo succinimide (8.9 g or 50 mmol) was added (protected from light). The combined reaction mixture was stirred at 0 to +5°C for 3 h. TLC (20% EtOAc/hexane) showed no starting material. The reaction mixture was poured into an ice cold sat. sodium chloride solution. This mixture was extracted 3 times with ether. The combined ether solution was washed with sat. sodium chloride solution, dried over Na₂SO₄, and evaporated in vacuo to give the crude brominated product. This product was dehydrobrominated in the following way. The bromo compound was dissolved into DMF (72 mL). This solution was added to a hot suspension of lithium bromide (11.6 g) and lithium carbonate (11.6 g) in DMF (300 mL). The reaction mixture was heated at reflux for 1 h. The reaction mixture was cooled and filtered and the residue was washed with some DMF. The filtrate and the washings were combined and added to ice/water. The aqueous solution was extracted with ether 3 times. The combined ether solution was washed with sodium bicarbonate solution 4% and water and dried over sodium sulfate and concentrated to a syrup. The crude material was purified on a silica gel column, eluted with 25% ethyl acetate/hexanes. Yield after recrystallization from ethyl acetate 8.4 g, 62% from the 21-alcohol 3. NMR and MS were in agreement with the proposed structure.

Synthesis of (10): To a stirred suspension of cuprous iodide (4.16 g, 22 mmol) in dry ether (30 mL), was added a 1.5 M methyl lithium, lithium bromide complex in ether (20.0 mL, 30 mmol). To this solution, cooled to 0-5°C was added the steroid acetate 9 (2.5 g, 7.3 mmol) dissolved into ether (30 mL) over a period of 10 min. Stirring was continued for an additional 15 min and then the reaction mixture was quenched with a saturated ammonium chloride solution. The aqueous phase was separated and extracted twice with ether. The combined organic phase was washed twice with ammonium chloride solution and then water and dried over MgSO₄. Evaporation of the solvent gave the crude material as a gum. Treatment of the crude material with p-toluene sulfonic acid in dichloromethane gave the target compound in a yield of 1.8 g, 69%. NMR and MS were in agreement with the proposed structure.

Synthesis of (11): To the acetate **10** (0.53 g, 1.48 mmol) dissolved into methanol (20 mL) was added KOH (40 mg) and the reaction mixture was stirred at room temperature for 2 h. TLC showed complete reaction. The solvent was removed under reduced pressure. Water was added to the residue and the aqueous phase was extracted with ether 3 times.

5 The combined ether phase was washed with saturated sodium chloride solution, dried over Na_2SO_4 and evaporated to give a gum (0.48 g). Addition of some ether induced crystallization. The crystals were collected to give 0.32 g of off-white (yellowish) crystals. Total yield 0.48 g, 100%. NMR and MS were in agreement with the proposed structure; the ^1H NMR spectrum of the product is shown in FIG. 20.

10 **Synthesis of (12):** A mixture of the steroid alcohol **11** (0.30 g, 0.95 mmol), vanillin (0.310 g, 2.04 mmol), and triphenylphosphine (0.53 g, 2.04 mmol) was dissolved into THF (8 mL). To this solution was added dropwise a solution of diethylazadicarboxylate (0.37 g, 2.1 mmol). After stirring for 2 h the reaction was complete. Most of the solvent was evaporated and the total residue was chromatographed on a silica gel column and was eluted
15 with 25% ethyl acetate/hexane. The fractions that contained the target compound were combined and evaporated to give 0.366 g of target compound. Yield 0.366 g, 85.5%. NMR and MS were in agreement with the proposed structure; the ^1H NMR spectrum of the product is shown in FIG. 21.

Synthesis of (13): To a stirred solution of the aldehyde **12** (0.150 g, 0.33 mmol) in
20 dichloroethane (4 mL) was added diethylamine (0.68 mL, 0.66 mmol). After 15 min of stirring (the solution became reddish) sodium-triacetoxy borohydride (0.097 g or 0.46 mmol) was added in two portions. After stirring for 2 h the reaction was complete. The reaction mixture was diluted with some dichloromethane and was then poured into an aqueous solution of sodium bicarbonate (4%). The organic phase was separated and the
25 aqueous phase was extracted once more with dichloromethane. The combined organic phase was washed with sodium bicarbonate solution and saturated sodium chloride solution was dried over Na_2SO_4 . Evaporation of the solvent gave a syrup that was purified on a silica gel column and eluted with 5% methanol/dichloromethane. The fractions that contained the target compound were evaporated to give 0.113 g, 67% of pure target compound. NMR and

MS were in agreement with the proposed structure; the ^1H NMR spectrum of the product is shown in FIG. 22.

Synthesis of SR 16233: To a stirred solution of **13** (0.085 g) in glacial acetic acid (3 ml) was added CuCl_2 (0.085 g). The mixture was stirred and heated at 100-105°C for 24 hours. The reaction mixture was cooled and poured into ice-cold water. The aqueous phase was extracted twice with dichloromethane. The organic phase was washed with NaHCO_3 and water and was dried over MgSO_4 . Evaporation of the solvent gave the target compound, which was then recrystallized from ethanol. Identity of the product, **SR 16233**, was confirmed using ^1H NMR spectroscopy.

EXAMPLE 5

SYNTHESIS OF 3-HYDROXY-7 α -METHYL-21-[2'-METHOXY-4'-(DIETHYLAMINOMETHYL)-PHENOXY]-19-NORPREGNA-1,3,5(10)TRIENE CITRATE ("SR 16234") FROM 21-HYDROXY-19-NORPREGNA-4-EN-3-ONE, METHOD 4:

SR 16234 was synthesized from crude 21-hydroxy-19-norpregna-4-en-3-one (**3**) as illustrated in FIG. 5, using the following procedure.

Synthesis of 21-Hydroxy-19-norpregna-4-en-3-one 21-acetate (34**):** Crude product **3** prepared in Example 1 (18.0 g) was dissolved in pyridine (100 mL), and to this solution was added acetate anhydride (25 mL). The reaction was stirred at room temperature for 5 h and then poured into ice/water. The aqueous solution was extracted with ether twice. The combined ether extract was washed with water, ice-cold 4% hydrochloric acid solution, and water, and then dried over sodium sulfate and evaporated to give a semi-crystalline compound. This material was purified by chromatography to give 14.0 g of **35** (86%). ^1H NMR (CDCl_3) δ 0.66 (s, 3H), 2.04 (s, 3H), 4.06 (m, 2H), 5.83 (s, 1H).

Synthesis of 3,21-Dihydroxy-19-norpregna-3,5-dien-diacetate (8**):** To a suspension of **35** (12.1 g, 40 mmol) in isopropenylacetate (120 mL) was added silica gel containing 3% sulfuric acid (0.55 g). This reaction mixture was heated at reflux for 4 h, filtered through a thin pad of Celite, and excess reagent removed to give a semisolid

product. The product was dried under high vacuum to give 15.6 g of crude product 8 (100%). The product from this reaction was used in the next step for the preparation of 21-hydroxy-19-norpregna-4,6-dien-3-on-21-acetate (37) without further purification. ¹H NMR (CDCl₃) was in accordance with the proposed structure.

5 **Synthesis of 21-Hydroxy-19-norpregna-4,6-dien-3-on-21-acetate (9):** Crude product 8 (15.6 g, ~40 mmol) was dissolved in a mixture of acetone (100 mL), water (32 mL), acetic acid (12 mL), and pyridine (7 mL), and to this solution was added sodium acetate (22.8 g). This mixture was cooled in an ice/water bath, and N-bromo-succinimide (8.9 g, 50 mmol) was added (protected from light). The combined reaction mixture was
10 stirred at 0° to +5 C for 3 h. The reaction mixture was poured into an ice-cold saturated sodium chloride solution and then extracted 3 times with ether and the ether extracts combined. The combined ether extract was washed with saturated sodium chloride solution, dried over Na₂SO₄, and evaporated under vacuum to give the crude brominated product.. This product was dehydrobrominated as follows: the bromo compound was dissolved in
15 dimethyl formamide (DMF, 72 mL) and then added to a hot suspension of lithium bromide (11.6 g) and lithium carbonate (11.6 g) in DMF (300 mL). The reaction mixture was heated at reflux for 1 h, then cooled and filtered. The residue was washed with DMF. The filtrate and the washings were combined and added to ice/water. The aqueous solution was extracted with ether three times and the extracts combined. The combined ether solution
20 was washed with 4% sodium bicarbonate solution and water, dried over sodium sulfate, and concentrated to a syrup. The crude material was purified on a silica gel column eluting with 25% ethyl acetate/hexanes to yield, after recrystallization from ethyl acetate, 9.2 g (68%) of 9 from 8. ¹H NMR (CDCl₃) δ 0.69 (s, 3H), 2.05 (s, 3H), 4.08 (m, 2H), 5.78 (s, 1H), 6.20 (m, 2H). MS (DCI) m/z 343 (M+H).

25 **Synthesis of 21-Hydroxy-7α-methyl-19-norpregna-4-en-3-on-21-acetate (10):** To a stirred suspension of cuprous iodide (1.14 g, 6 mmol) in dry ether (25 mL) was added a 1.5 M (9.6 mmol) methyl lithium/lithium bromide complex in 6.4 mL of ether. This solution was cooled to 0-5° C, and then the acetate 9 (0.69 g, 2 mmol) dissolved in ether (40 mL) was added over a period of 10 min. Stirring was continued for an additional 15 min,
30 and then the reaction mixture was quenched with a saturated ammonium chloride solution.

The aqueous phase was separated and extracted three times with ether. The combined organic phase was washed twice with ammonium chloride solution and once with water, and then dried over MgSO_4 . Evaporation of the solvent gave the crude material as a gum. Treatment of the crude material with *p*-toluenesulfonic acid in dichloromethane gave 0.48 g
5 (67%) of crude acetate **10**. ^1H NMR (CDCl_3) δ 0.67 (s, 3H), 0.78 (d, 3H), 2.05 (s, 3H), 4.06 (m, 2H), 5.83 (s, 1H). MS (DCI) m/z 359 (M+H).

Synthesis of 21-Hydroxy-7 α -methyl-19-norpregna-1,3,5(10)-triene (35): To a solution of **10** (0.400 g, 1.04 mmol) in 4.5 mL of acetic acid was added copper(II) chloride (0.400 g). This reaction mixture was heated at 100°C for 2 h. After 1 h, the reaction
10 mixture was cooled and poured into water. The aqueous phase was extracted three times with ether. The combined ether phase was washed with water, sodium bicarbonate, and sodium chloride solution and then dried over sodium sulfate. Evaporation of the solvent gave the crude product in quantitative yield (some phenolic acetate seemed to be present). The crude material was hydrolyzed with potassium hydroxide in a mixture of
15 methanol/water. Extraction with dichloromethane and evaporation of the solvent gave 0.28 g (85%) of purified material **35**. ^1H NMR (CDCl_3) δ 0.59 (s, 3H), 0.78 (d, 3H), 3.55 (m, 2H), 6.48 (d, 1H), 6.58 (q, 1H), 7.09 (d, 1H).

Synthesis of 3,21-Dihydroxy-19-norpregna-1,3,5(10)-triene-bis-mesylate (36): Alcohol **35** (0.945 g, 3 mmol) was dissolved in dichloromethane (15 mL) and triethylamine (2.0 mL). This solution was cooled to 0-5°C (ice/water bath), and methanesulfonyl chloride (0.90 g, 7.8 mmol) was added dropwise. The reaction mixture was stirred for 2 h at 0°C, then poured into ice/water. The dichloromethane was separated, and the water phase was extracted once more with dichloromethane. The dichloromethane was washed with water and then sodium chloride solution and dried over sodium sulfate. Evaporation of the
25 solvent gave 1.34 g (95%) of **36** as a slightly sticky, white crystalline material. ^1H NMR was in agreement with the proposed structure. The crude material was used without further purification in the preparation of **37**.

Synthesis of 3-Hydroxy-7 α -methyl-21-(2'-methoxy-4'-N,N-diethylamido)phenoxy-19-norpregna-1,3,5(10)-triene-3-mesylate (37): To a solution of 36 (1.20 g, 2.55 mmol) in 20 mL of DMF was added vanillic acid diethylamide (0.68 g, 3.06 mmol) and potassium carbonate (1.0 g, 3.06 mmol). The reaction mixture was heated at 90°C for 2 h, then cooled to room temperature and poured into ice/water. Some crystalline material appeared and was filtered off. The aqueous phase was extracted with ether twice. The combined ether phase was washed with water and sodium chloride solution. Evaporation of the solvent gave 1.39 g (91%) of off-white material 37. ¹H NMR (CDCl₃) δ 0.68 (s, 3H), 0.86 (d, 3H), 3.13 (s, 3H), 3.89 (s, 3H), 3.95 (m, 2H), 6.8-7.05 (aromatic, 4H), 7.32 (d, 1H). MS (DCI) m/z 597 (M+H).

Synthesis of (SR 16233): A solution of crude 37 (0.500 g, 0.84 mmol) in ether (15 mL) was added dropwise to a suspension of LAH (0.160 g) in ether (10 mL). The reaction mixture was stirred overnight. The residue was poured into CH₂Cl₂. The CH₂Cl₂ phase was washed with water and then sodium chloride and evaporated to give a crude material that was purified by column chromatography to give 0.378 g (95%) of SR 16233. Identity of the product, SR 16233, was confirmed using ¹H NMR spectroscopy. MS (DCI) m/z 505 (M+H).

Synthesis of SR 16234: The free base SR 16233 (240.5 g, 0.476 mol) was dissolved in methanol (total volume 1.700 mL, ~7 mL/g of base). To the hot solution was added citric acid (93.5 g, 0.487 mol) (2% excess). As the clear reaction mixture was stirred, crystallization began and proceeded fast. Finally the reaction mixture was left overnight. The crystalline material was filtered off and washed with a small amount of cold methanol and ether. The crystalline material was dried under vacuum to give 316 g of SR 16234 (95%).

EXAMPLE 6**SYNTHESIS OF 3-HYDROXY-7 α -METHYL-21-[2'-METHOXY-4'-(DIETHYLAMINOMETHYL)-PHENOXY]-19-NORPREGNA-1,3,5(10)TRIENE CITRATE ("SR 16234") FROM 21-HYDROXY-19-NORPREGNA-4-EN-3-ONE, METHOD 5:**

5 SR 16234 was synthesized from crude 21-hydroxy-19-norpregna-4-en-3-one (3) as illustrated in FIG. 9, using the following procedure.

Synthesis of (20): To a solution of 1.125 g (3.7 mmol) of crude product 3 in 60 mL of isopropanol was added 0.188 g (0.7 mmol) of iodine. The resulting mixture was refluxed under a stream of oxygen for 2 h, then cooled to room temperature. The mixture was
10 diluted with ether (150 mL), washed with water and then brine, dried, and concentrated to give an oil. Chromatographic separation (40% EtOAc in hexanes) gave 0.814 g (61%) of 20. ¹H NMR (CDCl₃) δ 0.64 (s, 3H), 1.32 (d, 3H, J = 1.9 Hz), 1.34 (d, 3H, J = 1.9 Hz), 2.77 (dd, 1H, J = 16.8 Hz, 3.3 Hz), 3.68 (m, 2H), 4.61 (m, 1H), 7.07 (dd, 1H, J = 8.4 Hz, 3.0 Hz), 7.33 (d, 1H, J = 8.4 Hz), 7.55 (d, 1H, J = 3.0 Hz).

15 **Synthesis of (4):** To a solution of 0.814 g (2.3 mmol) of 20 in 20 mL of CH₂Cl₂ was added 5 mL of dihydropyran (DHP) and 0.05 g of pyridium *p*-toluenesulfonate. The mixture was stirred at room temperature for 2 h, and Et₃N (0.5 mL) was added. The mixture was diluted with ether (30 mL), washed with water and then brine, dried, and concentrated to give 1.01 g (100%) of (4), which was used in the next reaction without purification. ¹H
20 NMR (CDCl₃) δ 0.64 (s, 3H), 1.32 (d, 3H, J = 1.9 Hz), 1.34 (d, 3H, J = 1.9 Hz), 2.76 (dd, 1H, J = 16.8 Hz, 3.3 Hz), 3.35-3.91 (m, 4H), 4.10 (m, 2H), 7.07 (dd, 1H, J = 8.4 Hz, 3.0 Hz), 7.33 (d, 1H, J = 8.4 Hz), 7.55 (d, 1H, J = 3.0 Hz). MS (DCI) *m/z* 441 (M+H).

Synthesis of (5): To a solution of 0.660 g (1.5 mmol) of 4 in 25 mL of THF was added 2.25 mL (4.5 mmol) of a 2.0 M solution of lithium diisopropyl amide (LDA) in THF
25 at 0°C. The mixture was stirred for 40 min, warmed to room temperature, and treated with 1 mL of MeI. The resulting mixture was refluxed for 40 min, then cooled to 0°C. Methanol (10 mL) and TsOH (1 g) were added, and the mixture was stirred for 2 h. The mixture was diluted with ether (50 mL), washed with saturated NaHCO₃ and then brine, dried, concentrated, and chromatographed (25% EtOAc in hexanes) to give 0.447 g (80%) of (5).
30 ¹H NMR (CDCl₃) δ 0.64 (s, 3H), 1.11 (d, 3H, J = 7.6 Hz), 1.32 (d, 3H, J = 1.5 Hz), 1.34 (d,

3H, $J = 1.5$ Hz), 3.70 (m, 2H), 4.61 (m, 1H), 7.07 (dd, 1H, $J = 8.4$ Hz, 3.0 Hz), 7.33 (d, 1H, $J = 8.4$ Hz), 7.55 (d, 1H, $J = 3.0$ Hz).

Synthesis of (28): To a solution of 0.225 g (0.6 mmol) of **5** in 30 mL of methanol was added 0.050 g of 10% Pd/C. The mixture was hydrogenated under 3 atm. of H_2 for 22 h, then filtered through a thin pad of silica gel. The filtrate was concentrated and chromatographed (20% EtOAc in hexanes) to give 0.168 g (77%) of **28**. 1H NMR ($CDCl_3$) δ 0.64 (s, 3H), 0.84 (d, 3H, $J = 7.1$ Hz), 1.32 (d, 3H, $J = 1.9$ Hz), 1.34 (d, 3H, $J = 1.9$ Hz), 3.69 (m, 2H), 4.61 (m, 1H), 6.61-6.73 (m, 2H), 7.21 (m, 1H).

Synthesis of (35): To a solution of 0.108 g (0.3 mmol) of **28** in 20 mL of CH_2Cl_2 was added 0.120 g (0.9 mmol) of $AlCl_3$ at room temperature. The resulting mixture was stirred for 2.5 h, then filtered through a thin pad of silica gel (with ether as eluent). The filtrate was concentrated to give 0.084 g (92%) of **35**. 1H NMR ($CDCl_3$) δ 0.64 (s, 3H), 0.84 (d, 3H, $J = 7.1$ Hz), 3.69 (m, 2H), 6.60-6.72 (m, 2H), 7.22 (m, 1H).

Synthesis of (36): Alcohol **35** (0.945 g, 3 mmol) was dissolved in dichloromethane (15 mL) and triethylamine (2.0 mL). This solution was cooled to 0-5°C (ice/water bath), and methanesulfonyl chloride (0.90 g, 7.8 mmol) was added dropwise. The reaction mixture was stirred for 2 h at 0°C, then poured into ice/water. The dichloromethane was separated, and the water phase was extracted once more with dichloromethane. The dichloromethane was washed with water and then sodium chloride solution and dried over sodium sulfate. Evaporation of the solvent gave 1.34 g (95%) of **36** as a slightly sticky, white crystalline material. 1H NMR was in agreement with the proposed structure. The crude material was used without further purification in the preparation of **37**.

Synthesis of (37): To a solution of **36** (1.20 g, 2.55 mmol) in 20 mL of DMF was added vanillic acid diethylamide (0.68 g, 3.06 mmol) and potassium carbonate (1.0 g, 3.06 mmol). The reaction mixture was heated at 90°C for 2 h, then cooled to room temperature and poured into ice/water. Some crystalline material appeared and was filtered off. The aqueous phase was extracted with ether twice. The combined ether phase was washed with water and sodium chloride solution. Evaporation of the solvent gave 1.39 g (91%) of off-white material **37**. 1H NMR ($CDCl_3$) δ 0.68 (s, 3H), 0.86 (d, 3H), 3.13 (s, 3H), 3.89 (s, 3H), 3.95 (m, 2H), 6.8-7.05 (aromatic, 4H), 7.32 (d, 1H). MS (DCI) m/z 597 (M+H).

-47-


Synthesis of SR 16233: A solution of crude 37 (0.500 g, 0.84 mmol) in ether (15 mL) was added dropwise to a suspension of LAH (0.160 g) in ether (10 mL). The reaction mixture was stirred overnight. The residue was poured into CH₂Cl₂. The CH₂Cl₂ phase was washed with water and then sodium chloride and evaporated to give a crude material that was purified by column chromatography to give 0.378 g (95%) of **SR 16233**. Identity of the product, **SR 16233**, was confirmed using ¹H NMR spectroscopy. MS (DCI) m/z 505 (M+H).

Synthesis of SR 16234: The free base **SR 16233** (240.5 g, 0.476 mol) was dissolved in methanol (total volume 1.700 mL, ~7 mL/g of base). To the hot solution was added citric acid (93.5 g, 0.487 mol) (2% excess). As the clear reaction mixture was stirred, crystallization began and quickly proceeded. Finally the reaction mixture was left overnight. The crystalline material was filtered off and washed with a small amount of cold methanol and ether. The crystalline material was dried under vacuum to give 316 g of **SR 16234** (95%).

EXAMPLE 7

BIOLOGICAL EVALUATION:

Compound SR 16312, having the structural formula



was synthesized as described in Example 4 without methylation at the 7-position of the steroid nucleus. The compound was evaluated for its inhibitory effect on androgen-independent human prostate cancer cells, DU145 cells and PC-3 cells, in a standard *in vitro* androgen-independent human prostate cancer assay.

DU145 and PC-3 human prostate cancer cell lines were obtained from the American Type Culture Collection, Rockville, MD. Eagle's minimum essential medium, RPMI-1640

medium, fetal calf serum, nonessential amino acids, and sodium pyruvate were purchased from Sigma, St. Louis, MO.

PC-3 cells were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS) and DU145 cells in Eagle's minimum essential medium (MEM) supplemented with 10% FCS. 1% nonessential amino acids, and 1mM pyruvate. All cells were cultured at 37°C in a 5% CO₂/95% air atmosphere in 100% humidity. To initiate the growth inhibition assay, cells were seeded at 5000 cells per well in a 24-well plate in 500 µl of the appropriate medium for the individual cell line and cultured under the same conditions described above. Cells were allowed to attach for 24 hours, then test compound was added in 10 µl aliquots. The test compound was dissolved in DMSO first and diluted with medium. The final DMSO concentration was kept at 0.1%. Control cultures received vehicle alone. The medium in each well was changed every other day, with fresh test compound added. After 7 days of treatment, viable cells in each well were measured using the MTT assay as described in "Cellular Proliferation Assay," in *Protocols and Applications*, 3rd Edition (Promega Corporation).

To perform the MTT assay, on Day 9, medium from each well was removed and 100 µl of fresh medium was added, followed by 15 µl of tetrazolium dye solution. The incubation was continued for 4 hours, and then 100 µl of solubilization/stop solution was delivered into each well. (During the four-hour incubation, viable cells converted the tetrazolium component of the dye solution to formazan, which gives a blue color.)


The plate was kept at room temperature overnight and the blue color measured at 575 nm on an ELISA plate reader. Based on the optical density of samples treated with the test compound and that of the control, the inhibitory effect of SR 16312 was evaluated. The results are set forth in FIG. 21. As may be seen in the figure, the compound resulted in virtually 100% inhibition at concentrations of 5 µM or higher

EXAMPLE 8

7- α METHYLATION OF 6-KETOESTRADIOL USING A THP PROTECTING GROUP:

The stereoselective methylation of a 6-keto steroid according to the following scheme was accomplished as described below.

-49-



Synthesis of 3,17β-Dihydroxy-6-keto-estra-1,3,5(10) triene-3,17-

5 **ditetrahydropyranyl ether(38).** To a solution of 0.100 gm of 6-ketoestradiol in 2.0 ml of dichloromethane was added 0.5 g of dihydropyran and 0.04 gm. of TsOH. The reaction was stirred for 18 h at room temperature under argon. The reaction was poured into 4% sodium bicarbonate and extracted with additional dichloromethane. The organic fractions were combined and dried over magnesium sulfate and evaporated to dryness to afford 0.157 gm

10 (96% yield) of an oil 38. The reaction was not further purified and was used in the following reaction as is.

Synthesis of 3,17β-Dihydroxy-6-keto-7α-methyl-estra-1,3,5(10) triene (39). To a solution of 0.140 g of diTHP analog 38 in 5 mL of dry tetrahydrofuran was added 0.47 mL of 2.0 M lithium diisopropylamide in 2.0 mL of tetrahydrofuran at room temperature. The

15 reaction was stirred for 1.0 h. and then 0.25 mL of methyl iodide was added. The mixture was refluxed for 3.0 h., cooled to 0°C, and diluted with 5.0 mL of methanol. To this mixture was added 0.025 g of p-toluene sulfonic acid. The reaction mixture was stirred for


an additional 2.0 h. Triethyl amine (1.0 ml) was then added and the reaction mixture evaporated at reduced pressure to yield 0.155 g of crude **39**. The crude mixture was analyzed by NMR and showed only one isomer at C-7 as determined by the presence of only one doublet at 1.05 ppm. The crude product was diluted with chloroform and
5 chromatographed on silica gel using 30% ethylacetate/hexane to afford pure **39** as an oil. ¹H NMR 7.36–7.0 (m, 3H, aromatic), 3.70 (t, 1H, 17-H) 1.05 (d, J= 7.5 Hz., 7 α -CH₃) 0.74 (s, 18-CH₃)

Synthesis of 7 α -methylestradiol: Compound **39** may be converted into 7 α -methylestradiol using standard reaction conditions. For example, 10% Pd/C can be to a
10 solution of **39** in methanol and then hydrogenated under 3 atm. of H₂ for several hours. The hydrogenated product may then be collected by filtration through a thin pad of silica gel.

-51-

CLAIMS

1. A compound having the structural formula (I)



wherein:

X is lower hydrocarbyl;

R¹ is CR¹¹R¹², wherein R¹¹ and R¹² are hydrogen or lower alkyl;


R² is selected from the group consisting of hydrogen, hydroxyl, alkyl, -OR¹³, and -SR¹³ wherein R¹³ is alkyl;

R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consisting of hydrogen and lower alkyl;

R⁹ is hydrogen or hydrocarbyl; and

R¹⁰ is methyl or ethyl.


2. The compound of claim 1, having the structural formula (II)



wherein X is lower alkyl.

3. A compound having the structural formula (III)

(III)



wherein:

R^1 is $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, $-OR^{13}$, and $-SR^{13}$ wherein R^{13} is alkyl;

R^3 is selected from the group consisting of hydrogen and hydrocarbyl;

R^4 , R^5 , and R^7 are independently hydrogen or lower alkyl;


R^9 is hydrogen or hydrocarbyl;

R^{10} is methyl or ethyl; and

R^{19} is hydroxyl, hydroxymethyl, protected hydroxyl, protected hydroxymethyl, activated hydroxyl, or activated hydroxymethyl.

4. The compound of claim 3, having the structural formula (IV)

(IV)



wherein:


-53-

R^3 is hydrogen or lower alkyl; and

R^{19} is hydroxyl, hydroxymethyl, -O-acetyl, or -O-tetrahydropyranyl.

5. A compound having the structural formula (V)

(V)



wherein:

R^1 is hydrogen or $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, $-OR^{13}$, and $-SR^{13}$ wherein R^{13} is alkyl;

R^3 is selected from the group consisting of hydrogen and hydrocarbyl;

R^4 , R^5 , and R^7 are independently selected from the group consisting of hydrogen and lower alkyl;


R^{6Mod} is selected from the group consisting of hydrogen, alkyl, acyl, $-C(O)$ -aryl, $-C(O)$ -alkyl, hydroxyl-protecting groups, and hydroxyl-activating groups;

R^{8a} is selected from the group consisting of hydrogen, hydroxyl, oxo, and $-OR^{18}$ wherein R^{18} is lower alkyl or lower acyl;

R^9 is hydrogen or alkyl;

R^{10} is methyl or ethyl; and


R^{20} is hydroxyl, hydroxymethyl, protected hydroxyl, protected hydroxymethyl, activated hydroxyl, activated hydroxymethyl, or



in which m is zero or 1, p is an integer in the range of 1 to 7 inclusive, t is zero or 1, with the proviso that when R^{8a} is oxo, t is 1, and when R^{8a} is hydrogen, t is zero, and R²¹ and R²² are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

5 Q¹, Q², Q³, and Q⁴ are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

6. The compound of claim 5, having the structural formula (VI)



15 wherein:


R³ is hydrogen or lower alkyl;

R^{6Mod} is hydrogen or a hydroxyl-protecting group;

R^{8b} is selected from the group consisting of hydrogen, hydroxyl, and oxo; and

20 R¹⁹ is hydroxyl, hydroxymethyl, protected hydroxyl, protected hydroxymethyl, activated hydroxyl, or activated hydroxymethyl.

7. A compound having the structural formula (XXVII)



30

wherein:

R^1 is hydrogen or $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, $-OR^{13}$, and
5 $-SR^{13}$ wherein R^{13} is alkyl;

R^4 , R^5 , and R^7 are independently selected from the group consisting of hydrogen
and lower alkyl;


R^{6Mod} is selected from the group consisting of hydrogen, alkyl, acyl, $-C(O)-aryl$,
 $-C(O)-alkyl$, hydroxyl-protecting groups, and hydroxyl-activating groups;

10 R^{10} is methyl or ethyl; and

R^{19} is hydroxyl, hydroxymethyl, protected hydroxyl, protected hydroxymethyl,
activated hydroxyl, or activated hydroxymethyl.

8. A compound having the structural formula (XXVIII)

(XXVIII)



wherein:

R^1 is hydrogen or $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl;

25 R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, $-OR^{13}$, and
 $-SR^{13}$ wherein R^{13} is alkyl;


R^4 , R^5 , and R^7 are independently selected from the group consisting of hydrogen
and lower alkyl;

30 R^{10} is methyl or ethyl; and

-56-

R^{19} is hydroxyl, hydroxymethyl, protected hydroxyl, protected hydroxymethyl, activated hydroxyl, or activated hydroxymethyl.

9. A compound having the structural formula (VII)



wherein:

R^3 is hydrogen or hydrocarbyl;

R^{6Mod} is selected from the group consisting of hydrogen, alkyl, acyl, $-C(O)-$ aryl, and $-C(O)-$ alkyl, hydroxyl-protecting groups, and hydroxyl-activating groups;

R^{8b} is selected from the group consisting of hydrogen, hydroxyl, and oxo;

m is zero or 1;

p is an integer in the range of 1 to 7 inclusive;


t is zero or 1, with the proviso that when R^{8a} is oxo, t is 1, and when R^{8a} is hydrogen, t is zero, and;

R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

Q^1 , Q^2 , Q^3 , and Q^4 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

-57-

10. A compound having the structural formula (XVI)



wherein:

10 R¹ is CR¹¹R¹², wherein R¹¹ and R¹² are hydrogen or lower alkyl;

R² is selected from the group consisting of hydrogen, hydroxyl, alkyl, -OR¹³, and -SR¹³ wherein R¹³ is alkyl;

R³ is hydrogen or hydrocarbyl;

15 R⁴ and R⁵ are independently selected from the group consisting of hydrogen and lower alkyl;

R⁷ is hydrogen or lower alkyl;

R¹⁰ is methyl or ethyl;

m is zero or 1;


p is an integer in the range of 1 to 7 inclusive;

20 R²¹ and R²² are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

Q¹, Q², Q³, and Q⁴ are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino, or a pharmacologically acceptable acid addition salt thereof.

25

11. The compound of claim 10, having the structural formula (XVII)



10 wherein:

m is zero or 1;


p is an integer in the range of 1 to 7 inclusive;

R³ is hydrogen or lower alkyl;

15 R²¹ and R²² are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

Q¹, Q², Q³, and Q⁴ are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino, or a pharmacologically acceptable acid addition salt thereof.

20 12. A method for synthesizing 21-hydroxy-19-norpregna-4-en-one and substituted analogs thereof, comprising treating a starting material having the structural formula (I)



30

-59-

with an alkali metal in the presence of ammonia or an alkylamine, wherein, in formula (I),

X is lower hydrocarbyl;

R^1 is $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, $-OR^{13}$, and

5 $-SR^{13}$ wherein R^{13} is alkyl;


R^4 , R^5 , R^6 , and R^7 are independently selected from the group consisting of hydrogen and lower alkyl;

R^9 is hydrogen or hydrocarbyl; and

R^{10} is methyl or ethyl, resulting in a reaction product having the structural formula (

10 (VIII)


(VIII)



15

13. A method for synthesizing 21-hydroxy-19-norpregna-4-en-3-one, comprising
20 treating (IX)

(IX)



25


wherein X and Y are independently lower alkyl, with an alkali metal in the presence of
30 ammonia or an alkylamine.

-60-

14. A method for synthesizing a 7-alkyl-6-keto-1,3,5(10) estratriene, comprising contacting a 19-norpregna-4-en-3-one with gaseous oxygen in the presence of base, followed by reaction of the intermediate so provided with an alkyl halide.

15. A method for synthesizing a 7-alkyl-6-keto-1,3,5(10) estratriene having the structural formula (VIa)

(VIa)



wherein:

R^{3A} is lower alkyl;

R^{6Mod} is hydrogen or a hydroxyl-protecting group;


R^{8a} is hydrogen or oxo; and

R^{19} is hydroxyl, hydroxymethyl, protected hydroxyl, or protected hydroxymethyl,

the method comprising the steps of

(a) contacting the 19-norpregna-4-en-3-one (X)

(X)




with oxygen in the presence of a base, and

(b) protecting the 3-hydroxyl group thus formed with a protecting group, and

-61-

(c) treating the 3-hydroxyl-protected intermediate with an alkyl halide.

16. A method for synthesizing an anti-estrogenic steroid having the structural formula (XI)



wherein:

R^1 is $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl, and when R^1 is absent, R^1 is hydrogen or alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, and $-OR^{13}$ wherein R^{13} is alkyl;

R^{3A} is lower alkyl;

R^4 , R^5 , R^6 , and R^7 are independently selected from the group consisting of hydrogen and lower alkyl; and

R^{10} is methyl or ethyl;

m is zero or 1;

p is an integer in the range of 1 to 7 inclusive;


R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

Q^1 , Q^2 , Q^3 , and Q^4 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino, said method comprising:

(a) providing a starting material having the structural formula (XII)


-62-

5 (XII)



- (b) converting the -OH group to an -O-LG moiety wherein LG is a leaving group
 10 displaceable by nucleophilic attack, and displacing LG by reaction with a hydroxyl-
 containing compound having the structural formula (XIII)

15 (XIII)




15

- (c) oxidizing the A ring and providing a 6-keto moiety by exposure to gaseous
 oxygen in the presence of base;
 20 (d) protecting the 3-hydroxyl group with a protecting group;
 (e) contacting the product of step (d) with an alkyl halide, to provide a 7 α -alkyl
 substituent; and
 (f) reducing the compound so provided to remove all keto moieties,
 with the proviso that steps (c) and (d) may occur prior to or simultaneously with
 25 step (b).

17. The method of claim 16, further including (g) treating the product of step (f)
 with an acid to produce an acid addition salt.

30

18. A method for synthesizing an anti-estrogenic steroid having the structural formula (XI)



wherein:

R^1 is $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, and $-OR^{13}$ wherein R^{13} is alkyl;

R^{3A} is lower alkyl;

R^4 , R^5 , R^6 and R^7 are independently selected from the group consisting of hydrogen and lower alkyl; and

R^{10} is methyl or ethyl.

m is zero or 1;

p is an integer in the range of 1 to 7 inclusive;


R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

Q^1 , Q^2 , Q^3 , and Q^4 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino, said method comprising:

(a) providing a starting material having the structural formula (XII)

-64-

5 (XII)



10 (b) protecting the -OH group and the oxy group with protecting groups, thereby converting the compound into a diene;


(c) deprotecting the oxy group to form a dienone;

(d) contacting the product of step (b) with an alkyl lithium in the presence of a lithium halide, to provide a 7 α -alkyl substituent;


15 (e) deprotecting the -OH group;

(f) effecting reaction between the -OH group and an aldehyde having the structural formula (XIV)


20 (XIV)



to result in an intermediate having the structural formula (XV)




(g) treating (XV) with an alkylamine having the structure $HNR^{21}R^{22}$ under reaction conditions effective to produce the amine (XVI)



(h) oxidizing and thereby aromatizing the A ring by reaction with a suitable oxidizing agent or agents.

19. The method of claim 18, further including (g) treating the product of step (h) with an acid to produce an acid addition salt.

20. A method for synthesizing an anti-estrogenic steroid having the structural formula (XI)



wherein:

R^1 is $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl, and when $r1$ is absent, R^1 is hydrogen or alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, and $-OR^{13}$ wherein R^{13} is alkyl;

R^{3A} is lower alkyl;

R^4 , R^5 , R^6 , and R^7 are independently selected from the group consisting of hydrogen and lower alkyl; and

R^{10} is methyl or ethyl;

m is zero or 1;

p is an integer in the range of 1 to 7 inclusive;


R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

Q^1 , Q^2 , Q^3 , and Q^4 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino, said method comprising:

(a) providing a starting material having the structural formula (XII)


-67-

5 (XII)



- (b) converting the -OH group to an -O-LG moiety wherein LG is a leaving group
 10 displaceable by nucleophilic attack, and displacing LG by reaction with a hydroxyl-
 containing compound having the structural formula (XIII)

(XIII)
 15



- (c) oxidizing the A ring to form a diene and protecting resulting the 3-hydroxyl
 group with a protecting group;
 20 (d) converting the protected 3-hydroxyl group into an oxo group thereby forming
 a dienone;
 (e) contacting the product of step (d) with an alkyl lithium in the presence of
 lithium halide, to provide a 7 α -alkyl substituent; and
 (f) reducing the compound so provided to remove all keto moieties.

25


21. The method of claim 20, further including (g) treating the product of step (f)
 with an acid to produce an acid addition salt.

-68-

22. A pharmaceutical composition for administration of a therapeutic agent, comprising a therapeutically effective amount of the compound of claim 8, in combination with a pharmaceutically acceptable carrier.


23. A pharmaceutical composition for administration of a therapeutic agent, comprising a therapeutically effective amount of the compound of claim 9, in combination with a pharmaceutically acceptable carrier.

24. A pharmaceutical composition for administration of a therapeutic agent, comprising a therapeutically effective amount of a compound having the structural formula



or a pharmaceutically acceptable acid addition salt thereof, in combination with a pharmaceutically acceptable carrier.

25. A pharmaceutical composition for administration of a therapeutic agent, comprising a therapeutically effective amount of a compound having the structural formula




or a pharmaceutically acceptable acid addition salt thereof, in combination with a pharmaceutically acceptable carrier.

26. A method for treating a human patient suffering from a prostate disorder, comprising administering to the patient, within the context of an effective dosage regimen, a therapeutically effective amount of the compound of claim 8.


27. A method for treating a human patient suffering from a prostate disorder, comprising administering to the patient, within the context of an effective dosage regimen, a therapeutically effective amount of the compound of claim 9.

28. A method for treating a human patient suffering from a prostate disorder, comprising administering to the patient, within the context of an effective dosage regimen, a therapeutically effective amount of a compound having the structural formula



or a pharmaceutically acceptable acid addition salt thereof.

29. A method for treating a human patient suffering from a prostate disorder, comprising administering to the patient, within the context of an effective dosage regimen, a therapeutically effective amount of a compound having the structural formula



or a pharmaceutically acceptable acid addition salt thereof.

-70-

30. A method for stereoselectively adding an alkyl moiety to the 7 α position of a 6 keto steroid comprising providing a C¹⁹ or C²⁰ tetrahydropyranyl-protected hydroxyl moiety on the steroid and reacting the protected steroid with an alkylhalide in the presence
5 of a base.

1/23




FIG. 1




FIG. 2

3/23




FIG. 3




FIG. 4

5/23




FIG. 5

6/23




FIG. 6

7/23




FIG. 7

8/23




FIG. 8

9/23




FIG. 9

10/23




FIG. 10

11/23




FIG. 11

12/23




FIG. 12





FIG. 13

14/23



15/23






FIG. 15

16/23

FIG. 16



SR 16233



17/23





FIG. 17

18/23

FIG. 18



19/23




FIG. 19




FIG. 20





FIG. 21



23/23




FIG. 23

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58919 A2(51) International Patent Classification⁷: C07J 1/00

94089 (US). CHAO, Wan-Ru; 1510 Oriole Avenue, Sunnyvale, CA 94087 (US). TANABE, Masato; 972 Moreno, Palo Alto, CA 94303 (US).

(21) International Application Number: PCT/US01/04266

(22) International Filing Date: 9 February 2001 (09.02.2001)

(74) Agents: REED, Dianne, E. et al.; Reed & Associates, 800 Menlo Avenue, Suite 210, Menlo Park, CA 94025 (US).

(25) Filing Language:

English

(81) Designated States (*national*): CA, JP.

(26) Publication Language:

English

(84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR).

(30) Priority Data:

60/181,738

11 February 2000 (11.02.2000) US

Published:

— without international search report and to be republished upon receipt of that report

(71) Applicant: SRI INTERNATIONAL [US/US]; 333 Ravenswood Avenue, Menlo Park, CA 94025 (US).

(48) Date of publication of this corrected version:

3 January 2002


(72) Inventors: PETERS, Richard, H.; 365 Springpark Circle, San Jose, CA 95136 (US). LIU, Jyanwei; 681 Endicott Drive, Sunnyvale, CA 94087 (US). JOHANSSON, John, G.; 186 Sand Hill Circle, Menlo Park, CA 94025 (US). RYAN, Kenneth, J.; 754 Lakemuir Drive, Sunnyvale, CA

(15) Information about Correction:

see PCT Gazette No. 01/2002 of 3 January 2002, Section II

[Continued on next page]

(54) Title: SYNTHESIS OF ANTI-ESTROGENIC AND OTHER THERAPEUTIC STEROIDS FROM 21-HYDROXY-19-NOR-PREGNA-4-EN-3-ONE



(57) Abstract: Syntheses of steroids such as 3-hydroxy-7 α -methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene citrate ("SR 16234") and analogs thereof are provided, wherein 21-hydroxy-19-norpregna-4-en-3-one serves as a starting material or intermediate. The latter compound may be readily prepared from estrone-3-methyl ether. Certain intermediates in these syntheses also have value as therapeutic agents, for example in the treatment of prostate disorders such as prostatic cancer.

WO 01/58919 A2

WO 01/58919 A2



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**SYNTHESIS OF ANTI-ESTROGENIC AND OTHER THERAPEUTIC
STERIODS FROM 21-HYDROXY-19-NORPREGNA-4-EN-3-ONE**

TECHNICAL FIELD

5

This invention relates generally to the chemical synthesis of steroids, and more particularly relates to the synthesis of anti-estrogenic and other therapeutic steroids such as 3-hydroxy-7 α -methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene citrate ("SR 16234") and analogs thereof. The invention additionally relates to starting materials and intermediates useful in conjunction with the novel synthesis.

10

BACKGROUND ART

Breast cancer is one of the most prevalent types of cancer, and epidemiological and clinical studies have shown that approximately two-thirds of breast tumors are estrogen-
15 dependent. This means that estrogens are required for the growth of such breast tumors in both premenopausal and postmenopausal patients. In postmenopausal women, in whom breast cancer most commonly occurs, breast tumor concentrations of estrone and estradiol are considerably higher than blood estrogen levels. Although retention of estrogens in breast tumors by high-affinity binding proteins contributes to the level of estrogens in
20 tumors, estrogen concentrations in the breast are higher than plasma levels in breast cancer patients regardless of whether their tumors are estrogen receptor-positive (ER+) or estrogen receptor-negative (ER-). *In situ* formation of estrogen from estrogen biosynthetic precursors within tumors is now known to make a major contribution to the estrogen content of breast tumors.

25

Numerous other estrogen-dependent conditions, disorders, and diseases have been identified as well, including, but not limited to, ovarian, uterine and pancreatic cancers, galactorrhea, McCune-Albright syndrome, benign breast disease, and endometriosis.

Estrogenic effects are mediated by specific receptors located in the nucleus of estrogen-responsive cells. The receptor contains a hormone-binding domain for binding

estrogen, transcription activating domains, and a DNA binding domain. The binding of the receptor-hormone complex to estrogen response elements (ERE's) in the DNA of target genes is necessary for regulating gene transcription.

Drugs that competitively block estrogen binding to its receptor, termed anti-estrogens, are capable of inhibiting the stimulatory effects of the hormone on cell proliferation and are therefore useful in the clinical treatment of breast cancer. Clinically, estrogen receptor-positive tumors respond with a higher frequency to anti-estrogens than do tumors lacking a significant level of receptors.

Anti-estrogenic drugs fall into two chemical classes: nonsteroidal and steroidal. The nonsteroidal anti-estrogen tamoxifen (Nolvadex™) has been used as an adjunctive treatment for breast cancer following chemotherapy or radiation therapy. However, tamoxifen itself exhibits estrogenic activity in reproductive tissue, resulting in an increased risk of endometrial cancer and possible recurrence of breast cancer after long-term therapy. Furthermore, tamoxifen behaves only as a partial agonist in the uterus.

To date, little work has been done in the development of selective competitive antagonists of estrogen. Several steroidal anti-estrogens have been synthesized which lack estrogenic activity. Included among these are ICI 164,384, ICI 182,780 and RU 58668. See, e.g.: Wakeling et al. *J. Steroid Biochem.* 31:645-653 (1988), which pertains to ICI 164,384; Wakeling et al., *Cancer Res.* 51:3867-3873 (1991), and Wakeling et al., *J. Steroid Biochem. Molec. Biol.* 37:771-774 (1990), which pertain to ICI 182,780; and Van de Velde et al., *Ann. N.Y. Acad. Sci.* 761:164-175 (1995), Van de Velde et al., *Pathol. Biol.* 42:30 (1994), and Nique et al., *Drugs Future* 20:362-366 (1995), which relate to RU 58668. Unfortunately, these drugs are not orally active and must be administered in high doses intramuscularly. Furthermore, the manufacture of these drugs is laborious, requiring a complicated, 14-16 step synthesis with very low overall yields. Potent steroidal anti-estrogens that are orally active have not yet been developed or commercialized, although the nonsteroidal mixed agonist/antagonist "raloxifene" is currently available.


Accordingly, steroidal active agents have recently been developed that are extremely effective anti-estrogenic agents, i.e., are potent antagonists of estrogen in breast and/or uterine tissue. The active agents are described in co-pending, commonly assigned

-3-

U.S. Patent Application Serial No. 08/998,877, filed December 24, 1997, and U.S. Patent Application Serial No. 09/220,408, filed December 23, 1998, as well as in PCT Publication No. WO 99/33859, published July 8, 1999. These active agents represent a significant advance in the art, particularly in the treatment of breast cancer and other diseases and conditions that are potentiated by the presence of estrogens. A number of those active agents have also been found to display tissue-selective pharmacology and are thus useful as tissue-selective estrogen agonists/antagonists, also termed "Selective Estrogen Receptor Modulators" or "SERMs." SERMs produce beneficial estrogen-like effects in some respects, notably on bone and lipid metabolism, while nevertheless acting as estrogen antagonists in the breast and/or uterus. The SERM profile may be distinguished from that of a pure estrogen such as 17β -estradiol, which behaves as an estrogen agonist in all tissues, and from that of a pure anti-estrogen, which exhibits an estrogen antagonist profile in all tissue types.

An exemplary and representative anti-estrogen in the aforementioned group is the citrate salt of 3-hydroxy-7 α -methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene, developed at SRI International (Menlo Park, California) and also referred to herein as "SR 16234." SR 16234 can be represented as follows:

SR 16234:



SR 16234 has been found to have potent antitumor activity with remarkable tissue-selective properties: complete antagonist-antiestrogenic activity in human breast tumor cells; complete anti-uterotrophic antagonist activity in rat and human uterine tissue; agonist-estrogenic activity in the cardiovascular system, as reflected in lowered low-density lipoprotein (LDL) and increased high-density lipoprotein (HDL) cholesterol levels in rats; and agonist-estrogenic activity in the skeletal system, as manifested by maintenance of bone

and prevention of bone loss in rats. In addition, SR 16234 has been established to have good oral bioavailability, absorption and half-life, with sufficient uptake to sustain therapeutically effective plasma levels of the drug.

Currently, SR 16234 is synthesized using a nine-step synthetic procedure as outlined in FIG. 1. While the synthesis is effective and provides the product in a reasonable overall yield, it would be desirable to provide a simpler, more straightforward synthesis so as to reduce cost (synthesizing SR 16234 using the method of FIG. 1 is quite expensive), to improve overall yield, to avoid use of highly toxic reagents, and to avoid costly and difficult reaction steps such as aromatization with CuCl_2 .

DISCLOSURE OF THE INVENTION

Accordingly, the invention is directed to a new method for synthesizing SR 16234 and substituted analogs thereof, which is simpler, more straightforward and more cost-effective than previous synthetic methods, avoids the use of highly toxic reagents, and furthermore avoids costly materials and difficult reaction steps.

It is another object of the invention to provide such a method that employs 21-hydroxy-19-norpregna-4-en-3-one or a substituted analog thereof as a starting material or intermediate.

It is still another object of the invention to provide intermediate compounds and synthetic steps useful in conjunction with the aforementioned syntheses.

It is still another object of the invention to provide certain of such intermediate compounds as therapeutic agents, e.g., in the treatment of prostate disorders such as prostatic cancer.

Additional objects, advantages and novel features of the invention will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art upon examination of the following, or may be learned by practice of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a synthetic scheme illustrating a prior method for synthesizing SR 16234.

FIGS. 2, 3 and 4 are schemes illustrating methods of the invention for synthesizing SR 16234 from estrone-3-methyl ether (1) via 21-hydroxy-19-norpregna-4-en-3-one (3) as an intermediate.

FIGS. 5, 6 and 7 are schemes illustrating alternative methods of the invention for synthesizing 3-hydroxy-7 α -methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene ("SR 16233"), the free amine precursor to SR 16234.

FIGS. 8 and 9 are schemes illustrating methods of the invention for synthesizing SR 16234 from a crude 21-hydroxy-19-norpregna-4-en-3-one (3a).

FIG. 10 is a ^1H NMR spectrum of compound 2, the structure of which is shown in FIGS. 2, 3 and 4 (synthesized as described in Example 1).

FIG. 11 is a ^1H NMR spectrum of compound 3, the structure of which is shown in FIGS. 2, 3 and 4 (synthesized as described in Example 1).

FIG. 12 is a ^1H NMR spectrum of compound 4, the structure of which is shown in FIGS. 2 and 3 (synthesized as described in Example 2).

FIG. 13 is a ^1H NMR spectrum of compound 5, the structure of which is shown in FIGS. 2 and 3 (synthesized as described in Example 2).

FIG. 14 is a ^1H NMR spectrum of compound 6, the structure of which is shown in FIGS. 2 and 3 (synthesized as described in Example 2).

FIG. 15 is a ^1H NMR spectrum of compound SR 16233, the structure of which is shown in FIGS. 2 and 3 (synthesized as described in Example 2).

FIG. 16 is a mass spectrum of compound SR 16233.

FIG. 17 is a ^1H NMR spectrum of compound SR 16234, the structure of which is shown in FIGS. 2 and 3 (synthesized as described in Example 2).

FIG. 18 is a mass spectrum of compound SR 16234.

FIG. 19 is a ^1H NMR spectrum of compound 7, the structure of which is shown in FIGS. 2 and 3 (synthesized as described in Example 3).

FIG. 20 is a ¹H NMR spectrum of compound 11, the structure of which is shown in FIG. 4 (synthesized as described in Example 4).

FIG. 21 is a ¹H NMR spectrum of compound 12, the structure of which is shown in FIG. 4 (synthesized as described in Example 4).

5 FIG. 22 is a ¹H NMR spectrum of compound 13, the structure of which is shown in FIG. 4 (synthesized as described in Example 4).

FIG. 23 is a graph illustrating the % inhibition versus concentration of SR 16312 as evaluated in an androgen-independent human prostate cancer assay, described in Example 7.

10

MODES FOR CARRYING OUT THE INVENTION

DEFINITIONS:

It is to be understood that unless otherwise indicated, this invention is not limited to specific starting materials, reagents or reaction conditions, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.

20

In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings:

The term "alkyl" as used herein refers to a branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *t*-butyl, octyl, decyl, tetradecyl, hexadecyl, eicosyl, tetracosyl and the like, as well as cycloalkyl groups such as cyclopentyl, cyclohexyl, and the like. The term "lower alkyl" intends an alkyl group of one to six carbon atoms, preferably one to four carbon atoms. The term "cycloalkyl" as used herein refers to a cyclic hydrocarbon of from 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

30

The term "alkenyl" as used herein refers to a branched or unbranched hydrocarbon group of 2 to 24 carbon atoms containing at least one double bond, such as ethenyl, *n*-propenyl, isopropenyl, *n*-butenyl, isobutenyl, octenyl, decenyl, tetradecenyl, hexadecenyl, eicosenyl, tetracosenyl, and the like. Preferred alkenyl groups herein contain 2 to 12 carbon atoms. The term "lower alkenyl" intends an alkenyl group of two to six carbon atoms, preferably two to four carbon atoms. The term "cycloalkenyl" intends a cyclic alkenyl group of three to eight, preferably five or six, carbon atoms.

The term "alkynyl" as used herein refers to a branched or unbranched hydrocarbon group of 2 to 24 carbon atoms containing at least one triple bond, such as ethynyl, *n*-propynyl, isopropynyl, *n*-butynyl, isobutynyl, octynyl, decynyl, and the like. Preferred alkynyl groups herein contain 2 to 12 carbon atoms. The term "lower alkynyl" intends an alkynyl group of two to six carbon atoms, preferably two to four carbon atoms.

The term "alkylene" as used herein refers to a difunctional branched or unbranched saturated hydrocarbon group of 1 to 24 carbon atoms, such as methylene, ethylene, *n*-propylene, *n*-butylene, *n*-hexylene, decylene, tetradecylene, hexadecylene, and the like. The term "lower alkylene" refers to an alkylene group of one to six carbon atoms, preferably one to four carbon atoms.

The term "alkenylene" as used herein refers to a difunctional branched or unbranched hydrocarbon group of 2 to 24 carbon atoms containing at least one double bond, such as ethenylene, *n*-propenylene, *n*-butenylene, *n*-hexenylene, and the like. The term "lower alkenylene" refers to an alkylene group of two to six carbon atoms, preferably two to four carbon atoms.

The term "alkoxy" as used herein intends an alkyl group bound through a single, terminal ether linkage; that is, an "alkoxy" group may be defined as -O-alkyl where alkyl is as defined above. A "lower alkoxy" group intends an alkoxy group containing one to six, more preferably one to four, carbon atoms.

The term "acyl" is used in its conventional sense to refer to a substituent alkyl-C-(O)- wherein alkyl is as defined above. The term "lower acyl" refers to an acyl group wherein the alkyl moiety of the group contains one to six, more preferably one to four, carbon atoms.

The term "aryl" as used herein, and unless otherwise specified, refers to an aromatic species containing 1 to 3 aromatic rings, either fused or linked, and either unsubstituted or substituted with 1 or more substituents typically selected from the group consisting of lower alkyl, lower alkoxy, halogen, and the like. Preferred aryl substituents contain 1 aromatic ring or 2 fused or linked aromatic rings. The term "arylene" refers to a difunctional aromatic species containing 1 to 3 aromatic rings substituted with 1 or more substituents as above. Preferred arylene substituents contain 1 aromatic ring (e.g., phenylene) or 2 fused or linked aromatic rings (e.g., biphenylene).

The term "aralkyl" refers to an aryl group with an alkyl substituent. The term "aralkylene" refers to an arylene group with an alkyl substituent.

The term "alkaryl" refers to an alkyl group that has an aryl substituent. The term "alkarylene" refers to an alkylene group that has an aryl substituent.

The term "heterocyclic" refers to a five- or six-membered monocyclic structure or to an eight- to eleven-membered bicyclic heterocycle. The "heterocyclic" substituents herein may or may not be aromatic, i.e., they may be either heteroaryl or heterocycloalkyl. Each heterocycle consists of carbon atoms and from one to three, typically one or two, heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, typically nitrogen and/or oxygen.

The terms "halo" and "halogen" are used in the conventional sense to refer to a chloro, bromo, fluoro, or iodo substituent. The terms "haloalkyl," "haloalkenyl," or "haloalkynyl" (or "halogenated alkyl," "halogenated alkenyl," or "halogenated alkynyl") refers to an alkyl, alkenyl, or alkynyl group, respectively, in which at least one of the hydrogen atoms in the group has been replaced with a halogen atom.

The term "hydrocarbyl" is used in its conventional sense to refer to a hydrocarbon group containing carbon and hydrogen, and may be aliphatic, alicyclic, or aromatic, or may contain a combination of aliphatic, alicyclic, and/or aromatic moieties. Aliphatic and alicyclic hydrocarbyl may be saturated or they may contain one or more unsaturated bonds, typically double bonds. The hydrocarbyl substituents herein generally contain 1 to 24 carbon atoms, more typically 1 to 12 carbon atoms, and may be substituted with various

substituents and functional groups, or may be modified so as to contain ether, thioether, -NH-, -NR-, -C(O)-, -C(O)-O-, and/or other linkages.

"Optional" or "optionally" means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not. For example, the phrase "optionally substituted" means that a non-hydrogen substituent may or may not be present, and, thus, the description includes structures wherein a non-hydrogen substituent is present and structures wherein a non-hydrogen substituent is not present. Similarly, the phrase an "optionally present" double bond as indicated by a dotted line ---- in the chemical formulae herein means that a double bond may or may not be present, and, if absent, a single bond is indicated.

By "anti-estrogenic" as used herein is meant a compound that tends to inhibit the *in situ* activity of estrogens such as estradiol, following administration to a mammalian individual. Anti-estrogenic activity can be evaluated in terms of inhibition of estradiol-induced alkaline phosphatase activity in human Ishikawa cells using, for example, the procedures described in Example 40 of PCT Publication No. WO 99/33859.

The terms "treating" and "treatment" as used herein refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage. Thus, for example, a method of "treating" an estrogen-dependent disorder, as the term is used herein, encompasses both prevention of the disorder in a clinically asymptomatic individual and treatment of the disorder in a clinically symptomatic individual. Similarly, a method of "treating" a prostate disorder, as the term is used herein, encompasses both prevention of the disorder in a clinically asymptomatic individual and treatment of the disorder in a clinically symptomatic individual.


By the terms "effective amount" or "pharmaceutically effective amount" of a therapeutic agent are meant a nontoxic but sufficient amount of the agent to provide the desired prophylactic or therapeutic effect. As will be pointed out below, the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the condition being treated, and the particular agent and mode of administration, and the like. Thus, it is not possible to specify an exact

-10-

"effective amount." However, an appropriate "effective" amount in any individual case may be determined by one of ordinary skill in the art using only routine experimentation.

By "pharmaceutically acceptable carrier" is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with the selected therapeutic agent without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. Similarly, a "pharmaceutically acceptable" salt or a "pharmaceutically acceptable" ester of a novel compound as provided herein is a salt or ester that is not biologically or otherwise undesirable.

In describing the location of groups and substituents, the following numbering system will be employed to conform the numbering of the cyclopentanophenanthrene nucleus to the convention used by the IUPAC or Chemical Abstracts Service:




The five- and six-membered rings of the steroid molecule are often designated A, B, C, and D as shown. The term "steroid" as used herein is intended to mean compounds having the aforementioned cyclopentanophenanthrene nucleus.

In these structures, the use of bold and dashed lines to denote particular conformation of groups follows the IUPAC steroid-naming convention. The symbols " α " and " β " indicate the specific stereochemical configuration of a substituent at an asymmetric carbon atom in a chemical structure as drawn. Thus " α ," denoted by a broken line, indicates that the group in question is below the general plane of the molecule as drawn, and " β ," denoted by a bold line, indicates that the group at the position in question is above the general plane of the molecule as drawn.

SYNTHETIC METHODS:

The synthetic methods of the invention all proceed from estrone-3-methyl ether via 21-hydroxy-19-norpregna-4-en-3-one as an intermediate. It will be understood by those working in the field of steroid chemistry that the cyclopentanophenanthrene nucleus may be substituted with one or more substituents that do not interfere with the synthetic steps described herein.

To prepare the substituted or unsubstituted 21-hydroxy-19-norpregna-4-en-3-one intermediate, a substituted or unsubstituted estrone-3-methyl ether is first converted to a compound having the structural formula (I) by reaction with a triethyl phosphonoacetate or an analogous reagent (see Example 1).



20 In structural formula (I):

X is lower hydrocarbyl;

R¹ is hydrogen or CR¹¹R¹², wherein R¹¹ and R¹² are hydrogen or lower alkyl;

R² is selected from the group consisting of hydrogen, hydroxyl, alkyl, -OR¹³, and -SR¹³ wherein R¹³ is alkyl;

25 R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consisting of hydrogen and lower alkyl;

R⁹ is hydrogen or hydrocarbyl; and


R¹⁰ is methyl or ethyl.

A preferred subset of the aforementioned compounds has the structure of formula

30 (II)

-12-

(II)




wherein X is lower alkyl and R^6 is hydrogen or lower alkyl.

For example, X may be ethyl, and R^6 may be methyl (see compound 2 in FIGS. 2, 3, and 4).

In order to convert compound (I) to the substituted or unsubstituted 21-hydroxy-19-norpregna-4-en-3-one intermediate (III)

(III)



compound (I) is treated with an alkali metal and ammonia or an alkylamine using known reaction conditions appropriate for a Birch reduction; see, e.g., March et al., *Advanced Organic Chemistry, Fourth Edition* (New York: Wiley, 1992), section 5-10 and references cited therein. Suitable alkali metals include lithium, potassium and sodium, and the reaction preferably takes place in liquid ammonia and optionally in the presence of an alcohol.

In compound (III):


R^1 , R^2 , R^4 , R^5 , R^7 , R^9 , and R^{10} are as defined for formula (I), R^3 is hydrogen or hydrocarbonyl, typically hydrogen or alkyl, preferably hydrogen or lower alkyl such as methyl, and R^{19} is hydroxyl, hydroxymethyl (CH_2OH), protected hydroxyl, protected

-13-

hydroxymethyl, activated hydroxyl, or activated hydroxymethyl. By "activated" is meant that a hydroxyl group is modified so as to enable reaction with an incoming nucleophile; generally, this means that a hydroxyl group -OH is converted to an -O-LG moiety wherein LG is a leaving group. Activation can involve, for example, reaction with MsCl, TsCl, SOCl₂, SOBr₂, or the like ("Ms" meaning mesyl and "Ts" meaning tosyl). By "protected" is meant that the hydroxyl group will not undergo reaction in a particular step, but by virtue of a protecting group Pr, the -O-Pr moiety remains intact and can be treated, e.g., with base or acid, to regenerate the unprotected hydroxyl group following reaction. Suitable hydroxyl-protecting groups at the latter position include, but are not limited to, Ms, Ts, acetyl (Ac), and tetrahydropyranyl (THP). It is to be understood that the above-indicated activating and protecting moieties may be used as either protecting groups or activating groups depending on the specific reaction condition.

Preferred intermediates encompassed by structural formula (III) have the structure of formula (IV)

(IV)




wherein:

R³ is hydrogen or lower alkyl; and

R¹⁹ is hydroxyl, hydroxymethyl, protected hydroxyl, or protected hydroxymethyl.

In a representative and specific example of the foregoing reaction, a method for synthesizing 21-hydroxy-19-norpregna-4-en-3-one is provided which comprises treating

(IX)




(IX)

wherein X and Y are independently lower alkyl, with an alkali metal in the presence of ammonia or an alkylamine.

SR 16234 or its free base SR 16233 is synthesized from compound (III) using one of several methods, exemplified in the schemes of FIGS. 2, 3, 4, 8, and 9. In the first three of these methods, when R¹⁹ is hydroxyl or hydroxymethyl, preferably hydroxymethyl, the alcohol moiety is initially converted to a leaving group displaceable with an incoming nucleophile as explained above. The remaining steps in the first three methods then differ, as illustrated in FIGS. 2, 3, and 4. In the fourth method, as illustrated in the scheme of FIG. 8, the R¹⁹ alcohol moiety is initially converted to a protecting group, as explained above, a 7α groups is attached to the B ring, the R¹⁹ protected group is unprotected and then activated with a leaving group. The fifth method, illustrated in FIG. 9, first protects the R¹⁹ position and then proceeds as indicated.


In methods 1 and 2 (illustrated in FIGS. 2 and 3), a compound having the structural formula (XII)



wherein m is zero or 1, and R¹, R², R⁴, R⁵, R⁷, and R¹⁰ are as defined above, is initially provided. This compound is a subset of formula III. The -OH group at the 20- or 21-position (depending on whether m is zero or 1, respectively) is then activated by conversion to an -O-LG moiety wherein LG is a leaving group displaceable by nucleophilic attack, as explained above; LG can be, for example, OMs, OTs, Cl, Br, etc.

At the same time that the -OH group at the 20- or 21-position is activated, or subsequently, the following three reaction steps are carried out: (1) the A ring of the steroid nucleus is oxidized (aromatized); (2) a 6-keto moiety is provided by exposure to gaseous oxygen in the presence of base (e.g., cesium carbonate or potassium acetate); and (3) a protecting group is introduced at the 3-position so as to provide a protected hydroxyl group -OPr wherein Pr is the protecting group. Suitable protecting groups include, but are not limited to alkyl, lower alkyl, Ms, Ts, Ac, and THP.

Next, the leaving group LG is displaced with a hydroxyl-containing compound having the structural formula (XIII)




wherein p is an integer in the range of 1 to 7 inclusive, R²¹ and R²² are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring, and Q¹, Q², Q³, and Q⁴ are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

Prior, during, or subsequent to the aforementioned reactions, substitution at the 7-position is effected by reaction with an alkyl halide such as methyl iodide, in a suitable base such as lithium diisopropylamide, to provide a 7 - lower alkyl, e.g., a 7-methyl, substituent. In method 1, illustrated in FIG. 2, alkylation at the 7-position is conducted prior to attachment of the aromatic side chain at the 17-position, using an alkyl halide such as methyl iodide. In method 2, illustrated in FIG. 3, alkylation at the 7-position is conducted after attachment of the aromatic side chain at the 17-position, again using an alkyl halide such as methyl iodide. In method 3, the 7-position is alkylated earlier, as implied above by the definition of R³ in structure (III). In either method 1 or 2, the compound provided (exemplified as 6 in FIGS. 2 and 3) can be generically represented as (XVIII)

-16-


5 (XVIII)



wherein R^{3A} represents the newly added lower alkyl group and the remaining substituents are as defined previously. It will be appreciated that other types of hydrocarbonyl groups could be added at the 7-position, i.e., as R^{3A} , by reaction with the appropriate hydrocarbonyl halide reagents.

Compound (XVIII) is then reduced so as to remove the 6-keto and amidocarbonyl moieties using a standard reducing agent and conditions, e.g., lithium aluminum hydride (LAH) in the presence of aluminum chloride ($AlCl_3$), which also deprotects at the 3-position to result in a free hydroxyl group. The resulting compound thus has the structure (XI)


20 (XI)




A representative compound of structure (XI) compound and key species is 3-hydroxy-7 α -methyl-21-[2'-methoxy-4'-(diethylaminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene (SR 16233) as illustrated in FIGS. 2 and 3. Compound (XI) may then be converted to an acid addition salt by reaction with a suitable acid using conventional procedures. For example, to convert the compound to SR 16234, the citrate salt of SR 16233, the reaction is conducted with citric acid.

-17-

In method 3, illustrated in FIG. 4, the reaction steps following synthesis of compound (III) (exemplified as 3 in the figure) differ from the foregoing syntheses, as follows. Following protection of the hydroxyl or hydroxymethyl group at R¹⁹, the 7 α -lower alkyl, e.g., 7 α -methyl, group is synthesized by reaction with, for example, alkyl lithium, e.g., methyl lithium, in the presence of lithium bromide (see FIG. 4). The hydroxyl or hydroxymethyl group at R¹⁹ is then deprotected by treatment with base (e.g., an inorganic hydroxide such as KOH or NaOH, in alcohol) using conventional means, followed by reaction with an aldehyde that may be generically represented as (XIV)




a specific example of such an aldehyde, as illustrated in FIG. 4, is vanillin, i.e., 4-hydroxy-3-methoxybenzaldehyde. This results in an intermediate having the structural formula (XV)



Then, in order to provide the desired amine, (XV) is treated with an alkylamine having the structure HNR²¹R²² under reaction conditions effective to produce the amine (XVI)


-18-

(XVI)



While compound (XVI) is a valuable intermediate in the ultimate synthesis of SR 16234 and analogs thereof, it has additional value as a therapeutic agent, particularly in the treatment of prostate disorders such as prostatic cancer. Preferred compounds within this group have the structural formula (XVII)

(XVII)



wherein:

R^{3A} is alkyl, most preferably lower alkyl such as methyl;

m is zero or 1;

p is an integer in the range of 1 to 7 inclusive;


R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

Q¹, Q², Q³, and Q⁴ are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

In method 3, the A ring is then oxidized (aromatized) using, for example, cuprous chloride in AcOH, or by using biological aromatization. SR 16233 results, which can be converted to SR 16234, as noted previously, by reaction with citric acid.

In method 4, as illustrated in FIG 8, a compound having the structural formula (XII) is used as the starting material. The -OH group at the 20- or 21-position (depending on whether m is zero or 1, respectively) is first protected by conversion to an -O-Pr moiety wherein Pr is a protecting group, as explained above. Suitable protecting groups include, but are not limited to alkyl, lower alkyl, Ms, Ts, Ac, and THP. As illustrated in FIG. 8, acetyl is a preferred protecting group for this purpose, as the acetate moiety allows for easy and efficient purification of the resultant acetate via recrystallization.


Next, a dienyl acetate having structural formula (XX) is formed by introduction of a protecting group, Pr^2 , at the 3-position.



In structural formula (XX), m, R¹, R², R⁴, R⁵, R⁷, and R¹⁰ are as defined above, and Pr¹ and Pr² are the respective protecting groups on the 20- or 21- and the 3- position and may be the same or different. As discussed above, preferred protecting groups include, but are not limited to, alkyl (particularly lower alkyl), acetyl, Ms, Ts, and THP. The 3-position protecting group, Pr², is then removed to form a dienone having structural formula (XXI)


-20-

(XXI)



wherein Pr^1 , m , R^1 , R^2 , R^4 , R^5 , R^7 , and R^{10} are as defined above. Once the dienone has been synthesized, the compound is reacted with, for example, a lower alkyl lithium, e.g., methyl lithium, in the presence of lithium bromide to form a 7α -alkylated compound having the structure (XXII)

(XXII)




wherein R^{3A} represents the newly added lower alkyl group and the remaining substituents are as defined above (see FIG. 8). The use of acetate as the Pr^1 protecting group greatly facilitates the addition of the 7-alkyl group in the α position. While not wishing to be limited by theory, it is believed that the acetate moiety forms a complex with the lithium and promotes introduction of the 7-alkyl functionality from the α face of the steroid.

The A ring of the 7α -alkyl steroid is then aromatized and the Pr^1 protecting group removed using, for example, cuprous chloride in AcOH, biological aromatization, or the like. The resulting diol will have structural formula (XXIII)


-21-

(XXIII)



wherein the various substituents are as defined above. The 3-position and 20- or 21-position alcohol moieties of the diol are then protected with a suitable protecting group such as Ts, Ms, or the like. As discussed above, Ms is a preferred protecting group. The protected compound is then treated with a hydroxyl-containing compound having structural formula (XIII), as discussed above with respect to method 1, resulting in a compound having the structure (XXIV)

(XXIV)




wherein Pr represents the protecting group on the 3-position and the remaining substituents are as defined previously. This compound is then reduced using a standard reducing agent and conditions, e.g., lithium aluminum hydride (LAH), to reduce the amido moiety to an amine and deprotect at the 3-position resulting in a free hydroxyl group. The resulting compound thus has the structure (XI), which, as previously discussed, may then be

-22-

converted to an acid addition salt by reaction with a suitable acid using conventional procedures.

In the last method, method 5, illustrated in FIG. 9, the 3-position of a compound having the structural formula (XII) is protected, the A ring aromatized and the desired 6-ketone introduced by the use of a catalytic amount of iodine in isopropanol while air is bubbled through the reaction mixture. This process results in a 6-ketone having the structural formula (XXVI)



wherein Pr, m, R¹, R², R⁴, R⁵, R⁷, and R¹⁰ are as defined above. The 20- or 21-position hydroxyl group, depending on m, is then protected, e.g., as a THP ether. Once the 20- or 21-position protecting group is in place, substitution is effected at the 7-position by reaction with a lower alkyl halide such as methyl iodide, in a suitable base such as lithium diisopropylamide, to provide a 7 α -alkyl, e.g., a 7 α -methyl, substituent and remove the 20- or 21-position protecting group. After the 7 α -alkyl group is in place, the 6-ketone is catalytically removed using hydrogen and a platinum or palladium catalyst, e.g., 10% palladium on carbon, and the 3-position is deprotected with a suitable reagent to provide an alcohol, resulting in the diol having the structure (XXIII). The remainder of the method then proceeds as described for method 4.

Surprisingly, it has been discovered that a THP ether protecting group when used in conjunction with an alkyl halide and a base, allows for a highly stereoselective addition of a 7-alkyl group in the α position on standard 6-keto steroid compounds. While not

wishing to be limited by theory, it is believed that the THP moiety sterically hinders addition of the 7-alkyl functionality from the β face of the steroid, thereby promoting introduction of the 7-alkyl functionality from the α face of the steroid. The use of a THP ether in the 7 α -methylation of 6-keto estradiol is described in Example 8.


5

ADDITIONAL INTERMEDIATES:

Additional compounds within the scope of the invention are useful as intermediates in one or more of the foregoing syntheses and have the structural formula (V)

10

(V)



15

wherein:

R^1 is hydrogen or $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, $-OR^{13}$, and $-SR^{13}$ wherein R^{13} is alkyl;

R^3 is selected from the group consisting of hydrogen and hydrocarbyl, preferably hydrogen and alkyl, e.g., lower alkyl such as methyl;

R^4 , R^5 , and R^7 are independently selected from the group consisting of hydrogen and lower alkyl;

R^{6Mod} is selected from the group consisting of hydrogen, alkyl, acyl, $-C(O)-aryl$, and $-C(O)-alkyl$, hydroxyl-protecting groups, and hydroxyl-activating groups;

R^{8a} is selected from the group consisting of hydrogen, hydroxyl, oxo ($=O$), and $-OR^{18}$ wherein R^{18} is lower alkyl or lower acyl;


R^9 is hydrogen or alkyl;

R^{10} is methyl or ethyl; and

-24-

R^{20} is hydroxyl, hydroxymethyl, protected hydroxyl, protected hydroxymethyl, activated hydroxyl, activated hydroxymethyl, or

5



in which m is zero or 1, p is an integer in the range of 1 to 7 inclusive, and t is zero or 1, with the proviso that when R^{8a} is oxo, t is 1, and R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and


Q^1 , Q^2 , Q^3 , and Q^4 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

15

Preferred compounds within this group have the structure of formula (VI)

(VI)

20



wherein:

R^3 is hydrogen or lower alkyl;

25

R^{6Mod} is hydrogen or a hydroxyl-protecting group;


R^{8b} is hydrogen, hydroxy, or oxo ($=O$); and

R^{19} is hydroxyl, hydroxymethyl, protected hydroxyl, or protected hydroxymethyl.

In particularly preferred compounds, R^{19} is hydroxylmethyl.

Other novel compounds useful as intermediates herein have the general structure

(VII)



wherein:

R^3 is hydrogen or hydrocarbyl, preferably hydrogen or alkyl, most preferably hydrogen or lower alkyl such as methyl;

15 R^{6Mod} is selected from the group consisting of hydrogen, alkyl, acyl, $-C(O)-aryl$, and $-C(O)-alkyl$, hydroxyl-protecting groups, and hydroxyl-activating groups;

R^{8b} is hydrogen, hydroxyl, or oxo ($=O$), but preferably is hydrogen or oxo ($=O$);

m is zero or 1;

p is an integer in the range of 1 to 7 inclusive;


20 t is zero or 1, with the proviso that when R^{8a} is hydrogen, t is zero, and when R^{8a} is oxo, t is 1;

R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

25 Q^1 , Q^2 , Q^3 , and Q^4 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

Still other compounds useful as intermediates herein have the general structure (VIII)


(VIII)




wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^{10} , and R^{19} are as defined previously.

Also useful are compounds having the structure (XXVII) and (XXVIII)

(XXVII)



(XXVIII)



wherein R^1 , R^2 , R^4 , R^5 , R^{6Mod} , R^7 , R^{10} , and R^{19} are as defined previously.

PHARMACEUTICAL UTILITY:


A number of those compounds identified herein as synthetic intermediates also find utility as pharmaceutical agents. For example, as alluded to in the preceding section, certain compounds useful as intermediates in the synthetic methods described in the preceding section are also useful in the treatment of prostate disorders, particularly prostatic cancer.

Prostatic cancer is the second most common malignancy in American men. Prostatic cancer may produce symptoms of urethral obstruction, either by direct extension into the bladder or by spreading behind the bladder through the seminal vesicles. Like benign prostatic hyperplasia, prostatic cancer increases in prevalence with patient age, requires androgens for growth and development, and responds to antiandrogen treatment. Bostwick, et al., *Cancer*, 70(1 Suppl): 291-301 (1992). Prostatic cancer has been treated medically with some success through surgical techniques such as radical prostatectomy, and through radiation therapy via either external beam or surgical implants of interstitial radioactive seeds into the prostate. Hormonal therapies available include ablation by castration, administration of exogenous estrogens to deprive prostatic tumors of circulating androgens, releasing hormone analogues that inhibit testosterone synthesis, and/or administering antiandrogens which block androgen action in the prostate itself. Chemotherapy has yielded discouraging results. See, e.g., *Cecil Textbook of Medicine*, 19th ed., 1353 (Wyngaarden et al., eds., W.B. Saunders 1992).

Although a number of therapies have been proposed to treat each of these disorders, there remains a need in the art to provide a more effective method of treating prostatic disorders such as prostatic cancer. It is, thus, a significant discovery that certain compounds of the invention are useful in the treatment of prostatic cancer.

-28-

One group of compounds that may be used to treat prostatic cancer has the structural formula (XVI).



In compound (XVI), the various substituents are as follows:

R^1 is $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, $-OR^{13}$, and $-SR^{13}$ wherein R^{13} is alkyl;

R^3 is hydrogen or hydrocarbonyl, preferably hydrogen or alkyl, more preferably hydrogen or lower alkyl such as methyl;

R^4 and R^5 are independently selected from the group consisting of hydrogen and lower alkyl;

R^7 is hydrogen or lower alkyl;

R^{10} is methyl or ethyl;

m is zero or 1;


p is an integer in the range of 1 to 7 inclusive;

R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

$Q^1, Q^2, Q^3,$ and Q^4 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

The compound may also be in the form of a pharmacologically acceptable acid addition salt.

Preferred compounds within the generic structure of formula (XVI) have the structural formula (XVII)




wherein:


R^3 , m , p , R^{21} , R^{22} , Q^1 , Q^2 , Q^3 , and Q^4 are as defined above for formula (XVI).

Two exemplary such compounds are as follows:

COMPOUND 13,
FIG. 4:



COMPOUND SR 16312:



The compounds may be in the form of pharmacologically acceptable salts, prodrugs, or other derivatives or analogs, or they may be modified by appending one or

more appropriate functionalities to enhance selected biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system, increase oral bioavailability, increase solubility to allow administration by injection, and the like.

5 Acid addition salts of the free amine compounds can be prepared using standard procedures known to those skilled in the art of synthetic organic chemistry and described, for example, by J. March, Advanced Organic Chemistry: Reactions, Mechanisms and Structure, 4th Ed. (New York: Wiley-Interscience, 1992); conventional preparation of an acid addition salt involves reaction of the free base with a suitable acid. Typically, the base
10 form of the compound is dissolved in a polar organic solvent such as methanol or ethanol and the acid is added at a temperature of about 0°C to about 100°C, preferably at ambient temperature. The resulting salt either precipitates or may be brought out of solution by addition of a less polar solvent. Suitable acids for preparing acid addition salts include both organic acids, e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic
15 acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like, as well as inorganic acids, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. An acid addition salt may be reconverted to the free base by treatment with a suitable base.
20 Preferred acid addition salts of the present compounds are the citrate, fumarate, succinate, benzoate, and malonate salts.

 The therapeutic agents may be conveniently formulated into pharmaceutical compositions composed of one or more of the compounds in association with a pharmaceutically acceptable carrier. See Remington: The Science and Practice of Pharmacy, 19th Ed.
25 (Easton, PA: Mack Publishing Co., 1995), which discloses typical carriers and conventional methods of preparing pharmaceutical compositions which may be used as described or modified to prepare pharmaceutical formulations containing the compounds of the invention. The compounds may also be administered in the form of pharmaceutically acceptable salts, or as pharmaceutically acceptable esters, as described in the preceding
30 section.

The compounds may be administered orally, parenterally, transdermally, rectally, nasally, buccally, or via an implanted reservoir in dosage formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants, and vehicles. The term "parenteral" as used herein is intended to include subcutaneous, intravenous, and
5 intramuscular injection. The amount of active compound administered will, of course, be dependent on the subject being treated, the subject's weight, the manner of administration, and the judgment of the prescribing physician. Generally, however, dosage will be in the range of approximately 0.01 mg/kg/day to 10.0 mg/kg/day, more preferably in the range of about 1.0 mg/kg/day to 5.0 mg/kg/day.

10 Depending on the intended mode of administration, the pharmaceutical compositions may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage form suitable for single administration of a precise dosage. The compositions will include, as noted above, an effective amount of the selected drug in
15 combination with a pharmaceutically acceptable carrier and, in addition, may include other pharmaceutical agents, adjuvants, diluents, buffers, etc.

For solid compositions, conventional nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, magnesium carbonate, and the like. Liquid
20 pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc., an active compound as described herein and optional pharmaceutical adjuvants in an excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of
25 nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, referenced above.

For oral administration, the composition will generally take the form of a tablet or capsule, or may be an aqueous or nonaqueous solution, suspension, or syrup. Tablets and capsules are preferred oral administration forms. Tablets and capsules for oral use will generally include one or more commonly used carriers such as lactose and cornstarch.

5 Lubricating agents, such as magnesium stearate, are also typically added. When liquid suspensions are used, the active agent is combined with emulsifying and suspending agents. If desired, flavoring, coloring, and/or sweetening agents may be added as well. Other optional components for incorporation into an oral formulation herein include, but are not limited to, preservatives, suspending agents, thickening agents, and the like.

10 Parenteral administration, if used, is generally characterized by injection. Injectable formulations can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Preferably, sterile injectable suspensions are formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The
15 sterile injectable formulation may also be a sterile injectable solution or a suspension in a nontoxic parenterally acceptable diluent or solvent. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.

20 The compounds of the invention may also be administered through the skin or mucosal tissue using conventional transdermal drug delivery systems, wherein the agent is contained within a laminated structure that serves as a drug delivery device to be affixed to the skin. In such a structure, the drug composition is contained in a layer, or "reservoir," underlying an upper backing layer. The laminated structure may contain a single reservoir,
25 or it may contain multiple reservoirs. In one embodiment, the reservoir comprises a polymeric matrix of a pharmaceutically acceptable contact adhesive material that serves to affix the system to the skin during drug delivery. Examples of suitable skin contact adhesive materials include, but are not limited to, polyethylenes, polysiloxanes, polyisobutylenes, polyacrylates, polyurethanes, and the like. Alternatively, the drug-
30 containing reservoir and skin contact adhesive are present as separate and distinct layers,

with the adhesive underlying the reservoir which, in this case, may be either a polymeric matrix as described above, or it may be a liquid or hydrogel reservoir, or may take some other form.

Alternatively, the pharmaceutical compositions of the invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycols.

The pharmaceutical compositions of the invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

Formulations for buccal administration include tablets, lozenges, gels and the like.

Alternatively, buccal administration can be effected using a transmucosal delivery system.

It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, the foregoing description as well as the examples that follow are intended to illustrate and not limit the scope of the invention.

Other aspects, advantages, and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

EXPERIMENTAL

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of synthetic organic chemistry, biological testing, and the like, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Fieser et al., Steroids (New York: Reinhold, 1959), Djerassi, Steroid Reactions: An Outline for Organic Chemists (San Francisco: Holden-Day, 1963), and Fried et al., Organic Reactions in Steroid Chemistry, vols. 1 and 2 (New York: Reinhold, 1972), for detailed information concerning steroid-related synthetic procedures. Reference may be had

to Littlefield et al., *Endocrinology* 127: 2757-2762 (1990) and Wakeling et al., *Endocrinology* 99: 447-453 (1983) for a description of the biological testing procedures useful to evaluate compounds such as some of the therapeutic agents described and claimed herein.

5 In the following examples, efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental error and deviation should be accounted for. Unless indicated otherwise, temperature is in degrees C and pressure is at or near atmospheric. All solvents were purchased as HPLC grade, and all reactions were routinely conducted under an inert atmosphere of argon unless otherwise
10 indicated. All reagents were obtained commercially unless otherwise indicated. Estrone 3-methyl ether was purchased from Berlichem U.S.; ethamivan (vanillic acid diethylamide) was obtained from Fluka. NMR analyses were conducted on a Varian Gemini 300 and were referenced to chloroform at δ 7.27. Mass spectra were recorded on an LKB Model 9000 combination gas chromatograph-mass spectrometer, interfaced with a tektrivent Vector-1
15 Data System.

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to prepare and use the compounds disclosed and claimed herein. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.) but some errors and deviations should be
20 accounted for.

EXAMPLE 1

SYNTHESIS OF 21-HYDROXY-19-NORPREGNA-4-EN-3-ONE (3):

This example describes preparation of 21-hydroxy-19-norpregna-4-en-3-one (3)
25 from estrone-3-methyl ether (1) as illustrated in the schemes of FIGS. 2, 3, and 4.

Synthesis of (2): To a mixture of 28.4 g (0.1 mol) of estrone-3-methyl ether (1) and 90 g (0.4 mol) of triethyl phosphonoacetate in 175 mL of THF and 90 mL of ethanol, heated to reflux, was added 130 mL (0.4 mol) of a 21% solution of sodium ethoxide in ethanol. The mixture was refluxed overnight. The mixture was cooled and the volume
30 reduced by half under vacuo. The mixture was poured into 2 L ice water with stirring. A

gummy solid precipitated which was filtered, washed with water and with stirring, and air-dried to give 2 as a solid. Yield 34 g (99 %). The identity of the product was confirmed using ^1H NMR spectroscopy, and the NMR spectrum is shown in FIG. 10.

Synthesis of (3): To a three-necked flask equipped with a dry-ice condenser, overhead stirrer, argon gas inlet, and dropping funnel in a dry-ice-acetone bath was added 1200 mL of liquid ammonia. To this -78°C liquid was added 23.6 (3 mol) g of lithium in 1- to 3-inch pieces. After stirring 15 min, 350 mL of dry THF was slowly added to the blue solution (containing lithium bronze). A solution of 30 g (84.6 mmol) of 2 in 380 mL of *t*-butanol and 120 mL of THF was slowly added to the blue mixture. After stirring on the dry-ice-acetone bath, 2 g (0.25 moles) more of lithium was added. After stirring for 2 hrs, on the dry-ice-acetone bath, the blue color was mostly gone and a white-solid mixture remained. After three more hrs of stirring, 100 mL of methanol was added and the stirred mixture was allowed to reach room temperature and the ammonia evaporated with a flow of argon overnight. A solution of 140 mL concentrated HCl, 350 mL of water and 500 mL of THF was slowly added to the white semi-solid mixture with overhead stirring. More concentrated HCl was added until $\text{pH} = 1$. The solution was stirred at room temperature for 3 hrs. The light yellow solution was poured into 1 L of water and extracted with 4x ethyl ether. The ether was washed with 500 mL of saturated brine, dried over magnesium sulfate, filtered, and evaporated to dryness. Yield 27 g (100%) of a semi-solid crude product 3. After silica gel column chromatography (0-20% ethyl acetate in dichloromethane), 21.8 g (85%) of 3 as a white solid was isolated. The identity of the product was confirmed using ^1H NMR spectroscopy, and the NMR spectrum is shown in FIG. 11.

EXAMPLE 2

25 SYNTHESIS OF 3-HYDROXY-7 α -METHYL-21-[2'-METHOXY-4'-(DIETHYLAMINOMETHYL)-PHENOXY]-19-NORPREGNA-1,3,5(10)TRIENE CITRATE ("SR 16234") FROM 21-HYDROXY-19-NORPREGNA-4-EN-3-ONE, METHOD 1:

SR 16234 was synthesized from 21-hydroxy-19-norpregna-4-en-3-one (3) as illustrated in FIG. 2, using the following procedure.

30 Synthesis of (4): To a solution of 1.32 g (4.36 mmol) of 3 (prepared in Example 1)

in 30 mL of CH_2Cl_2 was added 2 mL of DHP (dihydropyran). The mixture was cooled to 0°C and 40 mg (5%) of TsOH was added, and the mixture was stirred for 1.5 h.

Triethylamine (0.5 mL) was added to the mixture and the mixture was filtered through a pad of silica gel (ether). The filtrate was concentrated to give 1.79 g of crude product, which was used right away without purification. To this crude product was added 1.23 g (13.1 mmol) of phenol and 4.26 g (13.1 mmol) of Cs_2CO_3 followed by addition of 30 mL of sulfolane. The resulting mixture was heated at $125\text{--}130^\circ\text{C}$ under a stream of air for 6.5 hrs., and the mixture was cooled to 65°C , and 10.7 mL of isopropyl bromide was added. The mixture was stirred for 2 hrs., and was cooled to ambient temperature, diluted with ether and hexanes (80 mL/120 mL), washed with water (50 mL x 4), brine, dried, concentrated, and was chromatographed (10-15% EtOAc in hexanes) to give 735 mg (40%) of 4. The identity of the product was confirmed using ^1H NMR spectroscopy, and the NMR spectrum is shown in FIG. 12.

Synthesis of (5): To a solution of 210 mg (0.48 mmol) of 4 in 10 mL of THF was added 1 mL (2 mmol) of a 2.0 M solution of LDA (lithium diisopropylamide) in THF at 0°C . The mixture was stirred for 1 h, warmed to ambient temperature, and was treated with 1 mL of MeI. The resulting mixture was refluxed for 30 min, and was cooled to 0°C . Methanol (10 mL) and TsOH (0.5 g) was added, and was stirred for 1.5 h. Triethylamine (1 mL) was added, and the mixture was concentrated, and was chromatographed (30% EtOAc in hexanes) to give 70 mg (39%) of 5 as an oil. The identity of the product was confirmed using ^1H NMR spectroscopy, and the NMR spectrum is shown in FIG. 13.

Synthesis of (6): To a solution of 45 mg (0.12 mmol) of 5 and 1 mL of Et_3N in 10 mL of CH_2Cl_2 was added 0.5 mL of methanesulfonic anhydride at 0°C . The mixture was stirred for 20 min, and then filtered through a pad of silica gel (ether). The filtrate was concentrated to give an oil, which was dissolved in 5 mL of DMF, and 67 mg (0.28 mmol) of vanillic acid diethylamide and 97 mg (0.30 mmol) of Cs_2CO_3 was added. The resulting mixture was heated at 110°C for 3 h, and was cooled and diluted with ether (75 mL). The mixture was washed with water, brine, dried, concentrated, and was chromatographed (50% EtOAc in hexanes) to give 60 mg (85%) of 6. The identity of the product was confirmed using ^1H NMR spectroscopy, and the NMR spectrum is shown in FIG. 14.

Synthesis of SR 16233: To a solution of 20 mg (0.03 mmol) of 6 in 5 mL of CH_2Cl_2 was added 10 mg (0.07 mmol) of AlCl_3 at 0°C . The mixture was warmed to ambient temperature, stirred for 45 min, and filtered through a thin pad of silica gel (EtOAc). The filtrate was concentrated and dissolved in 10 mL of ether. This ether solution was added to a mixture of AlCl_3 (120 mg, 0.9 mmol) and LiAlH_4 (1 mL of a 1 M solution in ether) in 5 mL of ether at ambient temperature. The mixture was stirred overnight and an aqueous solution of NaOH (15%) was added to the mixture dropwise until a white suspension was formed, and was filtered through a pad of Celite. The filtrate was concentrated and chromatographed (5%-10% MeOH in CHCl_3) to give 6 mg (35%) of SR 16233. The identity of the product was confirmed using ^1H NMR spectroscopy, and the NMR spectrum is shown in FIG. 15. The mass spectrum is shown in FIG. 16.

Citrate salt of 3-hydroxy-7 α -methyl-21-[2'-methoxy-4'-(N,N-diethylaminomethyl)phenoxy]-pregna-1,3,5(10)-triene (SR 16234): The free base SR 16233 (240.5 g, 0.476 mol) was dissolved in a total volume of methanol (1.700 mL, ~ 7 mL/g of base). To the hot solution was added citric acid (93.5 g, 0.487 mol) (2% excess). The combined clear reaction mixture was stirred and crystallization started and quickly proceeded. Finally, the reaction mixture was left overnight. The crystalline material was filtered off and then washed with a small amount of cold methanol and ether. The crystalline material was dried under vacuum to give 309.0 g or 93% product as an off-white powder, m.p. 154-155 C. The ^1H NMR spectrum is shown in FIG. 17, and the mass spectrum is shown in FIG. 18.

EXAMPLE 3

SYNTHESIS OF 3-HYDROXY-7 α -METHYL-21-[2'-METHOXY-4'-(DIETHYLAMINOMETHYL)-PHENOXY]-19-NORPREGNA-1,3,5(10)TRIENE CITRATE ("SR 16234") FROM 21-HYDROXY-

19-NORPREGNA-4-EN-3-ONE, METHOD 2:

SR 16234 was synthesized from 21-hydroxy-19-norpregna-4-en-3-one (3) as illustrated in FIG. 3, using the following procedure.

Synthesis of (7): To a mixture of 1.512 g (5 mmol) of 3 (synthesized in Example 1) and 1.06 g (10.5 mmol) of Et_3N in 25 mL of sulfolane was added 1.03 g (9 mmol) of MsCl dropwise at ambient temperature, and then stirred for 30 min. To this mixture was added

-38-

1.34 g (6 mmol) of vanillic acid diethylamide and 1.96 g (6 mmol) of Cs_2CO_3 . The resulting mixture was heated at 110-115°C under a stream of air for 7 h, cooled to 85°C, and 2 mL of isopropyl bromide was added. The mixture was stirred for 1 h, and was diluted with ether and CHCl_3 (100 mL/20 mL), washed with water and brine, dried with sodium sulfate, concentrated, and chromatographed (5% acetone in CH_2Cl_2) to give 804 mg (27%) of 7 as a yellow glass. The identity of the product was confirmed using ^1H NMR spectroscopy. The NMR spectrum is shown in FIG. 19.

Synthesis of (6): To a solution of 302 mg (0.54 mmol) of 7 in 12 mL of THF was added 0.67 mL (1.35 mmol) of a 2.0 M solution of LDA in THF at 0°C. The mixture was stirred for 30 min, warmed to ambient temperature, and treated with 760 mg (5.4 mmol) of MeI. The resulting mixture was refluxed for 1.5 h, quenched into water, and extracted with ether (50 mL). The organic layer was dried (sodium sulfate), concentrated, and chromatographed (15% EtOAc in CH_2Cl_2) to give 233 mg (75%) of 6 as an oil.

SR 16233 and SR 16234 were then synthesized from 6 as described in Example 2.

EXAMPLE 4

SYNTHESIS OF 3-HYDROXY-7 α -METHYL-21-[2'-METHOXY-4'-(DIETHYLAMINOMETHYL)PHENOXY]-19-NORPREGNA-1,3,5(10)TRIENE CITRATE ("SR 16234") FROM 21-HYDROXY-19-NORPREGNA-4-EN-3-ONE, METHOD 3:

SR 16234 was synthesized from 21-hydroxy-19-norpregna-4-en-3-one (3) as illustrated in FIG. 4, using the following procedure.

Synthesis of (8): To a suspension of alcohol 3 prepared in 84% yield from estrone (12.1 g, 40 mmol) in isopropenylacetate (120 mL) was added silica gel containing 3% sulfuric acid (0.55 g). This reaction mixture was heated at reflux for 4 h (after 2 h no change in TLC 30% EtOAc/hexane). The reaction mixture was filtered through a thin pad of celite/silica gel and the excess reagent was removed in vacuo. The residue became semisolid. The product was dried under high vacuum to give a crude yield (15.6 g or 100%). This compound was used in the synthetic step without further purification. NMR was in accordance with the proposed structure.

Synthesis of (9): Crude product 8 (~40 mmol) was dissolved into acetone (100 mL), water (32 mL), acetic acid (12 mL), and pyridine (7 mL), and to this solution was added sodium acetate (22.8 g). This mixture was cooled in an ice/water bath and N-bromo succinimide (8.9 g or 50 mmol) was added (protected from light). The combined reaction mixture was stirred at 0 to +5°C for 3 h. TLC (20% EtOAc/hexane) showed no starting material. The reaction mixture was poured into an ice cold sat. sodium chloride solution. This mixture was extracted 3 times with ether. The combined ether solution was washed with sat. sodium chloride solution, dried over Na₂SO₄, and evaporated in vacuo to give the crude brominated product. This product was dehydrobrominated in the following way. The bromo compound was dissolved into DMF (72 mL). This solution was added to a hot suspension of lithium bromide (11.6 g) and lithium carbonate (11.6 g) in DMF (300 mL). The reaction mixture was heated at reflux for 1 h. The reaction mixture was cooled and filtered and the residue was washed with some DMF. The filtrate and the washings were combined and added to ice/water. The aqueous solution was extracted with ether 3 times. The combined ether solution was washed with sodium bicarbonate solution 4% and water and dried over sodium sulfate and concentrated to a syrup. The crude material was purified on a silica gel column, eluted with 25% ethyl acetate/hexanes. Yield after recrystallization from ethyl acetate 8.4 g, 62% from the 21-alcohol 3. NMR and MS were in agreement with the proposed structure.

Synthesis of (10): To a stirred suspension of cuprous iodide (4.16 g, 22 mmol) in dry ether (30 mL), was added a 1.5 M methyl lithium, lithium bromide complex in ether (20.0 mL, 30 mmol). To this solution, cooled to 0-5°C was added the steroid acetate 9 (2.5 g, 7.3 mmol) dissolved into ether (30 mL) over a period of 10 min. Stirring was continued for an additional 15 min and then the reaction mixture was quenched with a saturated ammonium chloride solution. The aqueous phase was separated and extracted twice with ether. The combined organic phase was washed twice with ammonium chloride solution and then water and dried over MgSO₄. Evaporation of the solvent gave the crude material as a gum. Treatment of the crude material with p-toluene sulfonic acid in dichloromethane gave the target compound in a yield of 1.8 g, 69%. NMR and MS were in agreement with the proposed structure.

Synthesis of (11): To the acetate 10 (0.53 g, 1.48 mmol) dissolved into methanol (20 mL) was added KOH (40 mg) and the reaction mixture was stirred at room temperature for 2 h. TLC showed complete reaction. The solvent was removed under reduced pressure. Water was added to the residue and the aqueous phase was extracted with ether 3 times.

5 The combined ether phase was washed with saturated sodium chloride solution, dried over Na_2SO_4 and evaporated to give a gum (0.48 g). Addition of some ether induced crystallization. The crystals were collected to give 0.32 g of off-white (yellowish) crystals. Total yield 0.48 g, 100%. NMR and MS were in agreement with the proposed structure; the ^1H NMR spectrum of the product is shown in FIG. 20.

10 **Synthesis of (12):** A mixture of the steroid alcohol 11 (0.30 g, 0.95 mmol), vanillin (0.310 g, 2.04 mmol), and triphenylphosphine (0.53 g, 2.04 mmol) was dissolved into THF (8 mL). To this solution was added dropwise a solution of diethylazodicarboxylate (0.37 g, 2.1 mmol). After stirring for 2 h the reaction was complete. Most of the solvent was evaporated and the total residue was chromatographed on a silica gel column and was eluted
15 with 25% ethyl acetate/hexane. The fractions that contained the target compound were combined and evaporated to give 0.366 g of target compound. Yield 0.366 g, 85.5%. NMR and MS were in agreement with the proposed structure; the ^1H NMR spectrum of the product is shown in FIG. 21.

Synthesis of (13): To a stirred solution of the aldehyde 12 (0.150 g, 0.33 mmol) in
20 dichloroethane (4 mL) was added diethylamine (0.68 mL, 0.66 mmol). After 15 min of stirring (the solution became reddish) sodium-triacetoxy borohydride (0.097 g or 0.46 mmol) was added in two portions. After stirring for 2 h the reaction was complete. The reaction mixture was diluted with some dichloromethane and was then poured into an aqueous solution of sodium bicarbonate (4%). The organic phase was separated and the
25 aqueous phase was extracted once more with dichloromethane. The combined organic phase was washed with sodium bicarbonate solution and saturated sodium chloride solution was dried over Na_2SO_4 . Evaporation of the solvent gave a syrup that was purified on a silica gel column and eluted with 5% methanol/dichloromethane. The fractions that contained the target compound were evaporated to give 0.113 g, 67% of pure target compound. NMR and

MS were in agreement with the proposed structure; the ^1H NMR spectrum of the product is shown in FIG. 22.

Synthesis of SR 16233: To a stirred solution of **13** (0.085 g) in glacial acetic acid (3 ml) was added CuCl_2 (0.085 g). The mixture was stirred and heated at 100-105°C for 24 hours. The reaction mixture was cooled and poured into ice-cold water. The aqueous phase was extracted twice with dichloromethane. The organic phase was washed with NaHCO_3 and water and was dried over MgSO_4 . Evaporation of the solvent gave the target compound, which was then recrystallized from ethanol. Identity of the product, SR 16233, was confirmed using ^1H NMR spectroscopy.

EXAMPLE 5

SYNTHESIS OF 3-HYDROXY-7 α -METHYL-21-[2'-METHOXY-4'-(DIETHYLAMINOMETHYL)-PHENOXY]-19-NORPREGNA-1,3,5(10)TRIENE CITRATE ("SR 16234") FROM 21-HYDROXY-19-NORPREGNA-4-EN-3-ONE, METHOD 4:

SR 16234 was synthesized from crude 21-hydroxy-19-norpregna-4-en-3-one (**3**) as illustrated in FIG. 5, using the following procedure.

Synthesis of 21-Hydroxy-19-norpregna-4-en-3-one 21-acetate (34**):** Crude product **3** prepared in Example 1 (18.0 g) was dissolved in pyridine (100 mL), and to this solution was added acetate anhydride (25 mL). The reaction was stirred at room temperature for 5 h and then poured into ice/water. The aqueous solution was extracted with ether twice. The combined ether extract was washed with water, ice-cold 4% hydrochloric acid solution, and water, and then dried over sodium sulfate and evaporated to give a semi-crystalline compound. This material was purified by chromatography to give 14.0 g of **35** (86%). ^1H NMR (CDCl_3) δ 0.66 (s, 3H), 2.04 (s, 3H), 4.06 (m, 2H), 5.83 (s, 1H).

Synthesis of 3,21-Dihydroxy-19-norpregna-3,5-dien-diacetate (8**):** To a suspension of **35** (12.1 g, 40 mmol) in isopropenylacetate (120 mL) was added silica gel containing 3% sulfuric acid (0.55 g). This reaction mixture was heated at reflux for 4 h, filtered through a thin pad of Celite, and excess reagent removed to give a semisolid

product. The product was dried under high vacuum to give 15.6 g of crude product 8 (100%). The product from this reaction was used in the next step for the preparation of 21-hydroxy-19-norpregna-4,6-dien-3-on-21-acetate (37) without further purification. ¹H NMR (CDCl₃) was in accordance with the proposed structure.

5 **Synthesis of 21-Hydroxy-19-norpregna-4,6-dien-3-on-21-acetate (9):** Crude product 8 (15.6 g, ~40 mmol) was dissolved in a mixture of acetone (100 mL), water (32 mL), acetic acid (12 mL), and pyridine (7 mL), and to this solution was added sodium acetate (22.8 g). This mixture was cooled in an ice/water bath, and N-bromo-succinimide (8.9 g, 50 mmol) was added (protected from light). The combined reaction mixture was
10 stirred at 0° to +5 C for 3 h. The reaction mixture was poured into an ice-cold saturated sodium chloride solution and then extracted 3 times with ether and the ether extracts combined. The combined ether extract was washed with saturated sodium chloride solution, dried over Na₂SO₄, and evaporated under vacuum to give the crude brominated product. This product was dehydrobrominated as follows: the bromo compound was dissolved in
15 dimethyl formamide (DMF, 72 mL) and then added to a hot suspension of lithium bromide (11.6 g) and lithium carbonate (11.6 g) in DMF (300 mL). The reaction mixture was heated at reflux for 1 h, then cooled and filtered. The residue was washed with DMF. The filtrate and the washings were combined and added to ice/water. The aqueous solution was extracted with ether three times and the extracts combined. The combined ether solution
20 was washed with 4% sodium bicarbonate solution and water, dried over sodium sulfate, and concentrated to a syrup. The crude material was purified on a silica gel column eluting with 25% ethyl acetate/hexanes to yield, after recrystallization from ethyl acetate, 9.2 g (68%) of 9 from 8. ¹H NMR (CDCl₃) δ 0.69 (s, 3H), 2.05 (s, 3H), 4.08 (m, 2H), 5.78 (s, 1H), 6.20 (m, 2H). MS (DCI) m/z 343 (M+H).

25 **Synthesis of 21-Hydroxy-7α-methyl-19-norpregna-4-en-3-on-21-acetate (10):** To a stirred suspension of cuprous iodide (1.14 g, 6 mmol) in dry ether (25 mL) was added a 1.5 M (9.6 mmol) methyl lithium/lithium bromide complex in 6.4 mL of ether. This solution was cooled to 0-5° C, and then the acetate 9 (0.69 g, 2 mmol) dissolved in ether (40 mL) was added over a period of 10 min. Stirring was continued for an additional 15 min,
30 and then the reaction mixture was quenched with a saturated ammonium chloride solution.

The aqueous phase was separated and extracted three times with ether. The combined organic phase was washed twice with ammonium chloride solution and once with water, and then dried over MgSO_4 . Evaporation of the solvent gave the crude material as a gum. Treatment of the crude material with *p*-toluenesulfonic acid in dichloromethane gave 0.48 g (67%) of crude acetate 10. ^1H NMR (CDCl_3) δ 0.67 (s, 3H), 0.78 (d, 3H), 2.05 (s, 3H), 4.06 (m, 2H), 5.83 (s, 1H). MS (DCI) m/z 359 (M+H).

Synthesis of 21-Hydroxy-7 α -methyl-19-norpregna-1,3,5(10)-triene (35): To a solution of 10 (0.400 g, 1.04 mmol) in 4.5 mL of acetic acid was added copper(II) chloride (0.400 g). This reaction mixture was heated at 100°C for 2 h. After 1 h, the reaction mixture was cooled and poured into water. The aqueous phase was extracted three times with ether. The combined ether phase was washed with water, sodium bicarbonate, and sodium chloride solution and then dried over sodium sulfate. Evaporation of the solvent gave the crude product in quantitative yield (some phenolic acetate seemed to be present). The crude material was hydrolyzed with potassium hydroxide in a mixture of methanol/water. Extraction with dichloromethane and evaporation of the solvent gave 0.28 g (85%) of purified material 35. ^1H NMR (CDCl_3) δ 0.59 (s, 3H), 0.78 (d, 3H), 3.55 (m, 2H), 6.48 (d, 1H), 6.58 (q, 1H), 7.09 (d, 1H).

Synthesis of 3,21-Dihydroxy-19-norpregna-1,3,5(10)-triene-bis-mesylate (36): Alcohol 35 (0.945 g, 3 mmol) was dissolved in dichloromethane (15 mL) and triethylamine (2.0 mL). This solution was cooled to 0-5°C (ice/water bath), and methanesulfonyl chloride (0.90 g, 7.8 mmol) was added dropwise. The reaction mixture was stirred for 2 h at 0°C, then poured into ice/water. The dichloromethane was separated, and the water phase was extracted once more with dichloromethane. The dichloromethane was washed with water and then sodium chloride solution and dried over sodium sulfate. Evaporation of the solvent gave 1.34 g (95%) of 36 as a slightly sticky, white crystalline material. ^1H NMR was in agreement with the proposed structure. The crude material was used without further purification in the preparation of 37.

Synthesis of 3-Hydroxy-7 α -methyl-21-(2'-methoxy-4'-N,N-diethylamido)phenoxy-19-norpregna-1,3,5(10)-triene-3-mesylate (37): To a solution of 36 (1.20 g, 2.55 mmol) in 20 mL of DMF was added vanillic acid diethylamide (0.68 g, 3.06 mmol) and potassium carbonate (1.0 g, 3.06 mmol). The reaction mixture was heated at 90°C for 2 h, then cooled to room temperature and poured into ice/water. Some crystalline material appeared and was filtered off. The aqueous phase was extracted with ether twice. The combined ether phase was washed with water and sodium chloride solution. Evaporation of the solvent gave 1.39 g (91%) of off-white material 37. ¹H NMR (CDCl₃) δ 0.68 (s, 3H), 0.86 (d, 3H), 3.13 (s, 3H), 3.89 (s, 3H), 3.95 (m, 2H), 6.8-7.05 (aromatic, 4H), 7.32 (d, 1H). MS (DCI) m/z 597 (M+H).

Synthesis of (SR 16233): A solution of crude 37 (0.500 g, 0.84 mmol) in ether (15 mL) was added dropwise to a suspension of LAH (0.160 g) in ether (10 mL). The reaction mixture was stirred overnight. The residue was poured into CH₂Cl₂. The CH₂Cl₂ phase was washed with water and then sodium chloride and evaporated to give a crude material that was purified by column chromatography to give 0.378 g (95%) of SR 16233. Identity of the product, SR 16233, was confirmed using ¹H NMR spectroscopy. MS (DCI) m/z 505 (M+H).

Synthesis of SR 16234: The free base SR 16233 (240.5 g, 0.476 mol) was dissolved in methanol (total volume 1.700 mL, ~7 mL/g of base). To the hot solution was added citric acid (93.5 g, 0.487 mol) (2% excess). As the clear reaction mixture was stirred, crystallization began and proceeded fast. Finally the reaction mixture was left overnight. The crystalline material was filtered off and washed with a small amount of cold methanol and ether. The crystalline material was dried under vacuum to give 316 g of SR 16234 (95%).

EXAMPLE 6

SYNTHESIS OF 3-HYDROXY-7 α -METHYL-21-[2'-METHOXY-4'-(DIETHYLAMINOMETHYL)-PHENOXY]-19-NORPREGNA-1,3,5(10)TRIENE CITRATE ("SR 16234") FROM 21-HYDROXY-19-NORPREGNA-4-EN-3-ONE, METHOD 5:

5 SR 16234 was synthesized from crude 21-hydroxy-19-norpregna-4-en-3-one (3) as illustrated in FIG. 9, using the following procedure.

Synthesis of (20): To a solution of 1.125 g (3.7 mmol) of crude product 3 in 60 mL of isopropanol was added 0.188 g (0.7 mmol) of iodine. The resulting mixture was refluxed under a stream of oxygen for 2 h, then cooled to room temperature. The mixture was
10 diluted with ether (150 mL), washed with water and then brine, dried, and concentrated to give an oil. Chromatographic separation (40% EtOAc in hexanes) gave 0.814 g (61%) of 20. ¹H NMR (CDCl₃) δ 0.64 (s, 3H), 1.32 (d, 3H, J = 1.9 Hz), 1.34 (d, 3H, J = 1.9 Hz), 2.77 (dd, 1H, J = 16.8 Hz, 3.3 Hz), 3.68 (m, 2H), 4.61 (m, 1H), 7.07 (dd, 1H, J = 8.4 Hz, 3.0 Hz), 7.33 (d, 1H, J = 8.4 Hz), 7.55 (d, 1H, J = 3.0 Hz).

15 Synthesis of (4): To a solution of 0.814 g (2.3 mmol) of 20 in 20 mL of CH₂Cl₂ was added 5 mL of dihydropyran (DHP) and 0.05 g of pyridium *p*-toluenesulfonate. The mixture was stirred at room temperature for 2 h, and Et₃N (0.5 mL) was added. The mixture was diluted with ether (30 mL), washed with water and then brine, dried, and concentrated to give 1.01 g (100%) of (4), which was used in the next reaction without purification. ¹H
20 NMR (CDCl₃) δ 0.64 (s, 3H), 1.32 (d, 3H, J = 1.9 Hz), 1.34 (d, 3H, J = 1.9 Hz), 2.76 (dd, 1H, J = 16.8 Hz, 3.3 Hz), 3.35-3.91 (m, 4H), 4.10 (m, 2H), 7.07 (dd, 1H, J = 8.4 Hz, 3.0 Hz), 7.33 (d, 1H, J = 8.4 Hz), 7.55 (d, 1H, J = 3.0 Hz). MS (DCI) *m/z* 441 (M+H).

Synthesis of (5): To a solution of 0.660 g (1.5 mmol) of 4 in 25 mL of THF was added 2.25 mL (4.5 mmol) of a 2.0 M solution of lithium diisopropyl amide (LDA) in THF
25 at 0°C. The mixture was stirred for 40 min, warmed to room temperature, and treated with 1 mL of MeI. The resulting mixture was refluxed for 40 min, then cooled to 0°C. Methanol (10 mL) and TsOH (1 g) were added, and the mixture was stirred for 2 h. The mixture was diluted with ether (50 mL), washed with saturated NaHCO₃ and then brine, dried, concentrated, and chromatographed (25% EtOAc in hexanes) to give 0.447 g (80%) of (5).

30 ¹H NMR (CDCl₃) δ 0.64 (s, 3H), 1.11 (d, 3H, J = 7.6 Hz), 1.32 (d, 3H, J = 1.5 Hz), 1.34 (d,

3H, $J = 1.5$ Hz), 3.70 (m, 2H), 4.61 (m, 1H), 7.07 (dd, 1H, $J = 8.4$ Hz, 3.0 Hz), 7.33 (d, 1H, $J = 8.4$ Hz), 7.55 (d, 1H, $J = 3.0$ Hz).

Synthesis of (28): To a solution of 0.225 g (0.6 mmol) of 5 in 30 mL of methanol was added 0.050 g of 10% Pd/C. The mixture was hydrogenated under 3 atm. of H_2 for 22 h, then filtered through a thin pad of silica gel. The filtrate was concentrated and chromatographed (20% EtOAc in hexanes) to give 0.168 g (77%) of 28. 1H NMR ($CDCl_3$) δ 0.64 (s, 3H), 0.84 (d, 3H, $J = 7.1$ Hz), 1.32 (d, 3H, $J = 1.9$ Hz), 1.34 (d, 3H, $J = 1.9$ Hz), 3.69 (m, 2H), 4.61 (m, 1H), 6.61-6.73 (m, 2H), 7.21 (m, 1H).

Synthesis of (35): To a solution of 0.108 g (0.3 mmol) of 28 in 20 mL of CH_2Cl_2 was added 0.120 g (0.9 mmol) of $AlCl_3$ at room temperature. The resulting mixture was stirred for 2.5 h, then filtered through a thin pad of silica gel (with ether as eluent). The filtrate was concentrated to give 0.084 g (92%) of 35. 1H NMR ($CDCl_3$) δ 0.64 (s, 3H), 0.84 (d, 3H, $J = 7.1$ Hz), 3.69 (m, 2H), 6.60-6.72 (m, 2H), 7.22 (m, 1H).

Synthesis of (36): Alcohol 35 (0.945 g, 3 mmol) was dissolved in dichloromethane (15 mL) and triethylamine (2.0 mL). This solution was cooled to 0-5°C (ice/water bath), and methanesulfonyl chloride (0.90 g, 7.8 mmol) was added dropwise. The reaction mixture was stirred for 2 h at 0°C, then poured into ice/water. The dichloromethane was separated, and the water phase was extracted once more with dichloromethane. The dichloromethane was washed with water and then sodium chloride solution and dried over sodium sulfate. Evaporation of the solvent gave 1.34 g (95%) of 36 as a slightly sticky, white crystalline material. 1H NMR was in agreement with the proposed structure. The crude material was used without further purification in the preparation of 37.

Synthesis of (37): To a solution of 36 (1.20 g, 2.55 mmol) in 20 mL of DMF was added vanillic acid diethylamide (0.68 g, 3.06 mmol) and potassium carbonate (1.0 g, 3.06 mmol). The reaction mixture was heated at 90°C for 2 h, then cooled to room temperature and poured into ice/water. Some crystalline material appeared and was filtered off. The aqueous phase was extracted with ether twice. The combined ether phase was washed with water and sodium chloride solution. Evaporation of the solvent gave 1.39 g (91%) of off-white material 37. 1H NMR ($CDCl_3$) δ 0.68 (s, 3H), 0.86 (d, 3H), 3.13 (s, 3H), 3.89 (s, 3H), 3.95 (m, 2H), 6.8-7.05 (aromatic, 4H), 7.32 (d, 1H). MS (DCI) m/z 597 (M+H).

-47-


Synthesis of SR 16233: A solution of crude **37** (0.500 g, 0.84 mmol) in ether (15 mL) was added dropwise to a suspension of LAH (0.160 g) in ether (10 mL). The reaction mixture was stirred overnight. The residue was poured into CH₂Cl₂. The CH₂Cl₂ phase was washed with water and then sodium chloride and evaporated to give a crude material that was purified by column chromatography to give 0.378 g (95%) of **SR 16233**. Identity of the product, **SR 16233**, was confirmed using ¹H NMR spectroscopy. MS (DCI) m/z 505 (M+H).

Synthesis of SR 16234: The free base **SR 16233** (240.5 g, 0.476 mol) was dissolved in methanol (total volume 1.700 mL, ~7 mL/g of base). To the hot solution was added citric acid (93.5 g, 0.487 mol) (2% excess). As the clear reaction mixture was stirred, crystallization began and quickly proceeded. Finally the reaction mixture was left overnight. The crystalline material was filtered off and washed with a small amount of cold methanol and ether. The crystalline material was dried under vacuum to give 316 g of **SR 16234** (95%).

EXAMPLE 7

BIOLOGICAL EVALUATION:

Compound **SR 16312**, having the structural formula



was synthesized as described in Example 4 without methylation at the 7-position of the steroid nucleus. The compound was evaluated for its inhibitory effect on androgen-independent human prostate cancer cells, DU145 cells and PC-3 cells, in a standard *in vitro* androgen-independent human prostate cancer assay.

DU145 and PC-3 human prostate cancer cell lines were obtained from the American Type Culture Collection, Rockville, MD. Eagle's minimum essential medium, RPMI-1640

medium, fetal calf serum, nonessential amino acids, and sodium pyruvate were purchased from Sigma, St. Louis, MO.

PC-3 cells were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS) and DU145 cells in Eagle's minimum essential medium (MEM) supplemented with 10% FCS, 1% nonessential amino acids, and 1mM pyruvate. All cells were cultured at 37°C in a 5% CO₂/95% air atmosphere in 100% humidity. To initiate the growth inhibition assay, cells were seeded at 5000 cells per well in a 24-well plate in 500 µl of the appropriate medium for the individual cell line and cultured under the same conditions described above. Cells were allowed to attach for 24 hours, then test compound was added in 10 µl aliquots. The test compound was dissolved in DMSO first and diluted with medium. The final DMSO concentration was kept at 0.1%. Control cultures received vehicle alone. The medium in each well was changed every other day, with fresh test compound added. After 7 days of treatment, viable cells in each well were measured using the MTT assay as described in "Cellular Proliferation Assay," in *Protocols and Applications*, 3rd Edition (Promega Corporation).

To perform the MTT assay, on Day 9, medium from each well was removed and 100 µl of fresh medium was added, followed by 15 µl of tetrazolium dye solution. The incubation was continued for 4 hours, and then 100 µl of solubilization/stop solution was delivered into each well. (During the four-hour incubation, viable cells converted the tetrazolium component of the dye solution to formazan, which gives a blue color.)


The plate was kept at room temperature overnight and the blue color measured at 575 nm on an ELISA plate reader. Based on the optical density of samples treated with the test compound and that of the control, the inhibitory effect of SR 16312 was evaluated. The results are set forth in FIG. 21. As may be seen in the figure, the compound resulted in virtually 100% inhibition at concentrations of 5 µM or higher

EXAMPLE 8

7- α METHYLATION OF 6-KETOESTRADIOL USING A THP PROTECTING GROUP:

The stereoselective methylation of a 6-keto steroid according to the following scheme was accomplished as described below.

-49-



Synthesis of 3,17β-Dihydroxy-6-keto-estra-1,3,5(10) triene-3,17-

- 5 **ditetrahydropyranyl ether (38).** To a solution of 0.100 gm of 6-ketoestradiol in 2.0 ml of dichloromethane was added 0.5 g of dihydropyran and 0.04 gm. of TsOH. The reaction was stirred for 18 h at room temperature under argon. The reaction was poured into 4% sodium bicarbonate and extracted with additional dichloromethane. The organic fractions were combined and dried over magnesium sulfate and evaporated to dryness to afford 0.157 gm
- 10 (96% yield) of an oil 38. The reaction was not further purified and was used in the following reaction as is.

- Synthesis of 3,17β-Dihydroxy-6-keto-7α-methyl-estra-1,3,5(10) triene (39).** To a solution of 0.140 g of diTHP analog 38 in 5 mL of dry tetrahydrofuran was added 0.47 mL of 2.0 M lithium diisopropylamide in 2.0 mL of tetrahydrofuran at room temperature. The
- 15 reaction was stirred for 1.0 h. and then 0.25 mL of methyl iodide was added. The mixture was refluxed for 3.0 h., cooled to 0°C, and diluted with 5.0 mL of methanol. To this mixture was added 0.025 g of p-toluene sulfonic acid. The reaction mixture was stirred for

-50-

an additional 2.0 h. Triethyl amine (1.0 ml) was then added and the reaction mixture evaporated at reduced pressure to yield 0.155 g of crude **39**. The crude mixture was analyzed by NMR and showed only one isomer at C-7 as determined by the presence of only one doublet at 1.05 ppm. The crude product was diluted with chloroform and
5 chromatographed on silica gel using 30% ethylacetate/hexane to afford pure **39** as an oil. ¹H NMR 7.36–7.0 (m, 3H, aromatic), 3.70 (t, 1H, 17-H) 1.05 (d, J= 7.5 Hz., 7 α -CH₃) 0.74 (s, 18-CH₃)


Synthesis of 7 α -methylestradiol: Compound **39** may be converted into 7 α -methylestradiol using standard reaction conditions. For example, 10% Pd/C can be to a
10 solution of **39** in methanol and then hydrogenated under 3 atm. of H₂ for several hours. The hydrogenated product may then be collected by filtration through a thin pad of silica gel.

-51-

CLAIMS

1. A compound having the structural formula (I)

(I)



wherein:

X is lower hydrocarbyl;

R¹ is CR¹¹R¹², wherein R¹¹ and R¹² are hydrogen or lower alkyl;

R² is selected from the group consisting of hydrogen, hydroxyl, alkyl, -OR¹³, and -SR¹³ wherein R¹³ is alkyl;


R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consisting of hydrogen and lower alkyl;

R⁹ is hydrogen or hydrocarbyl; and

R¹⁰ is methyl or ethyl.

2. The compound of claim 1, having the structural formula (II)


(II)



wherein X is lower alkyl.

3. A compound having the structural formula (III)

(III)



wherein:

R^1 is $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, $-OR^{13}$, and $-SR^{13}$ wherein R^{13} is alkyl;

R^3 is selected from the group consisting of hydrogen and hydrocarbyl;

R^4 , R^5 , and R^7 are independently hydrogen or lower alkyl;


R^9 is hydrogen or hydrocarbyl;

R^{10} is methyl or ethyl; and

R^{19} is hydroxyl, hydroxymethyl, protected hydroxyl, protected hydroxymethyl, activated hydroxyl, or activated hydroxylmethyl.

4. The compound of claim 3, having the structural formula (IV)

(IV)



wherein:


-53-

R^3 is hydrogen or lower alkyl; and

R^{19} is hydroxyl, hydroxymethyl, -O-acetyl, or -O-tetrahydropyranyl.

5. A compound having the structural formula (V)

(V)



wherein:

R^1 is hydrogen or $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, $-OR^{13}$, and $-SR^{13}$ wherein R^{13} is alkyl;

R^3 is selected from the group consisting of hydrogen and hydrocarbyl;

R^4 , R^5 , and R^7 are independently selected from the group consisting of hydrogen and lower alkyl;


R^{6Mod} is selected from the group consisting of hydrogen, alkyl, acyl, $-C(O)$ -aryl, $-C(O)$ -alkyl, hydroxyl-protecting groups, and hydroxyl-activating groups;

R^{8a} is selected from the group consisting of hydrogen, hydroxyl, oxo, and $-OR^{18}$ wherein R^{18} is lower alkyl or lower acyl;

R^9 is hydrogen or alkyl;

R^{10} is methyl or ethyl; and

R^{20} is hydroxyl, hydroxymethyl, protected hydroxyl, protected hydroxymethyl, activated hydroxyl, activated hydroxymethyl, or




-54-

in which m is zero or 1, p is an integer in the range of 1 to 7 inclusive, t is zero or 1, with the proviso that when R^{8a} is oxo, t is 1, and when R^{8a} is hydrogen, t is zero, and R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

- 5 Q^1 , Q^2 , Q^3 , and Q^4 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

6. The compound of claim 5, having the structural formula (VI)



wherein:


R^3 is hydrogen or lower alkyl;

R^{6Mod} is hydrogen or a hydroxyl-protecting group;

R^{8b} is selected from the group consisting of hydrogen, hydroxyl, and oxo; and

20 R^{19} is hydroxyl, hydroxymethyl, protected hydroxyl, protected hydroxymethyl, activated hydroxyl, or activated hydroxymethyl.

7. A compound having the structural formula (XXVII)



wherein:

R^1 is hydrogen or $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, $-OR^{13}$, and $-SR^{13}$ wherein R^{13} is alkyl;

R^4 , R^5 , and R^7 are independently selected from the group consisting of hydrogen and lower alkyl;


R^{6Mod} is selected from the group consisting of hydrogen, alkyl, acyl, $-C(O)$ -aryl, $-C(O)$ -alkyl, hydroxyl-protecting groups, and hydroxyl-activating groups;

R^{10} is methyl or ethyl; and

R^{19} is hydroxyl, hydroxymethyl, protected hydroxyl, protected hydroxymethyl, activated hydroxyl, or activated hydroxymethyl.

8. A compound having the structural formula (XXVIII)

(XXVIII)



wherein:

R^1 is hydrogen or $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, $-OR^{13}$, and $-SR^{13}$ wherein R^{13} is alkyl;


R^4 , R^5 , and R^7 are independently selected from the group consisting of hydrogen and lower alkyl;

R^{10} is methyl or ethyl; and

-56-

R^{19} is hydroxyl, hydroxymethyl, protected hydroxyl, protected hydroxymethyl, activated hydroxyl, or activated hydroxymethyl.

9. A compound having the structural formula (VII)



wherein:

R^3 is hydrogen or hydrocarbyl;

R^{6Mod} is selected from the group consisting of hydrogen, alkyl, acyl, $-C(O)-$ aryl, and $-C(O)-$ alkyl, hydroxyl-protecting groups, and hydroxyl-activating groups;

R^{8b} is selected from the group consisting of hydrogen, hydroxyl, and oxo;

m is zero or 1;

p is an integer in the range of 1 to 7 inclusive;


t is zero or 1, with the proviso that when R^{8a} is oxo, t is 1, and when R^{8a} is hydrogen, t is zero, and;

R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

$Q^1, Q^2, Q^3,$ and Q^4 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino.

-57-

10. A compound having the structural formula (XVI)




wherein:

- 10 R¹ is CR¹¹R¹², wherein R¹¹ and R¹² are hydrogen or lower alkyl;
 R² is selected from the group consisting of hydrogen, hydroxyl, alkyl, -OR¹³, and -SR¹³ wherein R¹³ is alkyl;
 R³ is hydrogen or hydrocarbyl;
 R⁴ and R⁵ are independently selected from the group consisting of hydrogen and
 15 lower alkyl;
 R⁷ is hydrogen or lower alkyl;
 R¹⁰ is methyl or ethyl;
 m is zero or 1;
 p is an integer in the range of 1 to 7 inclusive;
 20 R²¹ and R²² are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and
 Q¹, Q², Q³, and Q⁴ are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino, or a pharmacologically acceptable acid addition salt thereof.

25

11. The compound of claim 10, having the structural formula (XVII)



10 wherein:

m is zero or 1;

p is an integer in the range of 1 to 7 inclusive;


R^3 is hydrogen or lower alkyl;

R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered

15 heterocycloalkyl ring; and

Q^1 , Q^2 , Q^3 , and Q^4 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino, or a pharmacologically acceptable acid addition salt thereof.

20 12. A method for synthesizing 21-hydroxy-19-norpregna-4-en-one and substituted analogs thereof, comprising treating a starting material having the structural formula (I)



30

-59-

with an alkali metal in the presence of ammonia or an alkylamine, wherein, in formula (I),

X is lower hydrocarbyl;

R¹ is CR¹¹R¹², wherein R¹¹ and R¹² are hydrogen or lower alkyl;

R² is selected from the group consisting of hydrogen, hydroxyl, alkyl, -OR¹³, and

5 -SR¹³ wherein R¹³ is alkyl;


R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consisting of hydrogen and lower alkyl;

R⁹ is hydrogen or hydrocarbyl; and

R¹⁰ is methyl or ethyl, resulting in a reaction product having the structural formula

10 (VIII)


(VIII)



13. A method for synthesizing 21-hydroxy-19-norpregna-4-en-3-one, comprising

20 treating (IX)

(IX)




wherein X and Y are independently lower alkyl, with an alkali metal in the presence of
30 ammonia or an alkylamine.

-60-

14. A method for synthesizing a 7-alkyl-6-keto-1,3,5(10) estratriene, comprising contacting a 19-norpregna-4-en-3-one with gaseous oxygen in the presence of base, followed by reaction of the intermediate so provided with an alkyl halide.

15. A method for synthesizing a 7-alkyl-6-keto-1,3,5(10) estratriene having the structural formula (VIa)



wherein:

R^{3A} is lower alkyl;


R^{6Mod} is hydrogen or a hydroxyl-protecting group;

R^{8a} is hydrogen or oxo; and

R^{19} is hydroxyl, hydroxymethyl, protected hydroxyl, or protected hydroxymethyl,

the method comprising the steps of

(a) contacting the 19-norpregna-4-en-3-one (X)




with oxygen in the presence of a base, and

(b) protecting the 3-hydroxyl group thus formed with a protecting group, and

-61-

(c) treating the 3-hydroxyl-protected intermediate with an alkyl halide.

16. A method for synthesizing an anti-estrogenic steroid having the structural formula (XI)



wherein:

R^1 is $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl, and when R^1 is absent, R^1 is hydrogen or alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, and $-OR^{13}$ wherein R^{13} is alkyl;

R^{3A} is lower alkyl;

R^4 , R^5 , R^6 , and R^7 are independently selected from the group consisting of hydrogen and lower alkyl; and

R^{10} is methyl or ethyl;

m is zero or 1;

p is an integer in the range of 1 to 7 inclusive;


R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

Q^1 , Q^2 , Q^3 , and Q^4 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino, said method comprising:

(a) providing a starting material having the structural formula (XII)

-62-


5 (XII)



- (b) converting the -OH group to an -O-LG moiety wherein LG is a leaving group
 10 displaceable by nucleophilic attack, and displacing LG by reaction with a hydroxyl-
 containing compound having the structural formula (XIII)

15

(XIII)




- (c) oxidizing the A ring and providing a 6-keto moiety by exposure to gaseous
 oxygen in the presence of base;
 20 (d) protecting the 3-hydroxyl group with a protecting group;
 (e) contacting the product of step (d) with an alkyl halide, to provide a 7 α -alkyl
 substituent; and
 (f) reducing the compound so provided to remove all keto moieties,
 with the proviso that steps (c) and (d) may occur prior to or simultaneously with
 25 step (b).

17. The method of claim 16, further including (g) treating the product of step (f)
 with an acid to produce an acid addition salt.

30

18. A method for synthesizing an anti-estrogenic steroid having the structural formula (XI)



wherein:

R^1 is $CR^{11}R^{12}$, wherein R^{11} and R^{12} are hydrogen or lower alkyl;

R^2 is selected from the group consisting of hydrogen, hydroxyl, alkyl, and $-OR^{13}$ wherein R^{13} is alkyl;

R^{3A} is lower alkyl;

R^4 , R^5 , R^6 and R^7 are independently selected from the group consisting of hydrogen and lower alkyl; and

R^{10} is methyl or ethyl.

m is zero or 1;

p is an integer in the range of 1 to 7 inclusive;


R^{21} and R^{22} are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

Q^1 , Q^2 , Q^3 , and Q^4 are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino, said method comprising:

(a) providing a starting material having the structural formula (XII)

-64-

5 (XII)



10 (b) protecting the -OH group and the oxy group with protecting groups, thereby converting the compound into a diene;


(c) deprotecting the oxy group to form a dienone;

(d) contacting the product of step (b) with an alkyl lithium in the presence of a lithium halide, to provide a 7 α -alkyl substituent;

15 (e) deprotecting the -OH group;


(f) effecting reaction between the -OH group and an aldehyde having the structural formula (XIV)

20 (XIV)




-65-

to result in an intermediate having the structural formula (XV)




(g) treating (XV) with an alkylamine having the structure $\text{HNR}^{21}\text{R}^{22}$ under reaction conditions effective to produce the amine (XVI)



(h) oxidizing and thereby aromatizing the A ring by reaction with a suitable oxidizing agent or agents.

19. The method of claim 18, further including (g) treating the product of step (h) with an acid to produce an acid addition salt.

20. A method for synthesizing an anti-estrogenic steroid having the structural formula (XI)



wherein:

R¹ is CR¹¹R¹², wherein R¹¹ and R¹² are hydrogen or lower alkyl, and when R¹ is absent, R¹ is hydrogen or alkyl;

R² is selected from the group consisting of hydrogen, hydroxyl, alkyl, and -OR¹³ wherein R¹³ is alkyl;

R^{3A} is lower alkyl;

R⁴, R⁵, R⁶, and R⁷ are independently selected from the group consisting of hydrogen and lower alkyl; and

R¹⁰ is methyl or ethyl;

m is zero or 1;

p is an integer in the range of 1 to 7 inclusive;


R²¹ and R²² are lower alkyl or are linked together to form a five- or six-membered heterocycloalkyl ring; and

Q¹, Q², Q³, and Q⁴ are independently selected from the group consisting of hydrogen, hydroxyl, carboxyl, alkoxy, alkyl, halogen, amino, and alkyl-substituted amino, said method comprising:

(a) providing a starting material having the structural formula (XII)


-67-

(XII)



(b) converting the -OH group to an -O-LG moiety wherein LG is a leaving group
displaceable by nucleophilic attack, and displacing LG by reaction with a hydroxyl-
containing compound having the structural formula (XIII)

(XIII)



(c) oxidizing the A ring to form a diene and protecting resulting the 3-hydroxyl
group with a protecting group;

(d) converting the protected 3-hydroxyl group into an oxo group thereby forming
a dienone;

(e) contacting the product of step (d) with an alkyl lithium in the presence of
lithium halide, to provide a 7 α -alkyl substituent; and


(f) reducing the compound so provided to remove all keto moieties.

21. The method of claim 20, further including (g) treating the product of step (f)
with an acid to produce an acid addition salt.

22. A pharmaceutical composition for administration of a therapeutic agent, comprising a therapeutically effective amount of the compound of claim 8, in combination with a pharmaceutically acceptable carrier.


23. A pharmaceutical composition for administration of a therapeutic agent, comprising a therapeutically effective amount of the compound of claim 9, in combination with a pharmaceutically acceptable carrier.

24. A pharmaceutical composition for administration of a therapeutic agent, comprising a therapeutically effective amount of a compound having the structural formula



or a pharmaceutically acceptable acid addition salt thereof, in combination with a pharmaceutically acceptable carrier.

25. A pharmaceutical composition for administration of a therapeutic agent, comprising a therapeutically effective amount of a compound having the structural formula




or a pharmaceutically acceptable acid addition salt thereof, in combination with a pharmaceutically acceptable carrier.

26. A method for treating a human patient suffering from a prostate disorder, comprising administering to the patient, within the context of an effective dosage regimen, a therapeutically effective amount of the compound of claim 8.


27. A method for treating a human patient suffering from a prostate disorder, comprising administering to the patient, within the context of an effective dosage regimen, a therapeutically effective amount of the compound of claim 9.

28. A method for treating a human patient suffering from a prostate disorder, comprising administering to the patient, within the context of an effective dosage regimen, a therapeutically effective amount of a compound having the structural formula



or a pharmaceutically acceptable acid addition salt thereof.

29. A method for treating a human patient suffering from a prostate disorder, comprising administering to the patient, within the context of an effective dosage regimen, a therapeutically effective amount of a compound having the structural formula



or a pharmaceutically acceptable acid addition salt thereof.

30. A method for stereoselectively adding an alkyl moiety to the 7 α position of a 6 keto steroid comprising providing a C¹⁹ or C²⁰ tetrahydropyranyl-protected hydroxyl moiety on the steroid and reacting the protected steroid with an alkylhalide in the presence
5 of a base.

1/23




FIG. 1

SUBSTITUTE SHEET (RULE 26)

2/23




FIG. 2




FIG. 3

4/23




FIG. 4

5/23




FIG. 5

6/23




FIG. 6

7/23




FIG. 7

SUBSTITUTE SHEET (RULE 26)




FIG. 8

9/23




FIG. 9

SUBSTITUTE SHEET (RULE 26)

10/23




FIG. 10

11/23




FIG. 11

SUBSTITUTE SHEET (RULE 26)

12/23




FIG. 12

13/23




FIG. 13

SUBSTITUTE SHEET (RULE 26)

14/23




FIG. 14

15/23




FIG. 15

SUBSTITUTE SHEET (RULE 26)




FIG. 16

17/23




FIG. 17




FIG. 18

19/23




FIG. 19

20/23




FIG. 20

21/23




FIG. 21

SUBSTITUTE SHEET (RULE 26)

22/23





FIG. 22

23/23

**FIG. 23**



()

(

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58919 A3(51) International Patent Classification⁷: C07J 13/00,
5/00, 41/00, A61K 31/57, A61P 5/36

(21) International Application Number: PCT/US01/04266


(22) International Filing Date: 9 February 2001 (09.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/181,738 11 February 2000 (11.02.2000) US(71) Applicant: SRI INTERNATIONAL [US/US]; 333
Ravenswood Avenue, Menlo Park, CA 94025 (US).(72) Inventors: PETERS, Richard, H.: 365 Springpark Cir-
cle, San Jose, CA 95136 (US). LIU, Jyanwei: 681 Endicott
Drive, Sunnyvale, CA 94087 (US). JOHANSSON, John,G.: 186 Sand Hill Circle, Menlo Park, CA 94025 (US).
RYAN, Kenneth, J.: 754 Lakemuir Drive, Sunnyvale, CA
94089 (US). CHAO, Wan-Ru; 1510 Oriole Avenue, Sun-
nyvale, CA 94087 (US). TANABE, Masato; 972 Moreno,
Palo Alto, CA 94303 (US).(74) Agents: REED, Dianne, E. et al.; Reed & Associates, 800
Menlo Avenue, Suite 210, Menlo Park, CA 94025 (US).(81) Designated States (*national*): CA, JP.(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE, TR).Published:
— with international search report(88) Date of publication of the international search report:
2 May 2002

[Continued on next page]

(54) Title: SYNTHESIS OF ANTI-ESTROGENIC AND OTHER THERAPEUTIC STEROIDS FROM 21-HYDROXY-19-NOR-
PREGNA-4-EN-3-ONE(57) Abstract: Syntheses of steroids such as
3-hydroxy-7 α -methyl-21-[2'-methoxy-4'-(diethy-
laminomethyl)-phenoxy]-19-norpregna-1,3,5(10)triene
citrate ("SR 16234") and analogs thereof are provided,
wherein 21-hydroxy-19-norpregna-4-en-3-one serves as
a starting material or intermediate. The latter compound
may be readily prepared from estrone-3-methyl ether.
Certain intermediates in these syntheses also have value
as therapeutic agents, for example in the treatment of
prostate disorders such as prostatic cancer.

WO 01/58919 A3



(15) Information about Correction:

Previous Correction:

see PCT Gazette No. 01/2002 of 3 January 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/04266

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07J13/00 C07J5/00 C07J41/00 A61K31/57 A61P5/36		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07J A61K A61P		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) WPI Data, CHEM ABS Data, EPO-Internal, BEILSTEIN Data, PAJ, BIOSIS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	P. PLASMAN ET AL: "PHOTOINDUCED LONG RANGE ELECTRON TRANSFER IN RIGID BICHROMOPHIC MOLECULES" RECUEIL DES TRAVAUX CHIMIQUES DES PAYS-BAS., vol. 101, no. 10, October 1982 (1982-10), pages 363-364, XP002177430 ELSEVIER SCIENCE PUBLISHERS. AMSTERDAM., NL ISSN: 0165-0513 page 363, compound 1a <div style="text-align: center;">---</div> <div style="text-align: center;">-/--</div>	1,2
<div style="display: flex; justify-content: space-between;"> <input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex. </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents:</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*G* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center;">13 December 2001</div>		Date of mailing of the international search report <div style="text-align: center;">18. 01. 2002</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040. Tx. 31 651 epo nl. Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center;">Watchorn, P</div>

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/04266

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>B. J. MAGERLEIN ET AL: "Preparation and Reactions of 11-Substituted 1,3,5(10)-Estratrienes. I. 11-Oxygenated Estrones and Estradiols" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 80, 5 May 1958 (1958-05-05), pages 2220-2225, XP002177431 AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., US ISSN: 0002-7863 page 2221, scheme I, compounds II, III VII and VIIa</p>	1,2
X	<p>----- CHEMICAL ABSTRACTS, vol. 70, no. 19, 12 May 1969 (1969-05-12) Columbus, Ohio, US; abstract no. 88104, H. KANEKO ET AL: "Carbalkoxymethylene Steroids" page 379; column 1; XP002177435 abstract -& DATABASE WPI Section Ch, Derwent Publications Ltd., London, GB; Class B00, AN 1966-33967F XP002177436 & JP 43 021058 B (DAINIPPON SEIYAKU KK) abstract</p>	1,2
X	<p>----- K. ANNEN ET AL: "Eine neuartige einfache Dreiring-Synthese" CHEMISCHE BERICHTE., vol. 111, no. 9, 1978, pages 3094-3104, XP002177432 VERLAG CHEMIE GMBH. WEINHEIM., DE ISSN: 0009-2940 page 3096. Schema 1, compounds 6 and 7 page 3099, paragraphs 7,8</p>	1,2
X	<p>----- WICHA, JERZY ET AL: "Synthesis of pregn-17/20/-en-21-oic acid derivatives. The Wittig-Horner reaction on steroidal 17-ketones" SYNTH. COMMUN. (1977), 7(3), 215 -22, XP001027849 page 218, compound 6</p> <p style="text-align: center;">----- -/--</p>	1,2

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/04266

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	C. J. SIH ET AL: "Mechanisms of Steroid Oxidation by Microorganisms. XIII. C22-Acid Intermediates in the Degradation of the Cholesterol Side Chain" BIOCHEMISTRY, vol. 7, no. 2, February 1968 (1968-02), pages 796-807, XP002177433 EASTON, PA US page 797, chart I, compound IIb	1
Y	US 2 883 402 A (SPERO GEORGE B ET AL) 21 April 1959 (1959-04-21) column 1, line 50-55; example 3	12,13
Y	US 3 194 821 A (FREIBERG LESLIE A ET AL) 13 July 1965 (1965-07-13) examples 6,7A	12,13
X	WO 99 33859 A (STANFORD RES INST INT) 8 July 1999 (1999-07-08)	5-7, 16-21, 23,27
Y		10,11, 24,25, 28,29
A	pages 32-36, compounds 75,79-85 examples 15,21,25,32 page 95, scheme 15, in particular compound 72a page 100, paragraph 2 page 103, scheme 19, compound 86 page 104, paragraph 1 page 111; example 40; table 1	1,2,12, 13
Y	EP 0 007 515 A (SCHERING AG) 6 February 1980 (1980-02-06)	5,6,14, 15
A	example 9E	1,2,12, 13
X	TEDESCO R ET AL: "AN EXPEDITIOUS ROUTE TO 7alpha-SUBSTITUTED ESTRADIOL DERIVATIVES" TETRAHEDRON LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 38, no. 46, 17 November 1997 (1997-11-17), pages 7997-8000, XP004125331 ISSN: 0040-4039	30
Y		5,6,14, 15
A	page 7998, scheme 1 page 7998; example 3	1,2,12, 13

-/--

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/US 01/04266

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	A. SANDOVAL ET AL: "Steroids. LXI. Synthesis of 19-Nor-desoxycorticosterone, a Potent Mineralcorticoid Hormone" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 77, 1955, pages 148-151, XP002177434 AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., US ISSN: 0002-7863	3,4
A	page 149; example XIV page 151, column 1, last paragraph	1,2,12, 13
A	FR 2 332 759 A (ROUSSEL UCLAF) 24 June 1977 (1977-06-24) examples 1,2	1,2,12, 13
X	JOHNSON A L: "6 6 DI FLUORO-19 NORPROGESTERONE" JOURNAL OF MEDICINAL CHEMISTRY, vol. 15, no. 7, 1972, pages 784-785, XP002185597 ISSN: 0022-2623 page 784, column 2, paragraph 2	7
X	GB 1 277 265 A (AMERICAN HOME PRODUCTS CORP.) 7 June 1972 (1972-06-07) example 6	3,7
X	US 2 925 427 A (GEORGE ROSENKRANZ ET AL) 16 February 1960 (1960-02-16) example I	3
X	US 3 065 226 A (GEORGE ROSENKRANZ ET AL) 20 November 1962 (1962-11-20) example IV	3
X	A. M. KRUBINER ET AL: "The Conversion of 17-Keto Steroids to 20-Oxygenated Steroids. A Facile Synthesis of 19-Norprogesterone" JOURNAL OF ORGANIC CHEMISTRY., vol. 31, no. 1, January 1966 (1966-01), pages 24-26, XP002185598 AMERICAN CHEMICAL SOCIETY. EASTON., US ISSN: 0022-3263 page 26, column 1, last paragraph -column 2, paragraph 1	3
	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/04266

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BOLT, C. C. ET AL: "The 6.alpha.- and 6.beta.-methyl steroids in the 19-nor series" retrieved from STN Database accession no. 75:98710 XP002185600 abstract & RECL. TRAV. CHIM. PAYS-BAS (1971), 90(8), 849-60 ,	3
A	--- DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1981 KAWAHARA M ET AL: "TREATMENT OF PROSTATIC CANCER WITH PEPLMYCIN" Database accession no. PREV198273084810 XP002185601 abstract & NISHINIHON JOURNAL OF UROLOGY, vol. 43, no. 5, 1981, pages 1071-1076, ISSN: 0029-0726	5,7, 16-21,27
X	--- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MORITA, YOSHIMI ET AL: "3-Methoxy-19-nor-20-hydroxymethylpregna-1 ,3,5(10)-triene" retrieved from STN Database accession no. 92:181486 XP002185602 abstract & JP 54 117456 A (MITSUBISHI CHEMICAL INDUSTRIES CO., LTD., JAPAN) 12 September 1979 (1979-09-12)	5
X	--- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MORITA, YOSHIMI ET AL: "3-Hydroxy-19-nor-20-acyloxymethylpregna-1 ,3,5(10)-trienes" retrieved from STN Database accession no. 92:215635 XP002185603 abstract & JP 54 112850 A (MITSUBISHI CHEMICAL INDUSTRIES CO., LTD., JAPAN) 4 September 1979 (1979-09-04) --- -/--	5

INTERNATIONAL SEARCH REPORT

In. Application No

PCT/US 01/04266

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MORITA, YOSHIMI ET AL: "3-Benzoyloxy-19-nor-20-hydroxymethylpregn a-1,3,5(10)-triene" retrieved from STN Database accession no. 92:215638 XP002185604 abstract & JP 54 117455 A (MITSUBISHI CHEMICAL INDUSTRIES CO., LTD., JAPAN) 12 September 1979 (1979-09-12)</p>	5
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MORITA, YOSHIMI ET AL: "3-Acyloxy-19-nor-20-(2-tetrahydropyranyl) -oxymethylpregna-1,3,5(10)-trienes" retrieved from STN Database accession no. 92:198643 XP002185605 abstract & JP 54 117454 A (MITSUBISHI CHEMICAL INDUSTRIES CO., LTD., JAPAN) 12 September 1979 (1979-09-12)</p>	5
Y	<p>FR 2 190 427 A (SCHERING AG) 1 February 1974 (1974-02-01) page 4, line 18; examples 1,2,4</p>	5,6,14, 15
Y	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992 FENNELL M J ET AL: "EFFECTS OF ANDROGEN TESTOSTERONE 5-ALPHA DIHYDROTESTOSTERONE 19 NORTESTOSTERONE ADMINISTRATION ON GROWTH IN TURKEYS" Database accession no. PREV199293115262 XP002185606 abstract & POULTRY SCIENCE, vol. 71, no. 3, 1992, pages 539-547, ISSN: 0032-5791</p>	10,11, 24,25, 28,29

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/04266

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1991 GAILLARD J-L: "EQUINE TESTICULAR AROMATASE SUBSTRATES SPECIFICITY AND KINETIC CHARACTERISTICS" Database accession no. PREV199293015846 XP002185607 abstract & COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY B COMPARATIVE BIOCHEMISTRY, vol. 100, no. 1, 1991, pages 107-116, ISSN: 0305-0491</p>	10,11, 24,25, 28,29
Y	<p>--- DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995 SUNDARAM KALYAN ET AL: "Different patterns of metabolism determine the relative anabolic activity of 19-norandrogens." Database accession no. PREV199598421606 XP002185608 abstract & JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 53, no. 1-6, 1995, pages 253-257, ISSN: 0960-0760</p>	10,11, 24,25, 28,29
X	<p>--- SKADDAN, MARC B. ET AL: "Synthesis and Binding Affinities of Novel Re-Containing 7.alpha.-Substituted Estradiol Complexes: Models for Breast Cancer Imaging Agents" J. ORG. CHEM. (1999), 64(22), 8108-8121 , XP002185599 8109, scheme 1; page 8113, scheme 7</p>	30
P,Y	<p>--- PLATE R ET AL: "Synthesis of (3alpha,7beta,17alpha)-7-methyl-19-norpreg n-5(10)-en-20-yne-3,7,17-triol, a metabolite of ORG OD14, and its 7-epimer" STEROIDS, BUTTERWORTH-HEINEMANN, STONEHAM, MA, US, vol. 65, no. 9, September 2000 (2000-09), pages 497-504, XP004209376 ISSN: 0039-128X page 499, column 2, last paragraph -page 500, column 1, paragraph 3</p>	5,6,14, 15

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/04266

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 26-29 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 5
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
1,2,6,7,9-21,23-25,27-30 (in full) 3-5 (in part)
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 5

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty with regard to the compounds of claim 5. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claim(s) is impossible. Consequently, the search has been restricted to the compounds of claim 6 (dependent on claim 5).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1,2,12,13 (in full)

17-Carboxy-methylene-estra-1,3,5(10),17(20)-tetraene derivatives and their use as a starting material in the synthesis of intermediate compounds of formula VIII, and the compounds of formula VIII produced thereby (these being a sub-set of the compounds of formula III claimed per se in claims 3 and 4).

2. Claims: 7,9,16-21,23,27 (in full) 3-5 (in part)

Compounds of formula VII (claim 9, being a sub-set of the compounds of formula V of claim 5), pharmaceutical compositions containing them and the medical uses thereof. Processes for their production (claims 16-21) and intermediates of those processes (compounds of formula III of claims 3,4 in so far as they do not coincide with formula VIII of claim 12, compounds of formula V of claim 5 in so far as they contain an amine/amide group and compounds of formula XXVII of claim 7)

3. Claims: 8,22,26 (in full)

Compounds of formula XXVIII, pharmaceutical compositions and medical uses thereof.

4. Claims: 6,14,15 (in full) 5 (in part)

Process for the preparation of 7-alkyl-6-keto steroid compounds (claims 14 and 15), intermediates thereof (compounds of formula V of claim 5, which do not contain an amine or amide group and all compounds of claim 6).

5. Claims: 10,11,24,25,28,29

Compounds of formula XVI (Claims 10,11), pharmaceutical compositions (claims 24, 25) and medical uses thereof (claims 28, 29).

6. Claim : 30

A method for the alkylation of a 6-keto steroid.

7. Claims: 3,4

Intermediates of formulae V and VI

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

8. Claims: 5,6

Intermediates of formulae V and VI

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/04266

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 2883402	A	21-04-1959	NONE	
US 3194821	A	13-07-1965	FR 4347 M FR 1478325 A GB 1073387 A	12-07-1967 28-06-1967
WO 9933859	A	08-07-1999	US 6054446 A AU 2010499 A CN 1291196 T EP 1056768 A2 HU 0100136 A2 NO 20003254 A WO 9933859 A2 US 6281205 B1	25-04-2000 19-07-1999 11-04-2001 06-12-2000 28-08-2001 21-08-2000 08-07-1999 28-08-2001
EP 0007515	A	06-02-1980	DE 2832606 A1 AT 747 T DE 2962254 D1 EP 0007515 A1	31-01-1980 15-03-1982 08-04-1982 06-02-1980
FR 2332759	A	24-06-1977	FR 2332759 A1	24-06-1977
GB 1277265	A	07-06-1972	BE 736833 A CA 932721 A2 DE 1938283 A1 FR 2014016 A5 GB 1277268 A IL 32699 A JP 48030050 B NL 6911649 A US 3644440 A	30-01-1970 28-08-1973 05-02-1970 10-04-1970 07-06-1972 29-06-1973 17-09-1973 03-02-1970 22-02-1972
US 2925427	A	16-02-1960	NONE	
US 3065226	A	20-11-1962	NONE	
JP 54117456	A	12-09-1979	JP 1340442 C JP 61001035 B	14-10-1986 13-01-1986
JP 54112850	A	04-09-1979	JP 1335427 C JP 61002080 B	11-09-1986 22-01-1986
JP 54117455	A	12-09-1979	JP 1340441 C JP 61001034 B	14-10-1986 13-01-1986
JP 54117454	A	12-09-1979	JP 1340440 C JP 61001037 B	14-10-1986 13-01-1986
FR 2190427	A	01-02-1974	FR 2190427 A1	01-02-1974